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Abstract 
Parkinson’s disease (PD) is an incurable neurodegenerative disorder, characterized by the progressive loss 
of dopaminergic neurons in the midbrain of affected individuals. Both environmental and genetic factors 
contribute to the aetiology of PD, with more than a dozen genes implicated in disease development. Yet, 
the exact mechanisms by which each gene (and mutation) contribute to the pathophysiology of PD remain 
to be elucidated. Mitochondrial dysfunction is a recurring theme associated with neurodegeneration and 
recently the translocase of outer mitochondrial membrane (TOM) complex, which plays a role in the 
maintenance of healthy mitochondria, has been implicated in PD pathogenesis. The TOM complex, 
consisting primarily of TOM20, TOM22, TOM40 and TOM70, is involved in the translocation of nuclear-
encoded proteins into the mitochondria where they are needed for normal mitochondrial function. 
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of autosomal 
dominant PD and the LRRK2 protein has been associated with numerous cellular functions including 
mitochondrial homeostasis, the autophagy/lysosomal pathway, cell signalling and synaptic vesicle 
trafficking. The most common PD-causing mutation, G2019S, is located in the kinase domain of LRRK2 and 
has consistently been shown by various researchers to increase kinase activity. Recently, members of our 
group identified a novel variant (Q2089R) in LRRK2. This variant is also located in the kinase domain of 
LRRK2 and requires further investigation to determine its pathogenicity. The aim of the present study was 
to functionally characterize wild type (WT) and mutant LRRK2 (G2019S and Q2089R) under basal and 
stress [Carbonyl cyanide m-chlorophenyl hydrazone (CCCP)] conditions and also to determine whether 
WT LRRK2 interacts with the TOM complex.  
The frequency of LRRK2 Q2089R in South African PD patients and controls was determined using a custom 
Taqman™ SNP genotyping assay. In silico analysis of the effect of the amino acid substitution from 
Glutamine (Q) to Arginine (R) was performed using various prediction tools. Two cellular models of PD 
including (1) HEK293 cells transfected with WT and mutant LRRK2 constructs and (2) patient-derived 
dermal fibroblasts were used for the functional studies. LRRK2 mutant constructs were generated using 
site-directed mutagenesis in pcDNA-DEST53, a mammalian expression vector. We obtained skin biopsies 
from individuals harbouring G2019S, Q2089R or WT LRRK2 and cultured dermal fibroblasts as an ex vivo 
model of the disorder. We investigated the kinase activity of LRRK2 using autophosphorylation of Serine 
1292 and Western blot analysis. Metabolic activity was measured using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay and mitochondrial membrane potential (MMP) was measured 
using the JC-1 fluorochrome and flow cytometric analysis. Mitochondrial and glycolytic respiration 
experiments were performed using the Seahorse XF Analyzer and mitochondrial DNA copy number was 
determined by quantitative real-time PCR (qRT-PCR). Autophagic markers, LC3 II and P62, were detected 
using Western blot analysis. Co-localization experiments of WT LRRK2 and the TOM complex was 
performed using confocal and super resolution structured illumination microscopy (SR-SIM), while protein 
interactions were investigated using co-immunoprecipitation and Western blot analysis. 
The frequency of Q2089R was found to be 0.2% (1/493) in PD patients and 0.1% (1/776) in controls. 
Multiple in silico tools predicted the Q to R substitution to possibly be pathogenic [‘deleterious’ (CADD 
score=24.1, ‘possibly damaging’ (Polyphen) and ‘disease causing’ (Mutation Taster)]. The LRRK2 
constructs were successfully generated and fibroblasts were successfully cultured. Notably, in HEK293 
cells, we found that Q2089R almost completely abolished autophosphorylation activity of LRRK2 
(p=0.026). Q2089R-carrying cells also exhibited a decrease in metabolic activity in HEK293 cells (p=0.016) 
and fibroblasts (p<0.05). In addition, in both cell types a significantly decreased MMP was observed 
[p=0.043 and p=0.009 for HEK293 cells and fibroblasts (under stress), respectively]. Furthermore, Q2089R-
carrying fibroblasts showed an increase in basal respiration (p=0.012), proton leak respiration (p=0.0001), 
Stellenbosch University  https://scholar.sun.ac.za
maximal respiration (p<0.0001) and spare respiratory capacity (p<0.0001), while ATP-coupling efficiency 
(p=0.0014), glycolytic reserve (p=0.006) and glycolytic capacity (p=0.007) was significantly reduced. In 
both models, Q2089R cells exhibited an increase in autophagosome pool size (p<0.05 for LC3 II and p<0.05 
for P62). 
In the case of G2019S, a marked increase in autophosphorylation activity (p=0.019) was observed in 
HEK293 cells, which is in accordance with many previous studies. Decreased metabolic activity (p=0.021) 
and MMP (p=0.038) were also observed in these cells. G2019S-carrying fibroblasts displayed reduced 
metabolic activity (p<0.05) and increased basal respiration (p=0.029), ATP-linked respiration (p=0.029), 
glycolysis (p=0.001) and autophagosome pool size (p=0.022 for LC3 II). The MMP of these fibroblasts 
showed a non-significant trend for a decrease under stress conditions (p=0.057).  
Interestingly, WT LRRK2 was shown to co-localize and co-immunoprecipitate with a protein complex 
containing subunits TOM22, TOM40 and TOM70 but not TOM20 under basal conditions. Under stress 
conditions, an association between LRRK2 and TOM20 was observed while the association between LRRK2 
and the complex containing TOM22 and TOM70 increased. Finally, from our findings and the published 
literature, we propose a model for the involvement of LRRK2 (WT and Q2089R) in cellular functioning and 
cell death. This involves the loss of kinase activity and association with the TOM complex, which ultimately 
links LRRK2 with mitochondrial (dys)function, mitochondrial biogenesis and the autophagy/lysosomal 
pathway.  
In conclusion, we characterized a functional variant in the kinase domain of LRRK2 and propose additional 
functions for this large multi-domain protein. This study also provides evidence for a novel association 
between LRRK2 and the TOM complex. Interestingly, our findings challenge the notion that it is only 
increased LRRK2 kinase activity that is implicated in PD pathogenesis. We acknowledge, however, that our 
findings are preliminary and that further validation studies are necessary to validate our results and 
hypothesis. Future targeted experiments on LRRK2 are needed in order to unravel the complex 
pathobiology and to decipher the sequence of events that lead to development of PD in susceptible 
individuals. 
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Opsomming 
Parkinson se siekte (PS) is ‘n ongeneesbare neurodegeneratiewe versteuring wat gekenmerk word deur 
die progressiewe verlies van dopaminergiese neurone in die brein van geaffekteerde individue. Beide 
omgewings- en genetiese faktore dra by tot die etiologie van PS, met meer as ‘n dosyn gene wat 
geïmpliseer word by die ontwikkeling van hierdie siektetoestand. Desondanks moet die presiese 
meganisme waardeur elke geen (en mutasie) bydra tot die patofisiologie van PS nog uitgeklaar word. 
Mitochondriale disfunksie is ‘n herhalende tema wat verband hou met neurodegenerasie en die 
translokase van die buitenste mitochondriale membranekompleks (TOM), wat onlangs geïdetifiseer is as 
‘n belangrike rol-speler in die instandhouding van gesonde mitochondria. Die TOM kompleks wat 
hoofsaaklik bestaan uit TOM20, TOM22, TOM40 en TOM70 is betrokke by die vervoer van kern-
geënkodeerde proteïene tot binne in die mitochondria waar dit benodig word vir normale mitochondriale 
funksionering. Mutasies in die LRRK2 geen is die mees algeneme oorsaak van outosomale dominante PS 
en die LRRK2 proteïen word geassosieer met talle sellulêre funksies insluitend mitochondriale 
homeostase, die autophagy/lisosomale pad weg, sellulêre seine en sinaptiese vesikulêre vervoer. Die 
mees algemene PS-veroorsaakende mutasie, G2019S, is geleë in die kinase domein en verhoog kinase 
aktiwiteit van LRRK2. Lede van hierdie navorsingsgroep het onlangs ‘n nuwe variant (Q2089R) 
geïdentifiseer in LRRK2. Hierdie variant is ook geleë in die kinase domein van LRRK2 en vereis verdere 
ondersoek ten einde vas te stel of dit wel patogenies is. Die doel van die huidige studie was om funksionele 
kenmerke van wilde tipe (WT) en gemuteerde LRRK2 (G2019S en Q2089R) te ondersoek onder normale 
asook stremmings [Carbonyl cyanide m-chlorophenyl hydrazone (CCCP)] kondisies en ook om te bepaal 
of WT LRRK2 interaksie toon met die subeenhede van die TOM kompleks. 
Die frekwensie van LRRK2 Q2089R is vasgestel in Suid-Afrikaanse PS pasiënte en kontroles deur die 
gebruik van n Taqman™ SNP genotipeerings toets. In silico analise van die aminosuur verandering van 
Glutamien (Q) tot Arginien (R) is uitgevoer met behulp van verskeie voorspellings algoritmes. Twee 
sellulêre modelle van PS, insluitend (1) HEK293 selle wat getransfekteer is met WT en gemuteerde LRRK2 
vektore sowel as (2) pasiënt dermale fibroblaste, is gebruik vir fuksionele studies. LRRK2 mutante vektore 
was gegenereer deur gebruik te maak van plek-gerigte mutagenese in pcDNA-DEST53, ‘n soogdier 
uitdrukkings vektor. Velbiopsies van individue wat die G2019S, Q2089R of WT LRRK2 dra is gebruik om 
fibroblaste te kweek en te gebruik as ‘n ex vivo model vir die siekte. Die kinase aktiwiteit van LRRK2 is 
ondersoek deur gebruik te maak van outofosforilasie van Serien 1292 en Westerse klad analise. Sel-
metaboliese aktiwiteit is gemeet met behulp van ‘n 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromied (MTT) toets en die mitochondriale membraan potentiaal (MMP) is gemeet deur die JC-1 
fluorochroom en vloei-sitometrise ontleding. Mitochondriale en glikolitiese respirasie eksperimente was 
uitgevoer met behulp van die Seahorse XF Analyzer en die mitochondriale DNA kopiegetal is bepaal deur 
kwantitatiewe “real-time PCR (qRT-PCR)”. Merkers van autophagy, LC3 II en P62, is opgespoor met behulp 
van Westerse klad analise. Co-lokaliserings eksperimente van LRRK2 en die TOM kompleks is uitgevoer 
met behulp van konfokale en super resolusie gestruktureerde verligtings mikroskopie (SR-SIM), terwyl 
proteïen interaksies ondersoek is met behulp van mede-immunopresipitasie en Westerse klad analise. 
Die frekwensie van Q2089R was 0.2% (1/493) in PS pasiënte en 0.1% (1/776) in kontrole individue. 
Verskeie in silico toetse het voorspel dat die Q na R vervanging moontlik patogenies sal wees [‘nadelig’ 
(CADD telling=24.1), ‘moontlik skadelik’ (PolyPhen) en ‘siekte-veroorsakend’ (Mutation Taster)]. Die 
LRRK2 vektore was suksesvol gegenereer en die fibroblaste is suksesvol gekweek. In HEK293 selle is bevind 
dat Q2089R byna heeltemal die outofosforilasie aktiwiteit van LRRK2 afgeskaf het (p=0.026). Q2089R-
draende selle het ook ‘n afname in sel-metaboliese aktiwiteit getoon in HEK293 selle (p=0.016) en 
fibroblaste (p<0.05). Verder, in beide seltipes het die MMP aansienlik afgeneem [(p=0.043 en p=0.009 vir 
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HEK293 selle en fibroblaste (onder stres), onderskeidelik)]. In Q2089R-fibroblaste was n toename in basale 
respirasie (p=0.012), proton lek respirasie (p=0.0001), maksimale respirasie (p<0.0001) en vrye 
respiratoriese kapasiteit (p<0.0001) waargeneem, terwyl ATP-koppelings doeltreffendheid (p=0.0014), 
glikolitiese reserwe (p=0.006) en glikolitiese kapasiteit (p=0.007) aansienlik verminder is. In beide modelle 
van Q2089R is die autophagosoom poel grootte verhoog (p<0.05 vir LC3 II en p<0.05 vir P62). 
In die geval van G2019S, in ooreenstemming met veskeie vorige studies, is n verhoging in outofosforilasie 
aktiwiteit waargeneem in HEK293 selle. Verminderde sel lewensvatbaarheid (p=0.021) en MMP (p=0038) 
is ook opgemerk in hierdie selle. G2019S-draende fibroblaste het n afname getoon in selproliferasie terwyl 
basale respirasie (p=0.029), ATP-gekoppelde respirasie (p=0.029), glikoliese (p=0.001) en autophagosoom 
poel grootte (p=0.022 vir LC3 II) toegeneem het. Die MMP van hierdie fibroblaste het 'n nie-beduidende 
tendens van afname onder stremming getoon (p=0.057).  
Interessant genoeg is dit bevind dat WT LRRK2 co-lokaliseer en mede-immunopresipiteer met ‘n proteïen 
kompleks wat TOM22, TOM40 en TOM70 maar nie TOM20 bevat onder normale toestande nie. Onder 
stremming is 'n assosiasie tussen LRRK2 en TOM20 waargeneem terwyl die assosiasie tussen LRRK2 en die 
kompleks wat TOM22 en TOM70 bevat toegeneem het. Laastens, uit ons bevindinge en vanuit die 
gepubliseerde literatuur, stel ons 'n model voor vir die betrokkenheid van LRRK2 (WT en Q2089R) in sel 
funksionering en seldood. Dit behels die verlies van kinase aktiwiteit en assosiasie met die TOM kompleks, 
wat uiteindelik LRRK2 heg met mitochondriale (dis)funksie, mitochondriale biogenese en die 
autophagy/lisosomale pad weg. 
Ten slotte is daar ‘n funksionele variant in die kinase domein van LRRK2 gekarakteriseer en bykomende 
funksies vir hierdie groot multi-domein proteïen voorgestel. Hierdie studie bied ook bewyse van 'n nuwe 
assosiasie tussen LRRK2 en die TOM kompleks. Daarenteen bevraagteken hierdie studie die idee dat dit 
net verhoogde LRRK2 kinase aktiwiteit is wat betrokke is by PS ontwikkeling. Die navorsers van hierdie 
studie erken egter dat die bevindinge voorlopig is en dat verdere verifiering studies nodig is om die 
resultate asook hipotese te bevestig. Toekomstige geteikende eksperimente op LRRK2 is nodig om die 
komplekse patobiologie te ontrafel en om die volgorde van gebeure te ontsyfer wat aanleiding gee tot die 
ontwikkeling van PS in vatbare individue. 
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1.1 Introduction to Parkinson’s disease 
Parkinson’s disease (PD) is a common, incurable neurodegenerative disorder of the central nervous 
system affecting approximately 1% of individuals over the age of 60 and up to 5% of individuals aged over 
85 years (Reeve et al., 2014). Clinically, PD is characterized by the pronounced loss of dopaminergic 
neurons in the substantia nigra pars compacta in the midbrain (Figure 1.1) which ultimately causes 
impairment of the individual’s motor skills. These motor symptoms include resting tremor, rigidity and 
slowness of movement (bradykinesia). The reduction in neurotransmitter dopamine levels at the nerve 
terminals lead to the dysregulation of motor circuits. In addition to affecting an individual’s movement, 
motor circuit dysregulation disrupts the psychiatric and cognitive states of PD patients, and these are 
referred to as the non-motor symptoms (Cookson and Bandmann, 2010).  
 
Figure 1.1 A diagram of the midbrain and region affected by Parkinson’s disease. The cross-section 
images of the midbrain showing the diminished pigmentation of the dopamine-producing neurons in the 
substantia nigra of Parkinson’s disease affected individuals (bottom right) compared to the dark 
pigmented neurons of healthy individuals (top right). Taken with permission from 
http://www.braintrainuk.com/other-conditions-that-neurofeedback-supports/neurofeedback-for-
parkinsons/   
 
Even though previous research provided significant insight into neurodegenerative disorders, currently 
no treatment is available to prevent neurodegeneration progression in PD (Xiong et al., 2009). One of the 
major difficulties with this disorder is that 50-60% of nigral neurons and up to 80-85% of dopamine have 
been depleted when individuals first present with symptoms (Marsden, 1982; Isacson, 2002). These 
neurons never regenerate and thus highlights the importance for the identification of biomarkers for 
earlier disease detection and diagnosis. Therefore, more research is necessary to improve our 
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understanding of the molecular basis of the processes involved in PD. This knowledge is critical in order 
to facilitate development of effective neuroprotective strategies or even a cure for the disease. 
The global prevalence of PD has been estimated to be between 41 and 1,903 per 100,000 individuals 
between 40 and 80 years of age (Pringsheim et al., 2014). The incidence rate is reported to range from 3 
to 105 per 100 000 individuals of a population that is between 40 and 80 years of age (Hirsch et al., 2016). 
However, much lower prevalence and incidence rates are reported for countries in Sub-Saharan Africa 
(SSA) (Dotchin et al., 2008). These lower figures are thought to be underestimates due to the fact that 
patients are either misdiagnosed with diseases other than PD, or remain undiagnosed (Okubadejo et al., 
2006; Akinyemi, 2012). It could also be attributed to under-reporting where individuals diagnosed with 
PD do not declare their disease status in the fear of being stigmatized (Silberberg and Katabira, 2006; 
Kaddumukasa et al., 2015) or that patients living in rural areas will seek help from traditional healers 
instead of visiting medical facilities (Dotchin et al., 2008). Furthermore, the lack of appropriate medical 
and scientific equipment, the relatively poor medical infrastructure, and the low number of neurologists 
and movement disorder specialists, contribute to the limited knowledge on PD in SSA countries 
(Okubadejo et al., 2006; Dotchin et al., 2008). The lower frequency of PD in SSA could also be ascribed to 
the differences in age-distribution in these populations (Akinyemi, 2012). Another important reason for 
region/country specific prevalence differences could be due to different methodologies used for the 
studies. The genetic causes of PD in SSA, specifically in South African populations including the black and 
Afrikaner populations, has not yet been established (Merwe et al., 2012; Blanckenberg et al., 2013; Carr 
and Coller, 2014). This indicates that SSA populations carry unique mutations that remain to be identified. 
As increased age is a significant risk factor for PD, the prevalence of this disorder is set to increase 
significantly worldwide. It has been projected that the number of individuals with PD in five of Western 
Europe’s most populated nations (Germany, France, United Kingdom, Italy and Spain) will double by the 
year 2030 (from 4.6 million to approximately 9.3 million individuals) (Dorsey et al., 2007). More recently 
the rise in PD prevalence was predicted for both developed (in Europe and North America) and developing 
(Tanzania) countries with an estimated increase of 92% and 184%, respectively by the year 2050 (Bach et 
al., 2011; Dotchin et al., 2012). This alarmingly high increase in Tanzania, is in line with the rapidly changing 
population demographics in SSA, where the numbers of individuals aged 60 years and older in SSA 
countries are predicted to double by the year 2030 (and again by 2050) thus surpassing the numbers 
projected for many other regions including North America (Okubadejo et al., 2006; Velkoff and Kowal, 
2006). 
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PD was previously thought to be the archetypal environmental disorder and has been associated with 
various factors such as well-water drinking and exposure to pesticides (Preux et al., 2000; Adler, 2009). 
However, it has since been recognized that both genetic and environmental factors contribute to 
development of the disease (Sherer et al., 2002; Dawson, 2003). This, in conjunction with evidence of 
substantial phenotypic diversity between PD patients, led researchers to postulate that several different 
genes and various pathways could be involved in PD pathogenesis (Moore et al., 2005; Wirdefeldt et al., 
2011). To date, mitochondrial dysfunction, oxidative stress, autophagy, protein aggregation and 
misfolding and impaired drug and toxin management have all been implicated in neurodegeneration and 
PD development (Cookson and Bandmann, 2010; Wallings et al., 2015).   
 
 1.2 Genes implicated in Parkinson’s disease 
Over the past two decades, several PD-causing genes have been identified (Table 1.1). Although these 
genes have been the focus of many studies, the function of proteins such as P5 Subfamily of ATPase 
(ATP13A2) and Leucine rich repeat kinase 2 (LRRK2) has not yet been fully elucidated. Without a 
comprehensive understanding of PD-causing mutations and their functions, development of appropriate 
and effective therapeutic intervention will not be possible. Therefore, further investigation into these 
proteins and their corresponding functions are of upmost importance. The present study will focus on 
LRRK2 and will involve an investigation into its possible functions in cellular models of PD. 
 
1.2.1 LRRK2: discovery, domain structure and functions 
LRRK2, is located at the PARK8 locus on chromosome 12p11.2-q13.1 and encodes a large multi-domain 
protein comprising 2,527 amino acids (Funayama et al., 2002; Guo et al., 2006). Mutations in LRRK2 were 
first implicated in autosomal dominant (AD) late-onset PD using high-resolution recombination mapping 
and candidate gene sequencing (Paisán-Ruıź et al., 2004; Zimprich et al., 2004; Funayama et al., 2005). 
One of the first mutations, I2020T, was reported in a family from Germany (Zimprich et al., 2004)and later 
it was found in the original PARK8-linked Japanese family (Funayama et al., 2002, 2005). Later, several 
other families across different populations with AD late-onset PD was identified to carry mutations in 
LRRK2. 
The protein product of LRRK2, which mainly localizes to the cytoplasm and the outer mitochondrial 
membrane, contains several potential protein-protein interaction sites surrounding the core region 
(Biskup et al., 2006; Cookson, 2010). LRRK2 also consists of several functional domains which include an 
armadillo repeats (ARM) region, an ankyrin repeats (ANK) region, the leucine-rich repeat (LRR) domain, a 
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ROC GTPase domain, a C-terminal of Roc (COR) domain, a protein kinase catalytic domain (KIN) and a 
WD40 domain (Figure 1.2) (Smith et al., 2005; Lobbestael et al., 2013).   
  
Figure 1.2 Schematic diagram of LRRK2. The most extensively studied pathogenic mutations are 
illustrated on top (red). G2385R (orange) is an established susceptibility allele for PD. In vitro 
autophosphorylation sites are shown in green and cellular phosphorylation sites are indicated in blue at 
the bottom of the image. Modified from (Lobbestael et al., 2013; Steger et al., 2016). 
 
The ROC and COR domains are connected and function as a single unit (Bosgraaf and Van Haastert, 2003). 
These domains have GTPase activity, which hydrolyses GTP to GDP to donate a phosphate group to other 
proteins/pathways and act as molecular switches, regulates various processes including vesicular 
transport and cytoskeletal reorganization (Guo et al., 2006). Additionally, the ROC and COR domains are 
typically preceded by a LRR domain which serves as a protein recognition site and is involved in protein-
protein interactions (Kobe and Kajava, 2001). Similarly, the ARM domain, the ANK domain (both at the N-
terminal) and the WD40 domain (at the C-terminal) have also been shown to be involved in protein-
protein interactions (Sedgwick and Smerdon, 1999; Guo et al., 2006; Gilsbach and Kortholt, 2014). The 
kinase domain, which follows the COR domain, is responsible for phosphorylation of various proteins and 
plays an important role in signal transduction within the cell (Gilsbach and Kortholt, 2014). 
LRRK2, and its homolog LRRK1, form part of the ROCO protein family and are believed to be the only 
members of this family to harbor a GTPase and a kinase domain within the same protein (Biskup et al., 
2006). LRRK1 and LRRK2 are known to form heterodimers. Although, LRRK1 has not been directly 
implicated in PD, it has been shown  that a missense mutation in LRRK1 (L416M) resulted in a younger age 
of PD onset in a large LRRK2 G2019S Tunisian population consisting of familial and sporadic PD individuals 
(Dachsel et al., 2010). Additionally, several novel non-synonymous variants were identified in LRRK1 
through exome sequencing of affected individuals from a family with late-onset PD (Schulte et al., 2014). 
Although these variants did not affect cell viability and subcellular localization, the results suggest a role 
for LRRK1, in combination with LRRK2, as a possible disease-modifier. 
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Table 1.1 Genes that have been implicated in Parkinsonism 
Gene 
symbol 
Gene/ Protein name Inheritance    Proposed or known function           Reference(s) 
SNCA   Alpha synuclein AD Regulation of dopamine release and transport (Polymeropoulos et al., 1997) 
PARK2 
(Parkin) 
Parkin AR Removal of abnormal or damaged proteins and mitochondria 
(mitophagy) 
(Kitada et al., 1998) 
SCA2 Spinocerebellar ataxia type 2 protein AD Epidermal Growth Factor Receptor (EGFR) trafficking (Gwinn-Hardy et al., 2000) 
SCA3 Spinocerebellar ataxia type 3 protein AD Protein homeostasis and degradation of misfolded chaperone 
substrates 
(Gwinn-Hardy et al., 2001) 
DJ-1 Oncogene DJ-1 AR Protects cells against oxidative stress and cell death (Bonifati et al., 2003) 
GBA Glucocerebrosidase - Provides instructions for making beta-glucocerebrosidase which is 
active in lysosomes 
(Tayebi et al., 2003) 
LRRK2 Leucine rich repeat kinase 2 AD Phosphorylation of proteins, cell signaling and protein interactions (Paisán-Ruıź et al., 2004; 
Zimprich et al., 2004) 
PINK1 PTEN putative induced kinase AR Protects against mitochondrial dysfunction during cellular stress 
and involved in mitophagy 
(Valente et al., 2004) 
ATP13A2 P5 Subfamily of ATPase AD Intracellular cation homeostasis and the maintenance of neuronal 
integrity 
(Ramirez et al., 2006) 
FBXO7 F-Box Protein 7 AR Phosphorylation-dependent ubiquitination and regulation of 
hematopoiesis 
(Di Fonzo et al. 2009; Shojaee 
et al. 2008) 
PLA2G6 Phospholipase A2 Group 6 AR Involved in apoptosis and in regulating transmembrane ion flux (Paisan-Ruiz et al., 2009) 
VPS35 Vacuolar sorting protein 35 AD Transport of proteins from endosome to trans-Golgi network (Vilariño-Güell et al., 2011) 
EIF4GI Eukaryotic translation Initiation 
Factor 4 Gamma 1 
AD Recruitment of mRNA to the ribosome (Chartier-Harlin et al., 2011) 
DNAJC6 DnaJ heat shock protein family 
(Hsp40) member C6 
AR Regulate molecular chaperone activity by stimulating ATPase 
activity 
(Edvardson et al., 2012)  
SYNJ1 Synaptojanin 1 AR Synaptic transmission and membrane trafficking (Krebs et al., 2013; Quadri et 
al., 2013) 
DNAJC13 DnaJ heat shock protein family 
(Hsp40) Member C13 
AD Involved in membrane trafficking through early endosomes and 
plays a role in clathrin-mediated endocytosis 
(Vilariño-Güell et al., 2014) 
CHCHD2 Coiled-coil-helix-coiled-coil-helix 2 AD Possible role in oxidative phosphorylation (Funayama et al., 2015) 
TMEM230 Transmembrane protein 230 AD Involved in synaptic vesicle trafficking  (Deng et al., 2016) 
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; 
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In terms of the physiological processes in which LRRK2 is involved, the recurring cellular themes are 
vesicle cycling, autophagy, mitochondrial stress response (fission/fusion), miRNA processing and 
cytoskeletal regulation (Figure 1.3) (Sanna et al., 2012; Wallings et al., 2015). These processes are also 
highlighted in the Parkinson’s Disease Map (PDMap) (http://minerva.uni.lu/MapViewer/). Although it 
is not clear if these represent independent roles for LRRK2, it is certainly possible that LRRK2 might 
have important roles in a number of cellular processes given its multiple domain structure (Lazarou et 
al. 2012; Paisán-Ruiz et al. 2013).  
 
Figure 1.3 Schematic representation of LRRK2’s cellular functions. The diagram shows the cellular 
processes that have been associated with LRRK2 function in physiology and/or disease including 
mitochondrial functional, reactive oxygen species (ROS) stress response and autophagy. Reproduced 
with permission from (Wallings et al., 2015). 
 
A domain in LRRK2 that is of interest to the present study, especially with regards to PD pathogenesis, 
is the protein kinase domain. Protein kinases phosphorylate proteins on their serine (Ser), threonine 
(Thr), tyrosine (Tyr) or histidine (His) residues. Kinases are enzymes that transfer phosphate groups 
from donor molecules to specific substrates, and are used to transmit cellular signals to control inter-
cellular and intra-cellular processes. Phosphorylation is a reversible process and has been shown to 
modulate protein activity, regulate localization of proteins to a specific cellular compartment, stabilize 
proteins or target them for degradation (Cohen, 2001). Additionally, it has also been shown to affect 
protein-protein interactions by initiating or disrupting such interactions. 
 
1.2.2 PD-causing mutations of LRRK2 
Mutations in LRRK2 are the most common cause of PD worldwide (Paisán-Ruıź et al., 2004; Zimprich 
et al., 2004; Wirdefeldt et al., 2011), accounting for approximately 10% of AD PD and 4% of sporadic 
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PD cases in several European and US populations (Lesage and Brice, 2009). These mutations are 
typically associated with late-onset familial AD or sporadic forms of PD. Interestingly, only a few of 
these variants are considered to be pathogenic mutations (Figure 1.2). 
LRRK2 has 51 exons, however mutation screening studies mainly focus on exons 19, 24, 31, 35, 38 and 
41 since most of the PD-causing mutations reside in these particular exons (Foroud, 2005; Klein and 
Westenberger, 2012). Well-established pathogenic mutations include R1441C (exon 31) (Zimprich et 
al., 2004), R1441G (exon 31) (Paisán-Ruıź et al., 2004) and R1441H (exon 31) (Mata et al., 2005) (Roc 
GTPase domain), Y1699C (exon 35) (Paisán-Ruıź et al., 2004) (COR domain), G2019S (exon 41) (Di 
Fonzo et al. 2005) and I2020T (exon 41) (Zimprich et al., 2004; Funayama et al., 2005) (kinase domain) 
and the susceptibility allele, G2385R (exon 48) (WD40 domain) (Figure 1.2). Very recently, Mata and 
co-workers discovered another mutation, R1441S, in the Roc domain of LRRK2 (Mata et al., 2016). 
Numerous other mutations have also been identified including R1628P, N1437H, S1761R and 
E1874Stop, although it is unclear at this stage whether these mutations are truly pathogenic or not 
(Doggett et al., 2012; Lorenzo-Betancor et al., 2012; Mata et al., 2013; Li et al., 2014). Generally, the 
mutations in the Roc and COR domains, decrease GTPase activity, whereas mutations in the kinase 
domain e.g. G2019S increase kinase activity (Greggio et al., 2006; Guo et al., 2007; Lewis et al., 2007). 
However, the exact mechanism by which LRRK2 mutations result in disease remains unclear. The 
increased kinase activity observed with the G2019S mutation suggest a gain-of-function mechanism 
of LRRK2-linked disease, with a central role for kinase activity in PD development. However, other 
studies have reported variable findings for the I2020T mutation also located in the kinase domain; 
showing either increased kinase activity (Gloeckner et al., 2006; Ray et al., 2014; Ho et al., 2016), no 
change in kinase activity (Anand et al., 2009) or even a decrease in kinase activity (Jaleel et al., 2007a; 
Reynolds et al., 2014).  
Both the G2019S and R1441C mutations have been shown to play a role in post-synaptic calcium (Ca2+) 
imbalance, which lead to the excessive clearing of mitochondria from dendrites through a specialized 
form of autophagy known as mitophagy (Cherra et al., 2013). More recently it was shown that 
mutations in the ROC-COR domain of LRRK2 disrupts axonal transport in vitro and in vivo (Godena et 
al., 2014). These mutants induce locomotor deficits through the binding of de-acetylated 
microtubules. When microtubule acetylation increases the axonal transport and locomotor deficits 
are restored, identifying a possible therapeutic mechanism for PD. 
The frequency of the most common LRRK2 PD-causing mutation, G2019S, fluctuates across 
populations and is found to be most common in North African Arabs (30-40%) and Ashkenazi Jewish 
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populations (10-30%) primarily due to founder effects, and rare in Asian populations (0.4% in Japan) 
(Lesage et al., 2010; Alcalay et al., 2013; Trinh et al., 2014).  
1.2.3 LRRK2’s kinase domain and possible substrates 
Proteins with kinase activity assist in phosphorylation of target molecules, which is an essential step 
in turning on and off many cellular activities, whereas the GTPase activity in proteins may be involved 
in proliferation and differentiation (Scheffzek and Ahmadian, 2005). When LRRK2 was first implicated 
in PD pathogenesis, a great deal of focus was aimed towards the kinase domain of this protein. As 
mentioned, numerous studies have found that G2019S exhibits an increased kinase activity however 
this is not the case for all of the other PD-causing mutations, and further studies on the kinase activity 
are therefore warranted. Cellular phosphorylation and autophosphorylation assays on LRRK2 
confirmed kinase activity of endogenous as well as overexpressed forms of the protein (West et al., 
2005; Gloeckner et al., 2006; Smith et al., 2006; Sen et al., 2009). LRRK2’s  kinase activity is dependent 
on its ability to form homodimers and is regulated by its GTPase activity (Gloeckner et al., 2006; West 
et al., 2007; Sen et al., 2009; Webber et al., 2011). Numerous cellular phosphorylation sites have been 
identified in LRRK2 including Ser910, Ser935, Ser955 and Ser973 (Dzamko et al., 2010; Doggett et al., 2012). 
However, these are not LRRK2 autophosphorylation sites per se, but are believed to be regulated by 
LRRK2’s kinase activity, and have previously been used as an indirect measure of kinase activity. This 
was possible since the phosphorylation status of these cellular phosphorylation sites are linked to 
pathogenic LRRK2 mutations (Zhao et al., 2012; Reynolds et al., 2014).  
Recently, Ser1292 was identified as an autophosphorylation site in vitro and in vivo (Sheng et al., 2012). 
Autophosphorylation of Ser1292 has been used as an indirect measure of LRRK2’s kinase activity and it 
has been suggested that autophosphorylation could potentially be a useful tool to determine the 
degree of kinase activity in experimental and pathological conditions (Sheng et al., 2012; Reynolds et 
al., 2014). The development of phospho-specific antibodies, such as anti-LRRK2 phospho-Ser1292, 
serves as a convenient method for the detection of autophosphorylation in vitro, and analysis of 
autophosphorylation mutants could aid in elucidating the role of each domain in the regulation of 
LRRK2’s functions (Sheng et al., 2012; Reynolds et al., 2014).  
A variety of physiological kinase substrates have been proposed for LRRK2 with the consensus 
phosphorylation sequence for LRRK2 being F/Y-x-T-x-R/K (Pungaliya et al., 2010). LRRK2 was shown to 
phosphorylate threonine 558 in moesin (a protein responsible for anchoring the actin cytoskeleton to 
the plasma membrane), the peptide LRRKtide (a synthetic substrate of LRRK2) as well as myelin basic 
protein (MBP) which is responsible for myelination of nerves (West et al., 2005; Jaleel et al., 2007a). 
G2019S mutant LRRK2 has since been shown to also phosphorylate and bind to Beclin-2 (Bcl-2) at the 
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threonine at position 56 (Su et al., 2015). Results from this study show that the expression of Bcl-2 
phosphor mutant (Bcl-2 T56A) abolishes mitochondrial depolarization and autophagy induced by 
G2019S mutants in an overexpression model. Furthermore, Ho and colleagues showed that LRRK2 also 
phosphorylates the threonine at positions 304 and 377 in p53, a tumor suppressor (Ho et al., 2015). 
Additionally, the ribosomal protein s15 was also shown to be a pathogenic substrate of LRRK2, 
indicated by the significant increase in phosphorylation by mutant LRRK2 (G2019S and I2020T)  in a 
Drosophila melanogaster model (from now on referred to as Drosophila) as well as in a human 
neuronal model of PD (Martin et al., 2014). The G2019S mutant-induced dopamine neuronal 
degeneration and neurite loss could be rescued by the substitution of the threonine at position 136 in 
s15 with an alanine. It was subsequently postulated that elevated mutant LRRK2 phosphorylation of 
substrates, such as s15, could contribute to LRRK2-mediated toxicity. 
Recently, phosphoproteomics, genetics, and pharmacology was used to identify additional substrates 
of LRRK2 (Steger et al., 2016). It was shown that LRRK2 is able to phosphorylate a subset of Rab 
GTPases namely Rab3a, Rab7a, Rab8a, Rab10 and Rab12 on conserved residues both in vivo and in 
vitro, recognizing them as true physiological substrates of LRRK2. Thus, identifying additional functions 
of LRRK2 in protein cycling between the cytosol and membrane compartments and Rab homeostasis.  
 
1.3 Parkinson’s disease and mitochondrial dysfunction  
Substantial evidence exists for a key role of mitochondrial dysfunction in PD. Mitochondria are highly 
dynamic organelles that perform a variety of essential physiological functions in all eukaryotic cells 
(Chan, 2006; Perier and Vila, 2012). This includes the control of apoptosis in response to both 
intracellular and extracellular events, Ca2+ homeostasis, importing of mitochondrial proteins and the 
production of energy in the form of ATP via oxidative phosphorylation (Perier and Vila, 2012; Dudek 
et al., 2013; Abeliovich and Dengjel, 2016). ATP is produced as a result of the transfer of electrons 
from NADH (reduced nicotinamide adenine dinucleotide) or FADH2 (reduced flavin adenine 
dinucleotide) to oxygen (O2) in the inner mitochondrial membrane (IMM) through a selection of 
complexes (complex I-V) (Berg et al., 2002). 
Some of the earliest evidence for the involvement of mitochondrial dysfunction in PD, came from the 
observation of Parkinsonism in heroin abusers who were accidentally exposed to 1-methyl-4-phenyl-
1,2,3,4-tetrahydropyridine (MPTP) (Langston et al., 1983). This inhibitor of complex I of the 
mitochondrial electron transport chain (ETC) can cross the blood-brain barrier and cause substantia 
nigra dopaminergic neuronal cell death which results in irreversible features of Parkinsonism. 
Following oxidation of MPTP to MPP+, MPP+ accumulates in mitochondria and thus inhibits NADH 
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ubiquinone oxidoreductase (complex I). Exposure to environmental toxins, such as pesticides, that 
inhibit mitochondrial respiration and promotes the production of reactive oxygen species (ROS) is 
another mechanism implicated in PD development (Greenamyre and Hastings, 2004; Dias et al., 2013). 
The increased production of ROS is a general by-product of mitochondrial impairment, which could 
explain the oxidative damaged lipids, DNA and proteins and the decrease in complex I activity detected 
in the brains of PD patients (Dias et al., 2013; Hwang, 2013). The inhibition of mitochondrial complex 
I has also been implicated in ubiquitin proteasome system (UPS) dysregulation by producing a toxic 
build-up of oxidatively damaged proteins (Shamoto-Nagai et al., 2003). 
Notably, a number of PD-causing genes are known to be involved in the maintenance of healthy 
mitochondria including PARK2 (hereafter referred to as Parkin), PINK1, DJ-1 and SNCA. Also, 
mitochondrial dysfunction including respiration deficits, oxidative stress and Ca2+ homeostasis, have 
been observed in almost all genetic models of PD including PINK1, Parkin, DJ-1 and LRRK2 mutant or 
deficient models (Zhu and Chu, 2010). These models range from invertebrates such as Caenorhabditis 
elegans (C. elegans), Drosophila and zebrafish to vertebrates such as dog, monkey, mouse as well as 
patient-derived cell lines (fibroblasts or induced pluripotent stem cells - iPSCs). 
DJ-1 mutant studies in animal models have revealed decreased mitochondrial membrane potential 
(MMP), decreased mitochondrial complex activities and increased ROS (Wang et al., 2012a). The role 
of DJ-1 in mitophagy is still unclear although it has been suggested that a decrease in MMP results in 
the translocation of DJ-1 to the OMM, where mitophagy would be initiated through as-yet-unknown 
processes. In wild type (WT) form, the DJ-1 protein protects the cell against oxidative stress (Bonifati 
et al., 2003). However, when PD-causing mutations are present in DJ-1, the DJ-1 protein is not able to 
function normally thus eliminating its protective effect against oxidative stress. Furthermore, 
defective α-synuclein (SNCA) has also been shown to be associated with mitochondrial dysfunction 
and endoplasmic reticulum (ER) stress (Cooper et al., 2006; Martin et al., 2006; Schapira, 2008). 
Previous studies have shown that the complete knockout of PINK1 in a mouse model caused a 
decrease in dopamine release that leads to major mitochondrial defects within striatal neurons of the 
animals (Exner et al., 2007; Lutz et al., 2009; Malkus et al., 2009). Furthermore, mutant PINK1 resulted 
in dysregulation of mitochondrial Ca2+ homeostasis giving rise to the increased production of ROS.  
Parkin and PINK1 are known to work together in a pathway known as the PINK1/Parkin pathway. 
PINK1 levels are strictly controlled in healthy mitochondria by the continuous turnover of PINK1 with 
the assistance of mitochondrial membrane potential-dependent presenilin-associated rhomboid-like 
protein (PARL) cleavage (Jin et al., 2010; Narendra et al., 2010). PINK1 starts off as a 63kDa precursor 
protein in the cytosol and later becomes a 52kDa mature protein as it is translocated and imported 
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into the mitochondria. Following the import into mitochondria under normal physiological conditions, 
PINK1 is rapidly degraded and therefore confirms that these mitochondria are healthy (Figure 1.4 A).  
 
Figure 1.4 A representation of the PINK1/Parkin-mediated mitophagy. A) Under normal physiological 
conditions, when the mitochondrial membrane potential is high, PTEN-induced putative kinase 1 
(PINK1) is imported into the mitochondria and degraded to maintain low levels of endogenous PINK1 
in healthy mitochondria. B) When the mitochondrial membrane potential decreases under 
pathological conditions, PINK1 accumulates on the outer mitochondrial membrane recruiting Parkin 
through the cytoplasm to mitochondria. Parkin is responsible for ubiquitinating (Ub) several outer 
mitochondrial membrane proteins which are then recognized by autophagy protein, p62. These 
adaptor proteins link the ubquitinated cargo to the autophagosome. Damaged mitochondria are 
engulfed and upon fusion with lysosomes the content of the autolysosome is degraded. Abbreviations: 
P62, Sequestosome 1; ∆ᴪ mitochondrial membrane potential. Reproduced with permission from 
EMBO.(Exner et al., 2012).  
 
However, when mitochondria are stressed and the MMP is lost due to the treatment of cells with 
uncouplers such as the protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP), or other 
external or internal stressors, the import of PINK1 is impaired causing it to accumulate on the OMM. 
This accumulation serves as a warning signal and recruits cytosolic Parkin to the OMM (Figure 1.4 B). 
Upon activation of selected stress-signaling pathways or blockade of the mitochondrial protein 
import, Parkin’s E3 ubiquitin ligase activity is activated by the kinase activity of PINK1 which recruits 
cytosolic Parkin to stressed mitochondria (Bertolin et al. 2013). Parkin is subsequently responsible for 
the ubiquitination of several OMM proteins such as Porins, Mitofusin, and Miro proteins, which 
targets dysfunctional mitochondria for degradation (Chan et al., 2011; Narendra et al., 2012; Sarraf et 
al., 2013). This process involves the degradation of OMM proteins and autophagy-dependent removal 
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of mitochondrial fragments, known as mitophagy (Lemasters, 2005; Park et al., 2006; Narendra et al., 
2008, 2012). 
Drosophila PD models also revealed that PINK1 and Parkin function to maintain mitochondrial 
dynamics,  protecting the cell against oxidative stress and to maintain mitochondrial integrity (Clark 
et al., 2006a; Park et al., 2006; Pridgeon et al., 2007; McLelland et al., 2014; Li and Hu, 2015). This 
supports studies suggesting that mitochondrial dysfunction may be an important contributing factor 
in PD development (Schapira and Jenner, 2011; Lazarou et al., 2012). 
 
1.4 Role of the TOM complex and mitophagy in Parkinson’s disease 
In order for mitochondria to function properly, mitochondrial proteins, of which almost all are nuclear 
encoded and synthesized in the cytosol, are imported into the mitochondria through the Translocase 
of Outer Mitochondrial Membrane (TOM) complex (Figure 1.5). It has been shown that the import of 
precursor proteins into mitochondria generally occurs in a post-translational manner, and that 
cytosolic ribosomes responsible for translating mRNAs for mitochondrial precursor proteins are 
associated with the OMM (Eliyahu et al., 2010; Dudek et al., 2013). The mitochondrial targeting 
sequence (MTS) is in the precursor protein, often in the form of a cleavable N-terminal presequence 
and consists of 10-80 basic and hydrophobic amino acids (Roise and Schatz, 1988; Pfanner and 
Chacinska, 2002). Mitochondrial presequences form α-helices at the N-terminals and contain specific 
information that directs proteins to the mitochondria. In yeast the recruitment of mRNAs to the OMM 
is dependent on the outer membrane precursor protein receptors tom20 and tom70, two subunits of 
the TOM complex (Eliyahu et al., 2010; Gadir et al., 2011).  
The TOM complex, consisting of TOM5, TOM6, TOM7, TOM20, TOM22, TOM40 and TOM70 (in 
humans), is responsible for mediating the import of nearly all mitochondrial proteins. This system is 
essential for mitochondrial function and it relies on a negative MMP (Chacinska et al., 2009; Dudek et 
al., 2013; Sokol et al., 2014). The central part of the TOM complex is TOM40, an integral membrane 
protein with a β-barrel structure that forms the channel for precursor protein translocation across the 
OMM (Figure 1.5).  
TOM20 serves as the first recognition site for presequence-containing proteins and thereafter they 
are transferred to TOM22 (the central receptor). Alternatively, TOM70 functions as the initial docking 
site for precursor proteins of Inner Mitochondrial Membrane (IMM) metabolite carriers after which 
they are also transferred to TOM22. Following successful recognition, the pre-proteins are inserted 
into the TOM40 channel and imported into the mitochondria (Figure 1.5). The targeting, import and 
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sorting of precursor proteins are dependent on specific import signals with the most common signal 
being the N-terminal extension known as the presequence. Both TOM20 and TOM70 function as 
quality control proteins, serving as initial docking sites for precursor proteins and they only allow 
proteins with the appropriate identification (target signal) to enter the mitochondria. 
 
Figure 1.5 Schematic representation of mitochondrial protein import. Proteins containing pre-
sequences are directed through the TOM complex, TIM23 complex and PAM to reach the 
mitochondrial matrix via TOM20 and TOM22. Proteins containing internal target sequences are 
recognized by TOM70 and translocated to TOM22 and through TOM40, the pore subunit of the TOM 
complex. Abbreviations: MtHsp70, matrix heat shock protein 70; PAM, presequence translocase-
associated motor; TIM, translocase of the inner membrane; TOM, translocase of the outer membrane; 
∆ᴪ, mitochondrial membrane potential. Reproduced with permission from EMBO (Bolender et al., 
2008). 
 
Protein import into mitochondria through the TOM complex is essential for organelle biogenesis, and 
subsequent survival of the entire cell. Recent evidence has implicated the TOM complex in PD 
pathogenesis (Bender et al., 2013). Also, when PINK1 accumulates at the OMM of dysfunctional 
mitochondria, it does so at the TOM machinery and recruits Parkin specifically to this complex (Lazarou 
et al., 2012). Therefore, this suggest that the TOM machinery is a key molecular switch in the 
maintenance of healthy mitochondria via the PINK1/Parkin pathway and is of particular interest in the 
search for PD-causing pathways and possible therapeutic targets.  
Although the role of the TOM complex and its individual subunits in the import of PINK1 is well-
established due to studies showing the complex formation between PINK1 and the TOM subunits, the 
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exact import pathway of PINK1 remains to be elucidated (Lazarou et al., 2012; Bertolin et al., 2013; 
Kato et al., 2013). Also, whether TOM activity is a deliberate decision in the activation of mitophagy is 
unclear (Sokol et al., 2014). It has been postulated that when mitochondria becomes repolarized, the 
accumulated PINK1 on the OMM could be imported into mitochondria and thus rescue the organelle 
from mitophagy (Lazarou et al., 2012). This import is believed to be initiated by the association 
between PINK1 and the TOM complex. 
Impaired mitochondrial import through the TOM machinery was previously proposed to play a crucial 
role in the activation of the PINK1/Parkin-dependent mitochondrial clearance pathway. The core 
subunit of this complex, TOM40, is down regulated in PD patients midbrain samples and PD mouse 
models (Greene et al., 2012; Bender et al., 2013; Bertolin et al., 2013). Bertolin and colleagues 
confirmed that PINK1 accumulates at the TOM complex when mitochondrial import is blocked and 
that Parkin is in close proximity to this complex; showing a strong positive Förster resonance energy 
transfer (FRET) signal with TOM70  (Bertolin et al., 2013). This study also showed that PD-causing 
mutations in Parkin results in a weakened and disrupted interaction between Parkin and both TOM40 
and TOM70 (Bertolin et al., 2013). Subsequently, it was hypothesized that the weakened interaction 
between mutant Parkin and specific subunits of the TOM complex will lead to defective mitochondria 
not being cleared, thus acting as the primary pathogenic mechanism in autosomal recessive PD.  
Importantly, LRRK2 is also known to interact with Parkin (Smith et al., 2005). This interaction is 
confined to the cytosol and was identified for both WT and mutant forms of LRRK2 using co-
immunoprecipitation analysis. Smith and colleagues also observed an increase in cytoplasmic protein 
aggregation containing LRRK2 and enhanced Parkin-dependent ubiquitination of these protein 
aggregates when co-expressing Parkin and LRRK2 in cells (Smith et al., 2005). Furthermore, the effect 
of Parkin on the ubiquitination of these protein aggregates could possibly be ascribed to the 
stimulation of Parkin’s ubiquitin ligase activity via LRRK2 interaction; thus possibly linking LRRK2 to 
mitochondrial maintenance via a Parkin pathway. However, subsequent studies could not confirm a 
direct link between LRRK2 and Parkin (Dächsel et al., 2006). These differences could possibly be due 
to inadequate biological tools such as non-specific antibodies or techniques with low sensitivity that 
were used in early studies.  
The remaining sections of this Chapter will focus on evidence for LRRK2 playing an integral role in 
maintenance of healthy mitochondria, which forms the basis of this doctoral thesis. 
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1.5 Localization of LRRK2 to the mitochondria 
LRRK2 is located predominantly in the cytoplasm of cells and has been shown to aggregate upon 
overexpression in mammalian cells (Smith et al., 2005; Greggio et al., 2006; MacLeod et al., 2006) 
(Figure 1.6). Subsequent studies found LRRK2 to be associated with the mitochondria primarily in the 
OMM thus providing evidence for mitochondrial involvement for this protein (Biskup et al. 2006; West 
et al. 2005). Overexpression of LRRK2 in cultured cells also showed an associated with the OMM (West 
et al. 2005) and was subsequently confirmed when investigating endogenous LRRK2 in mammalian 
brain tissue (Biskup et al., 2006).  
 
Figure 1.6 Cytoplasmic localization of overexpressed LRRK2. COS7 cells were transfected with LRRK2 
(WT and mutant) that were either N-terminally (N-GFP) or C-terminally (C-GFP) tagged to GFP. GFP 
alone (top row, left) was located in the cytosol and nucleus whereas GFP-LRRK2 (top row, second and 
third panel) is localized mainly in the cytoplasm. Protein aggregates are observed upon overexpression 
of mutant LRRK2 (white arrows). Reprinted from (Greggio et al., 2006) with permission from Elserivier. 
 
Gloeckner and co-workers also found LRRK2 to be significantly associated with the OMM (Gloeckner 
et al., 2006) when it was overexpressed in human embryonic kidney (HEK293) cells and subcellular 
fractionation and fluorescence microscopy was used to determine its exact localization. Fractionation 
results showed that LRRK2 was exclusively detected in the membranous fractions which were 
enriched in mitochondria and in microsomal membranes, suggesting that LRRK2 is strongly associated 
with or possibly attached to these organelles or structures in the cytoplasm. Fluorescence microscopy 
further showed that LRRK2 co-localizes with mitochondria, (when using TOM20 immunostaining as a 
mitochondrial marker) (Figure 1.7), the ER, the Golgi apparatus and the microtubular cytoskeleton. 
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Figure 1.7 LRRK2 co-localizes to the mitochondria. Immunofluorescence microscopy show that 
overexpressed GFP-tagged LRRK2 (green) co-localizes to mitochondria (red) in HEK293 cells. TOM20 
(red) was used as the mitochondrial marker. Reproduced from (Gloeckner et al., 2006) by permission 
of Oxford University Press. 
1.6 LRRK2’s involvement in mitochondrial dynamics 
Although a variety of pathways have been suggested for the development of PD, the pathogenesis of 
this debilitating disease appears to concentrate on a small number of overlapping mechanisms 
including mitochondrial dysfunction and oxidative stress (Greenamyre and Hastings, 2004). The 
maintenance of mitochondria, including the continuous biogenesis and removal of damaged 
mitochondrial pools, are of upmost importance to normal cellular health and function. Failure to 
maintain healthy mitochondrial homeostasis has been implicated in development of PD, and is 
thought to be one of the hallmarks of neurodegeneration (Beal 1998; Chan 2006; Schon and 
Przedborski 2011; Narendra, Walker, and Youle 2012; Exner et al. 2012).  
Mitochondrial function is highly dependent on the health of the mitochondrial pool. This is controlled 
by the continuous fission and fusion of mitochondria which is reliant on a variety of proteins including 
mitochondrial fission protein 1 (Fis1) and dynamin-like protein (DRP1), (responsible for fission), and 
mitochondrial dynamin-like GTPase 1 (OPA1), mitofusion 1 (Mfn1) and mitofusion 2 (Mfn2), 
(responsible for fusion dynamics) (Chan, 2006) (Figure 1.8). Mitochondrial fusion may play a protective 
role in neurons, whereas fission is likely to aid in enhancing the general dispersion of mitochondria 
throughout high energy dependent cells such as neurons (Chen and Chan, 2009). 
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Figure 1.8: Illustration of mitochondrial dynamics. A) Mitochondrial fusion. Mitofusion-1 and 2 
(Mfn1 and Mfn2) are transmembrane GTPases in the outer mitochondrial membrane (OMM). The C-
terminals of these proteins are responsible for binding adjacent mitochondria to promote OMM 
fusion. Optic atrophy protein-1 (OPA-1) is a dynamin-related protein in the inner mitochondrial 
membrane (IMM). OPA-1 mediates the attachment and fusion of the IMM. Mitochondrial fusion is 
associated with an increase in the mitochondrial potential (Δᴪ), oxygen consumption, and ATP 
production. B) Mitochondrial fission. Two proteins, dynamin-related protein-1 (DRP1) and fission 
protein-1 (Fis1), are responsible for fission. DRP1 is a large cytosolic GTPase. Mitochondrial fission is 
associated with a decrease in ∆ᴪ, oxygen consumption, and ATP production. Reproduced with 
permission from (Chiong et al., 2014). 
Upon mitochondrial fusion, the outer and inner membranes of two organelles fuse together. This is 
followed by mixing of the mitochondrial matrix content, including the mixing of mitochondrial DNA 
(mtDNA) gene products within mitochondria. In mammalian cells, two GTPases located on the OMM 
known as mitofusins, Mfn1 and Mfn2, and one IMM dynamin family GTPase protein, OPA1, are 
essential for mitochondrial fusion. On the other hand, when mitochondria enter the process of fission 
(where mitochondria divide), a single dynamin family member, DRP1 (a mitochondrial fission regulator 
protein), is required (Smirnova et al., 2001). It has been shown that mitochondrial fragmentation is 
caused by the increased recruitment of DRP1 (Labrousse et al., 1999; Wang et al., 2008b). DRP1 is 
largely a cytosolic GTPase which is recruited and localized to specific locations on the OMM; and binds 
to adaptor proteins such as Fis1  (Chan, 2006; Bliek et al., 2013).   
Interestingly, protein interactions between WT LRRK2 and the four main regulators of mitochondrial 
dynamics (DRP1, Mfn1, Mfn2 and OPA1) have been verified in vitro (Stafa et al., 2014). LRRK2 has been 
linked to regulation of mitochondrial dynamics through a direct interaction with mitochondrial DRP1 
(Wang et al., 2012b). A study investigating the mitochondrial fragmentation caused by the expression 
of WT and G2019S LRRK2 (Niu et al., 2012) demonstrated specific interactions between both WT and 
mutant LRRK2 and DRP1 using co-immunoprecipitation analysis. Therefore, LRRK2 was responsible for 
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the recruitment of DRP1 to the OMM through cytosolic translocation, regulating mitochondrial 
dynamics (Niu et al., 2012; Wang et al., 2012b). These interactions were however independent of 
DRP1 activity, since LRRK2 was able to interact with the dominant-negative mutant form of DRP1 
(K38A) (Wang et al., 2012b).  
Subsequently, the overexpression of both LRRK2 and DRP1 was shown to lead to the recruitment of 
DRP1 from the cytoplasm exclusively to the mitochondrial membrane (Niu et al., 2012), and caused 
either rapid clearance of mitochondria, or the accumulation of mitochondria around the nuclei of 
cervical cancer (HeLa) cells. The co-dependence of LRRK2 and DRP1 on mitochondrial fragmentation 
was also interrogated using a knockdown model of DRP1 in HeLa cells (Wang et al., 2012b). 
Surprisingly, when DRP1 expression was reduced mitochondrial fragmentation also declined, 
indicating that LRRK2-induced mitochondrial fragmentation is dependent on DRP1 expression. 
To explain how LRRK2 activates DRP1 recruitment, researchers investigated the interactions between 
different forms of LRRK2 (including LRRK2 WT, LRRK2 G2019S and a kinase dead LRRK2 D1994A) and 
DRP1. DRP1 interacted with of both LRRK2 WT and G2019S (Wang et al., 2011; Niu et al., 2012). 
However, the interaction was abolished when cells expressed LRRK2 D1994A, indicating that the 
LRRK2-mediated DRP1 recruitment is dependent on the kinase activity of LRRK2. Therefore, the 
increase in LRRK2 kinase activity results in increased mitochondrial fission and decreased 
mitochondrial fusion.  
Interestingly, transmitochondrial cytoplasmic hybrid cell lines (cybrids) showed that LRRK2 kinase 
activity increases DRP1 activation through phosphorylation activity (Esteves et al., 2015). Cybrids were 
created by depleting the endogenous mtDNA of NT2 (NT2 rho0) cells with long term exposure to 
ethidium bromide, a chemical which inhibits mitochondrial DNA replication. PD patient or control 
platelet mitochondria were then isolated from blood and introduced into the mitochondria-depleted 
NT2 rho0 cells. Ultimately, these hybrid cells contained nuclear genes from the NT2 rho0 cells and 
mitochondrial genes from PD patients or controls. It has also been shown that LRRK2 G2019S cybrids 
exhibit an increase in kinase activity, similar to previous studies, which the researchers believe is a 
compensatory response to already dysfunctional mitochondria (Cardoso and Esteves, 2015). When 
the kinase activity of LRRK2 was inhibited in these cells by LRRK2-IN-1, a potent inhibitor of LRRK2 
activity, mitochondrial elongation was promoted and the level of phospho-DRP1 decreased. This 
triggered a reduction in DRP1-dependent mitochondrial fission which resulted in decreased 
mitophagy, ultimately causing accumulation of dysfunctional mitochondria. However, Luerman and 
co-workers showed LRRK2-IN-1 to be non-specific and to have off-target effects and thus highlights 
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the need to validate previous results on LRRK2 inhibition and to identify novel, and more specific 
inhibitors of LRRK2 (Luerman et al., 2014). 
The impaired mitochondrial function and morphology caused by LRRK2 G2019S in patient derived 
fibroblasts further supports the idea of mitochondrial fission/fusion dynamics underlying the distinct 
phenotypic presentations of mutant LRRK2-affected PD patients (Mortiboys et al., 2010; Wang et al., 
2012b), possibly in a PINK1/Parkin/LRRK2-associated manner. Stafa and colleagues subsequently 
proposed that the widespread distribution and multifunctional nature of LRRK2 could suggest a 
general housekeeping function in the regulation of membrane biogenesis and dynamics within 
neurons (Stafa et al., 2014).  
 
1.7 LRRK2’s involvement in mitochondrial respiration and mitochondrial 
membrane potential  
Oxidative phosphorylation within mitochondria results in the movement of protons and ions across 
the IMM, creating a voltage difference/gradient (Gottlieb et al., 2003). The difference in electrical 
potential between inner and outer membranes is defined as membrane potential and MMP is 
essential for mitochondrial processes including the production of ATP, Ca2+ uptake, detoxification of 
ROS and general mitochondria functionality (Nicholls, 2004). Essentially, MMP is responsible for ATP 
synthesis since it is the driving force behind protons being pumped through the ATP synthase complex 
(complex V) (Figure 1.9). When MMP is decreased or disrupted, both ATP production and cellular 
integrity is compromised, whereas the total loss of MMP will cause mitochondrial permeabilization 
and ultimately lead to cell death.  
Several studies have implicated LRRK2, and more specifically its kinase activity, in MMP disruption. 
For example, overexpression of LRRK2 G2019S in a human neuroblastoma cell line (SHSY5Y) causes 
mitochondrial uncoupling leading to reduced MMP and increased O2 consumption (Papkovskaia et al., 
2012). Similarly, MMP is reduced in cells expressing LRRK2 WT and more significantly in cells 
expressing LRRK2 G2019S and R1441C compared to control or vector cells (Wang et al., 2012b).  
Interestingly, MMP remained unchanged in cells expressing kinase dead forms of LRRK2 (K1347A and 
D1994A) (Wang et al., 2012b). An increase in intracellular ROS levels was also detected for LRRK2 WT 
and more so for G2019S and R1441C mutant cells compared to non-transfected or empty-vector 
transfected control cells. The loss of MMP caused by either WT or mutant LRRK2 overexpression has 
been reported in primary mouse cortical neurons, various cell lines as well as in fibroblasts from PD 
patients and is believed to play an essential role in the development of neurodegeneration 
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(Papkovskaia et al., 2012; Wang et al., 2012b; Cherra et al., 2013). Furthermore, ex vivo models in the 
form of skin fibroblasts derived from PD patients showed that LRRK2 G2019S exhibit markedly 
decreased MMP and total ATP production (Mortiboys et al., 2010). 
 
 
Figure 1.9 The mitochondrial electron transport chain (ETC). The mammalian ETC includes the NADH-
ubiquinone oxidoreductase (complex I) and cytochrome bc1 (complex III) enzymes responsible for 
proton-pumping and cytochrome c oxidase (complex IV) responsible for generating proton force 
required to drive F1FO-ATP synthase (complex V). Ubiquinone (Q), embedded in the Inner 
mitochondrial membrane (IMM), and soluble cytochrome c (Cyt c) in the Intermembrane space (IMS), 
mediates the electron transport between these complexes. Electrons from NADH enters complex I 
and are then passed through complex III and IV where molecular oxygen (O2) is used to produce water 
(H2O). As the electrons move from complex to complex, protons (H+) are pumped from the 
mitochondrial matrix to the IMS. A proton gradient is generated across IMM to drive the protons back 
to the matrix through complex V (). These protons are used to generate adenosine  triphosphate (ATP) 
from adenosine diphosphate (ADP) and inorganic phosphate (Pi). 
 
Mitochondria are the main producers of ROS in mammalian cells and when mitochondria are 
dysfunctional, oxidative stress is increased through ROS production, subsequently leading to 
continuous fission and subsequently cell death (Lin and Beal, 2006). Mitochondrial dysfunction 
includes dysfunctional ATP production and increased oxidative stress as a results of an imbalance 
between ROS production and antioxidant activity (Hwang, 2013). ROS form part of a group of 
molecules that have a shortage of electrons in their outer orbital known as free radicals (Brand and 
Nicholls, 2011). O2 is one of these molecules and contains two unpaired electrons in its outer orbital. 
ROS will scavenge these unpaired electrons in order to find stability, which leads to oxidation of these 
O2 molecules. During oxidative phosphorylation and subsequent ATP production, hydrogen peroxide 
(H2O2) and superoxide (O2-) radicals are produced in the mitochondria. When mitochondrial 
dysfunction is induced, for example through mtDNA mutations or complex I inhibition, the production 
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of ROS is dramatically increased and leads to unwanted oxidation of lipids and proteins and 
subsequently causes cellular damage. Antioxidant mechanisms are not able to manage this rapid 
increase in ROS which later causes cytochrome c to be released into the cytosol, ultimately leading to 
cell death via apoptosis. 
Oxidative stress and mitochondrial complex I inhibition were first found to be associated with PD when 
complex I deficiency was found to be present in the substantia nigra of PD patients (Parker et al., 1989; 
Schapira et al., 1989). Since then, many studies have focused on the involvement of mitochondrial 
function and ETC activity in PD development. Mitochondrial alterations were also observed when 
expressing LRRK2 G2019S in transgenic mice (Ramonet et al., 2011). 
LRRK2 is known to bind to one of the most well-known H2O2 scavengers in the mitochondria known as 
peroxiredoxin 3 (PRDX3) (Angeles et al., 2011). Mutant LRRK2 enhances PRDX3 phosphorylation in cell 
cultures, consequently decreasing peroxidase activity and increasing cytotoxicity. This was later 
confirmed in a Drosophila model of PD (Angeles et al., 2014). It was subsequently hypothesized that 
the enhanced phosphorylation and inhibition of PRDX3 antioxidant activity could be a mechanism 
involved in oxidative stress induced by the LRRK2 kinase mutant since the co-expression of PRDX3 and 
G2019S ameliorated G2019S induced peroxidase activity, neuronal cell death, shortened lifespan and 
mitochondrial defects. Oxidative stress may cause mutations in mtDNA and upregulate the apoptotic 
pathway in DA neurons. Previously, when LRRK2 (WT and G2019S) was expressed in DA cells (SN4741) 
and treated with H2O2 to mimic oxidative stress, neurotoxicity as well as intracellular ROS (to a lesser 
extent) were increased in both instances, although G2019S presented a more severe phenotype (Heo 
et al., 2010b). Similarly, it was shown that the overexpression of LRRK2 WT and LRRK2 G2019S 
significantly increase ROS levels in HEK293 cells (Niu et al., 2012). The kinase dead form of LRRK2 did 
not have any effect on ROS levels, indicating that the induction of oxidative stress via LRRK2 is 
dependent on kinase activity in this cell model. Additionally, iPSCs carrying G2019S show increased 
sensitivity to H2O2 exposure leading to an increase in the apoptotic marker, caspase 3 (Nguyen et al., 
2011). In contrast, Greggio and colleagues previously showed cellular toxicity in the absence of 
oxidative stress when over-expressing LRRK2 G2019S in neuronal cell lines (Greggio et al., 2006). Taken 
together, the evidence suggests that LRRK2 and its kinase activity are implicated in mitochondrial 
function leading to cellular toxicity however, its exact involvement in oxidative stress related pathways 
remains vague and in some cases, controversial.  
Mitochondrial dysfunction also occurs as a result of alterations in the rate of mitochondrial respiration 
(Brand and Nicholls, 2011). Cells generally operate at basal respiration (which is controlled by ATP 
turnover and substrate oxidation) but when cellular stress is induced, the demand for cellular energy 
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is increased, requiring cells to function at maximal respiratory capacity. The difference between ATP 
production via oxidative phosphorylation at basal capacity and ATP production at maximal activity is 
known as the spare respiratory capacity (Desler et al., 2012). Under normal physiological conditions, 
the spare respiratory capacity will provide cells with extra energy to manage cellular stress. However, 
when reserve respiratory capacity is not sufficient or able to provide the required energy, affected 
cells could be destined for cell death. Previously, the exhaustion of spare respiratory capacity has been 
linked to neurodegeneration in models of PD (Nicholls, 2008). Mitochondria are responsible for ATP 
production, to isolate excess Ca2+ from the cytoplasm, and to both produce and detoxify superoxide 
free radicals. When sodium (Na2+), Ca2+ and other positively charged ions enter the N-methyl-d-
aspartate receptor (NMDA receptor) on the membranes of nerve cells, a large energetic load is exerted 
on cells, sometimes utilizing the entire respiratory capacity of the mitochondria. Thus, even the 
slightest disruption in mitochondrial capacity for example caused by low concentrations of ETC 
inhibitors such as rotenone in models of PD, will exacerbate neuronal toxicity. 
 
1.8 LRRK2’s involvement in autophagy and mitophagy 
Autophagy-related genes and their associated enzymes are responsible for mediating the three 
pathways involved in autophagy; macroautophagy, microautophagy and chaperone-mediated 
autophagy (CMA). The main pathway, macroautophagy (and typically referred to as autophagy), is an 
essential process which removes damaged cell organelles as well as unused or unwanted proteins 
(Klionsky and Emr, 2000; Glick et al., 2010). Induced autophagy is essential in the initial stages of 
cellular stress but later becomes detrimental to the cell (Hayat, 2016). Macroautophagy is 
characterized by the formation of autophagosomes (Saito and Sadoshima, 2015). The formation of the 
autophagosome is induced by the autophagy-related gene (Atg6) also known as Beclin-1 (Bcl-1), 
ubiquitin-like conjugation reactions and interaction with the class III phosphoionositide-3-kinases 
(PI3KC3)/Vps34 (Kang et al., 2011). This double membrane vesicle forms around the targeted 
cytoplasmic organelles or proteins and transports the engulfed material through the cytoplasm to the 
lysosome (Figure 1.10). The autophagosomes and lysosomes fuse together to form an autolysosome, 
causing the contents of the autolysosome to be degraded by the acidic lysosomal hydrolases. 
Mitophagy is a type of macroautophagy (Cheung and Ip, 2009; Saito and Sadoshima, 2015). 
Microautophagy comprises the direct engulfment of parts of damaged organelles or unused or 
unwanted proteins into the lysosome which is then followed by degradation of the cytoplasmic 
material. 
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The third pathway, CMA, is complex and specific and includes the recognition by the heat shock 
conjugate protein of 70 kDa (hsc70)-containing complexes. Therefore, in order for the CMA-
substrate/chaperone complex to be formed, it is essential that the target protein contains the 
recognition site for hsc70 complex which will allow it to bind to the chaperone. The CMA 
substrate/chaperone complex translocates to the lysosomal membrane bound protein, which will 
recognize and bind with the CMA receptor (lysosomal-associated membrane protein 2A; LAMP-2A), 
allowing it to enter the organelle. Once recognized, the targeted substrate protein unfolds and 
translocates across the lysosomal membrane via the lysosomal hsc70 chaperone. This is a particularly 
selective pathway and is strictly regulated.  
Two of the autophagy pathways, namely macroautophagy (including mitophagy) and CMA, have been 
implicated in PD (Zhu et al., 2003; Martinez-Vicente et al., 2008; Ashrafi and Schwarz, 2013). Zhu and 
colleagues suggested a link between mitochondrial dysfunction, autophagy and the MAP kinase/ERK 
signaling pathway. Although SNCA can be degraded via CMA, mutant SNCA blocks the lysosomal 
translocation and thus disrupts SNCA degradation via the CMA pathway (Zhu et al., 2003; Martinez-
Vicente et al., 2008). Several other studies have implicated LRRK2 in the macroautophagy pathway 
showing LRRK2 localizing to lysosomal compartments and membranous structures (Biskup et al., 2006; 
Alegre-Abarrategui et al., 2009; Gómez-Suaga et al., 2012). It has also been noted that the large 
protein structure of LRRK2 contains several putative CMA motifs and that LRRK2 may potentially be a 
substrate for CMA, similar to that of SNCA (Orenstein et al., 2013). Upon further investigation it was 
shown that not only could LRRK2 WT and LRRK2 G2019S be degraded via CMA, but that high levels of 
WT LRRK2 were able to inhibit CMA. An increase in the translocation complex component, LAMP-2A, 
was observed as a response to CMA blockage via LRRK2. This increase in LAMP-2A levels was also 
detected in brains of LRRK2 transgenic mice and LRRK2 G2019S mutant patients. Orenstein and co-
workers confirmed that SNCA and LRRK2 function in similar pathways, working together to inhibit the 
typical degradation of dysfunctional proteins via CMA. The inhibition of degradation subsequently 
leads to the accumulation of unwanted proteins such as SNCA which has previously been suspected 
to underlie the development of PD. 
The majority of evidence has associated autophagy with a cytoprotective role in cells such as neurons. 
Autophagy has been shown to play a preventative role in Alzheimer’s disease, Huntington’s disease, 
spinocerebellar ataxia and some forms of familial PD and is essential for neuronal homeostasis 
(Komatsu et al., 2006; Zhang et al., 2013) where the removal of dysfunctional proteins and organelles 
are believed to aid in cell survival. However, others believe that autophagy is an essential promoter of 
non-apoptotic programmed cell death (Anglade et al., 1997; Tsujimoto and Shimizu, 2005; Ghavami 
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et al., 2014). More recent studies showed that LRRK2 and autophagy is directly associated with 
neurodegeneration (Scott et al., 2007; Plowey et al., 2008; Manzoni et al., 2013a, 2013b; Saha et al., 
2015). Therefore, it is likely that cell damage and cell death can occur either due to an increase or a 
decrease in autophagic flux, which can be defined as the rate of autophagic degradation (Nelson and 
Shacka, 2013; Loos et al., 2014). Although there is a lot of controversy surrounding the role of 
autophagy in cellular health, the maintenance of normal autophagic function and balance is crucial 
for all cells, especially non-dividing neuronal cells since the dysregulation of autophagy can 
significantly contribute to neurodegeneration (Nixon et al., 2005; Wang et al., 2006; Janda et al., 
2012). 
Mutations in the functional domains of LRRK2 lead to alterations in markers for autophagy-lysosomal 
functions when compared to WT LRRK2 cells (Plowey et al., 2008; Alegre-Abarrategui et al., 2009; 
Ramonet et al., 2011; Bravo-San Pedro et al., 2013). LRRK2’s regulatory role in autophagy response 
was investigated using human neuroglioma cells (H4), SHSY5Y as well as HEK293 cells that were 
exposed to the well-known LRRK2 inhibitor, LRRK2-IN-1 (Manzoni et al., 2013a). An increase in the 
autophagic marker light chain type 3 (LC3 II) was observed, and was later ascribed to autophagy 
induction, thus providing more evidence for the involvement of LRRK2 kinase activity in autophagy. 
When autophagy is induced, the cytosolic from of LC3 (LC3 I) is converted to LC3 II. LC3 II is then 
integrated into the lipid membrane of the autophagosomes, after which it is subsequently degraded 
with the autophagolysosome (Figure 1.10). Therefore, the amount of LC3 II present in the samples 
corresponds to the number of autophagosomes present (Mizushima and Yoshimori, 2007). 
 
Figure 1.10 Schematic diagram of macroautophagy. Autophagy is initiated by the formation of an 
isolation membrane. P62 molecules binds ubiquitinylated proteins which are transported to the 
autophagosome through the interaction between p62 and LC3 II. The autophagosome fuse to the 
lysosome to form an autophagolysosome. Reproduced with permission from (Choi and Kim, 2013). 
 
Previously, Manzoni and co-workers investigated whether autophagy is involved in a PD model 
(Manzoni et al., 2013b). PD patient derived fibroblasts carrying the G2019S, R1441G and Y1699C 
mutations were collected and results confirmed that these mutations in the kinase, ROC and COR 
domains of LRRK2 caused a significant disruption in autophagic response to starvation, supporting a 
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pathogenic mechanism in the autophagic-lysosomal pathway. Similar results were reported by others 
(Sánchez-Danés et al., 2012; Bravo-San Pedro et al., 2013). These studies used patient fibroblasts and 
neurons derived from iPSCs of patients carrying the G2019S mutation which supported the hypothesis 
that a causal link exists between impaired autophagy and the development of PD.  
Interestingly, Esteves and co-workers recently considered the impact of inhibiting LRRK2’s kinase 
activity in PD cellular function and showed that the inhibition of LRRK2 decreased normal fission 
dynamics (Esteves et al., 2015). This resulted in elongation of the mitochondrial networks which 
contributed to the inadequate degradation of dysfunctional mitochondria. Furthermore, the inhibition 
of LRRK2 stimulated the clustering of lysosomes around the nucleus through Rab7 which is said to 
impede autophagosome degradation. The Rab family proteins, only active in the GTP-bound form, are 
responsible for regulating the transport and fusion of autophagosomes and recently a study revealed 
that LRRK2 regulates a subset of Rab GTPases in vivo and in vitro (Bento et al., 2013; Toyofuku et al., 
2015; Steger et al., 2016). Although the exact mechanism by which LRRK2 interacts with Rab7 remains 
unclear (Esteves and Cardoso, 2016), it has been shown that LRRK2 acts as a negative regulator of 
Rab7 (Beilina et al., 2014) and that this protein is mainly responsible for the perinuclear localization 
of lysosomes (Bucci et al., 2000; Dodson et al., 2012). The inhibition of LRRK2 kinase activity was also 
shown to reduce autophagic degradation, highlighting the importance of this domain in autophagy 
regulation (Schapansky et al., 2014). Schapansky and others also demonstrated that silencing 
endogenous LRRK2 gives rise to autophagy induction deficits via the stimulation of toll-like receptor 4 
(TLR4) in macrophages. This study, along with others, demonstrates the importance of LRRK2 in the 
regulation and control of autophagy (Anglade et al., 1997; Plowey et al., 2008; Alegre-Abarrategui et 
al., 2009; Ramonet et al., 2011; Tong et al., 2012; Manzoni et al., 2013b) 
In summary, LRRK2’s involvement in autophagy has long been an intriguing area of study, especially 
with respect to neurodegeneration and neurodegenerative diseases. Numerous studies have 
implicated WT and mutant forms of LRRK2 in this highly dynamic and coordinated cellular process, 
providing support for the premise that LRRK2 contributes to the pathophysiology of PD by functioning 
in an autophagy-dependent pathway. 
 
1.9 The present study 
Evidence provided in the preceding sections supports the link between LRRK2 and mitochondrial 
function. Although LRRK2 has been the focus of many studies, more research is required to elucidate 
additional functions and roles of this multifaceted protein. Given the overlapping evidence of LRRK2, 
PINK1 and Parkin’s involvement in mitochondrial (dys)function, mitochondrial clearance and general 
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mitochondrial homeostasis we believe that LRRK2 could function in pathways similar to those of 
Parkin and PINK1. Furthermore, since Parkin and PINK1 are known to associate with the TOM complex 
(Bertolin et al., 2013; Kato et al., 2013) and to interact with LRRK2 (Venderova et al., 2009), we 
hypothesize that LRRK2 could possibly also associate with the TOM protein complex similar to PINK1 
and Parkin.  
Recently, members of our group identified a novel variant (Q2089R) in LRRK2. This variant is located 
in the kinase domain of LRRK2, the same domain as G2019S, and warrants further investigation. It was 
therefore hypothesized that Q2089R would affect kinase activity and that mutations in LRRK2 will 
influence metabolic activity, mitochondrial function and autophagy. Additionally, we postulated that 
LRRK2 may also interact with subunits of the TOM protein complex, which could suggest a mechanistic 
link between this protein complex, mitochondrial dysfunction and PD development. 
Therefore, the aim of the present study was to functionally characterize WT and mutant LRRK2 
(Q2089R and G2019S) using a variety of techniques and approaches, such as basal and stress-induced 
growth conditions using DMSO and CCCP (a potent mitochondrial uncoupler) respectively, in different 
cellular models. Also, we aimed to investigate the potential association between WT LRRK2 and the 
TOM protein complex. The aim was achieved through the following objectives: 
1. To determine the frequency of the LRRK2 Q2089R variant in South African PD patients and 
controls using TaqMan™ allelic discrimination.  
2. To use in silico tools including SIFT, Polyphen, Mutation Taster, Combined Annotation 
Dependent Depletion (CADD) scores, Project Hope, SWISS-MODEL and Modeller to predict the 
effect of Q2089R on protein folding and function. 
3. To determine whether the kinase activity of LRRK2 is affected by Q2089R using 
autophosphorylation (as an indicator of kinase activity) in HEK293 cells overexpressing 
Q2089R. 
4. To investigate the effect of the common G2019S mutation and the Q2089R variant on cellular 
metabolic activity in transfected HEK293 cells and patient-derived fibroblasts using an MTT 
assay. 
5. To investigate the effect of G2019S and Q2089R on mitochondrial membrane potential in 
transfected HEK293 cells and patient-derived fibroblasts under both normal and stressed-
induced conditions (CCCP-treated) using the JC-1 assay. 
6. To study the effect of G2019S and Q2089R on mitochondrial respiration and glycolysis in 
transfected HEK293 cells and patient-derived fibroblasts using the Seahorse extracellular flux 
analyzer. 
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7. To determine the effect of G2019S and Q2089R on autophagy in transfected HEK293 cells and 
patient-derived fibroblasts using autophagic markers, LC3 II and P62, and Western blot 
analysis. 
8. To determine if WT LRRK2 co-localizes and interacts with specific subunits of the TOM protein 
complex using  
a. Confocal microscopy in transfected COS7 cells. 
b. Super Resolution Structured Illumination Microscopy (SR-SIM) in transfected HEK293 
cells under normal and stress-induced conditions.  
c. Co-immunoprecipitation (Co-IP) analysis in transfected HEK293 cells under normal 
and stressed-induced conditions. 
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2.1 Summary of Methodology          
A broad outline of the methodology used in the present study is shown in figure 2.1. 
 
Figure 2.1 A schematic outline of the techniques and approaches used in the present study 
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2.2 Constructs, bacterial strains, cell lines and primary cells    
2.2.1 Constructs 
2.2.1.1 Commercially available constructs 
Two commercially available constructs cloned into the pcDNA-DEST53 vector (Appendix I), a kind gift 
from Dr. Mark Cookson (Addgene, www.addgene.org, United States) were used for overexpression 
studies. One contains the full length wild type (WT) sequence of LRRK2 (pDEST53 LRRK2 WT, Addgene 
plasmid #25044) and the other contains the full length sequence of LRRK2 G2019S in the pcDNA-
DEST53 vector backbone (LRRK2 G2019S, Addgene plasmid #25045). Additionally, a reporter gene, β-
glucuronidase (GUS), was cloned in-frame into the pcDNA-DEST53 vector and used as the control 
plasmid in transfection experiments. LRRK2 as well as GUS was tagged to the GFP. 
 
2.2.1.2 Generation of construct using site-directed mutagenesis 
The Q5® Site-Directed Mutagenesis Kit (New England Biolabs® Inc., United States) was used to 
generate pDEST53 LRRK2 Q2089R according to the manufacturer’s instructions. In brief, the pDEST53 
LRRK2 WT plasmid (Addgene plasmid #25044) was used as template DNA in a PCR reaction with a 
mutagenic forward primer, containing the single base pair change that leads to the generation of the 
Q to R substitution, and back-to-back reverse primer (Figure 2.2 and Table 2.1) 
 
Figure 2.2 Q5® site-directed mutagenesis primer design. In order to generate a single base pair 
change, a mutagenic forward (black arrow) and a back-to-back reverse (red arrow) was designed. 
Taken from https://www.neb.com/products/e0554-q5-site-directed-mutagenesis-kit  
 
Table 2.1 Primer sequences used to generate the novel LRRK2 Q2089R construct 
Primer Sequence (5’-3’) Tm (°C) Ta (°C) 
Q5 Q2089R Forward 5'- TAG AAA TAC GAG GAA AAT TAC CTG ATC C -3' 54.6 
57 
Q5 Q2089R Reverse 5’-ATT CAT CAA ACT CAT TTG GAA ACT TCA AAC -3’ 55.4 
The blue G indicates the variant base pair that will be introduced during site-directed mutagenesis. 
Abbreviations: A, adenine; C, cytosine; G, guanine; T, thymine; Ta, annealing temperature; ̊ C, degrees 
Celsius.  
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Following the PCR reaction according to cycling conditions in Table 2.2, the kinase, ligase and DpnI 
enzyme mixture was added to the PCR product and incubated at room temperature for five minutes. 
This mixture is used to efficiently phosphorylate, ligate and circularize the new construct and remove 
the template construct. After the incubation period, 5µl of reaction mixture was used for bacterial 
transformation. 
 
Table 2.2 PCR cycling conditions for generation of Q5® site-directed mutagenesis construct 
Step Temperature Time 
Initial denaturation 98°C 30 seconds 
25 cycles 
98°C 10 seconds 
57°C 30 seconds 
72°C 7 minutes 
Final extension 72°C 2 minutes 
Hold 4°C ∞ 
Abbreviations: °C, Degrees Celsius. 
 
2.2.2 Bacterial strains  
In order to propagate the desired constructs, the Escherichia coli (E.coli) DH5α bacterial strain was 
transformed. Transformed bacterial colonies were selected based on their ability to grow on LB agar 
plates (Appendix II) containing appropriate antibiotics. When selecting for the pDEST53 vector, 
Ampicillin (Amp) was used as selection antibiotic. Colonies containing the correct plasmids were 
identified by bacterial colony PCR using gel electrophoresis and sequencing with the appropriate 
exonic primers (Table 2.4).   
   
2.2.3 Cell lines 
The human neuroblastoma SHSY5Y cell line was purchased from the European Collection of Cell 
Cultures (ECACC, United Kingdom) and used for CRISPR-Cas9 genome editing. The SHSY5Y cell line is 
routinely used as a model of neuronal function as they are adrenergic in phenotype but also express 
dopaminergic markers. The human embryonic kidney 293 (HEK293) cell line was used for all 
overexpression studies, functional assays, super resolution structured illumination microscopy (SR-
SIM) and co-immunoprecipitation (Co-IP) analysis since they are more amenable to transfection than 
SHSY5Y cells. HEK293 cells were purchased from American Type Culture Collection (ATCC, United 
States). The COS7 cells were a kind gift from Dr. Olga Corti and were used to study subcellular co-
localization using confocal microscopy since mitochondria are easily visible in these cells.  
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2.2.4 Generation of CRISPR-Cas9 cell line 
In order to generate a cell line endogenously expressing either LRRK2 G2019S or LRRK2 Q2089R, the 
GeneArt® CRISPR Nuclease Vector Kit was purchased from Invitrogen™ (United States) and used 
according to the manufacturer’s instructions. This kit facilitates the generation of constructs that 
express non-coding guide RNA (gRNA) including Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) RNA, a target complementary CRISPR RNA (crRNA), an auxiliary trans-activating 
crRNA (tracrRNA) and the Cas9 nuclease to be used in CRISPR mediated gene editing in mammalian 
cells. The crRNA and tracrRNA acts as short guide RNAs to target the Cas9 nuclease to specific genomic 
loci. GeneArt® CRISPR Nuclease Vectors with Orange Fluorescent Protein (OFP) allows for 
Fluorescence-activated cell sorting (FACS) of Cas9 and CRISPR RNA expressing cell populations using 
flow cytometry. The linearized GeneArt® CRISPR Nuclease Vectors provide a rapid and efficient way 
to clone double-stranded oligonucleotides encoding a desired CRISPR RNA target into an expression 
cassette that allows targeting of the Cas9 nuclease in a sequence specific manner. 
Genome editing involves the use of engineered nucleases in conjunction with endogenous repair 
mechanisms to insert, delete, or replace DNA sequences from a specific location in genomic DNA 
(gDNA). Engineered nucleases induce a double stranded break (DSB) at a specific location in the 
genome, after which endogenous repair mechanisms repair the break via non-homologous end joining 
(NHEJ) or homology directed repair (HDR) (Appendix III, Figure 1). Imprecise NHEJ-mediated repair can 
produce insertion and/or deletion mutations of variable length at the site of the DSB. HDR-mediated 
repair can introduce precise point mutations or insertions from a single-stranded or double-stranded 
DNA donor template. Essential for cleavage is a sequence motif immediately downstream on the 3’ 
end of the target region, known as the protospacer-adjacent motif (PAM). The PAM is present in the 
target DNA, but not the crRNA that targets it.  The PAM sites selected in exon 41 and 42 of LRRK2 are 
shown in Appendix III, figure 3. 
In brief, a target sequence ranging from 19 to 20 nucleotides in length adjacent to a PAM sequence 
on the 3' end of the target sequence was selected. Thereafter, the crRNA specific oligonucleotide 
primers were designed with the top strand oligonucleotide containing the specific top stand 3’ 
overhang (Appendix III, Figure 2A and Table 1) and the bottom strand in the reverse complement 
containing the specific bottom stand 3’ overhang (Appendix III, Figure 2B and Table 1). Annealing the 
two single-stranded oligonucleotides results in a double-stranded oligonucleotide with compatible 
ends for cloning into the GeneArt ® CRISPR Nuclease OFP Vector (Appendix III, Figure 2C). Following 
annealing and ligation reactions, the GeneArt ® CRISPR Nuclease OFP Vectors were transformed into 
E.coli (DH5α). Successfully transformed colonies were cultured, plasmid DNA extracted and sequenced 
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for sequence verification. These vectors could then be used to transfect the mammalian cell line of 
choice (SHSY5Y in this study) along with specifically designed mutant donor DNA templates for CRISPR 
genome editing (Appendix III, Table 1). 
 
2.2.5 Primary cell lines 
Primary cell lines derived from diseased and healthy control individuals are widely used as a cellular 
model, especially in PD. The use of ex vivo models is minimally invasive and serves as a useful tool to 
study disease-related cellular phenotypes, creating a model system with the desired mutation/variant 
and age-accumulated cellular changes (Auburger et al., 2012). In the present study skin biopsies were 
obtained from individuals carrying either LRRK2 G2019S or LRRK2 Q2089R (Table 2.3). Primary dermal 
fibroblasts were derived from these skin biopsies. Five WT control individual fibroblast samples were 
also collected through the course of this study (Table 2.3). The control individuals had no history of 
neurological disease and were confirmed to not harbor G2019S or Q2089R. It should be noted that 
not all WT fibroblast samples were available for all functional assays (Table 2.3, last column). 
 
2.3 Culturing of cells       
2.3.1 Isolation of dermal fibroblasts from skin biopsies 
Dermal fibroblasts were isolated by means of skin punch biopsies taken from individuals carrying 
either WT or mutant/variant LRRK2. Skin punch biopsies were performed by a registered nurse at 
Tygerberg Hospital (Cape Town, South Africa), after which dermal fibroblast cell lines were established 
by Unistel Medical Laboratories (Pty) Ltd. (Cape Town, South Africa). The 2mm x 2mm skin punch 
biopsies were taken from the inner lower arm and cultured in a sterile tissue culture environment. A 
volume of 300μl collagenase (Sigma-Aldrich, United States) per 1ml culture media of was added to the 
biopsy and incubated for one hour at 37°C with manual agitation in a 15ml polypropylene tube. The 
suspension was centrifuged at 160 x g (1200rpm) for 10 minutes in a Sorvall® GLC-6 general laboratory 
centrifuge (Separations, South Africa). The supernatant was discarded and the pellet resuspended in 
5ml fibroblast isolation media (Appendix II), and the suspension transferred to a CellBind® T25 tissue 
culture flask (Corning Inc., United States). Culture flasks were incubation at 37°C in in a Farma 
thermosteri-cycle 5% CO2 humidified incubator (Farma International, United States).  
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Table 2.3 List of fibroblast samples used in the present study 
Lab ID Ethnicity Male/Female AAO (years) DOB AAB 
Mutation/ 
Variant 
        Assay 
LRRK2 WT        
WT4 White Female unaffected 2013 54 n/a 
 JC-1 Assay 
 Metabolic activity 
 Autophagic flux 
WT525 Mixed ancestry Male unaffected 2016 77 n/a 
 Autophagic flux 
 Mitochondrial respiration 
WT5 White Male unaffected 2014 67 n/a 
 Mitochondrial respiration 
WT251 Mixed ancestry Female unaffected 2015 53 n/a  Mitochondrial respiration 
WT260 Mixed ancestry Female unaffected 2015 57 n/a  Mitochondrial respiration 
LRRK2 
mutant/variant 
      
G2019S White Female 42 2014 75 LRRK2 G2019S 
 JC-1 Assay 
 Metabolic activity 
 Autophagic flux 
 Mitochondrial respiration 
Q2089R Afrikaner Male unaffected* 2015 47 LRRK2 Q2089R 
 JC-1 Assay 
 Metabolic activity 
 Autophagic flux 
 Mitochondrial respiration 
Abbreviations: AAO, age at onset; DOB, date of biopsy; AAB, age at biopsy; n/a, not applicable; *skin biopsy collected from the son of the proband who was 
unaffected at the time.
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2.3.2 Culture of cells from frozen stocks 
Frozen cells (commercial cell lines or human derived fibroblasts) were rapidly thawed by immersing 
the cryovial in a waterbath at 37°C for 3 to 5 minutes. The vial was then sterilized with 70% ethanol 
and placed in the Esco Airstream® Class II Biohazard Safety cabinet (Esco Technologies Inc., United 
States) to be cultured. 
 
2.4 Transformation and transfection of plasmids into prokaryotic and 
eukaryotic cells   
2.4.1 Bacterial plasmid transformations   
Prior to transforming plasmids of interest into the bacteria, tubes containing 200μl aliquots of E.coli 
DH5α cells were removed from the -80°C freezer and thawed on ice for 20 minutes. Once the cells had 
thawed, 5μl of plasmid preparation was added to the tube and the mixture was incubated on ice for 
an additional 20 minutes.  
Following this incubation step, the samples were heat-shocked for exactly 45 seconds at 42°C in a 
heating block (Dry Block Heater HB2) (Hägar designs, South Africa). The samples were removed and 
incubated at room temperature for two minutes. Following this, 1ml of LB media (Appendix II) was 
added to each sample and incubated at 37°C for one to two hours shaking at 200rpm in a YIH DER 
model LM-530 (Scilab Instrument Co., Ltd., Taiwan) shaking incubator. The samples were subsequently 
centrifuged for four minutes in a bench top centrifuge (Labnet International Inc., United States). Next, 
200μl of the supernatant was drawn off with a pipette and the rest discarded.  The 200μl supernatant 
was used to resuspend the pellet and plate the sample on LB agar plates (Appendix II) containing the 
appropriate antibiotic. The plates were inverted and incubated for 16 hours at 37°C in a model 329 
stationary CO2 incubator (Former Scientific, United States). 
 
2.4.2 Transfection of cell lines 
COS7 and HEK293 cells were seeded at optimized densities in specific sterile cell culture plates 
(Appendix IV, Table 1) and transfected using either Lipofectamine2000 (Invitrogen™, United States) or 
DMRIE-C transfection reagent (Invitrogen™, United States). Several experiments were performed to 
optimize transfection efficiency including using different transfection reagents (NanoJuice® Merck 
Milipore, TransIT® Mirus Bio and Amaxa® Nucleofector™ Lonza) at different concentrations with 
various DNA concentrations. The HEK293 cells were subsequently transiently transfected using the 
Lipofectamine2000 transfection reagent at optimized conditions which can be seen in Appendix IV, 
Table 2. In brief, depending of the volume of the culture plate, optimized concentrations of plasmid 
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DNA and volumes of Lipofectamine2000 were separately incubated with a pre-determined volume of 
serum free media (SFM) for five minutes at room temperature (Appendix IV, Table 2). Thereafter, the 
two volumes were combined, gently mixed and incubated for 20 minutes at room temperature. 
Subsequently, a volume equal to the transfection volume was removed from each well and the 
transfection mixture added dropwise to each well and plates incubated at 37°C, 5% CO2. After six hours 
the media was removed and replaced with pre-warmed complete media. Cells were further incubated 
overnight. The transfection efficiency was determined by staining the transfected cells with a GFP 
antibody (Appendix IV, Table 7, ab290) and the nucleic acid stain (Hoechst H-33342). Three replicate 
transfections were used and the GFP-positive cells and nuclei in a minimum of five fields in three 
different wells were counted. The efficiency was determined by reporting the percentage GFP-positive 
cells to the total amount of cells counted. 
The COS7 cells were transiently transfected using the DMRIE-C transfection reagent at optimized 
conditions which can be seen in Appendix IV, Table 3. In brief, 1µg of plasmid DNA and 0.7µl of DMRIE-
C transfection reagent were separately incubated with 75µl of SFM for 30 minutes at room 
temperature (Appendix IV, Table 3). Thereafter, the two volumes were combined, gently mixed and 
incubated for another 30 minutes at room temperature. Subsequently, all of the media was removed 
from the 24-well culture plates and replaced with 150µl transfection mixture and plates incubated at 
37°C, 5% CO2. After four to five hours the transfection media was removed and replaced with pre-
warmed complete media followed by overnight incubation at 37°C, 5% CO2. 
 
2.5 DNA extraction           
2.5.1 Bacterial plasmid purification using PureYield™ Plasmid Miniprep System 
The specific E.coli colonies containing the plasmids of interest were inoculated in 50ml polypropylene 
tubes containing 10ml of LB media (Appendix II) as well as the appropriate antibiotic. The cultures 
were incubated at 37°C shaking in a YIH DER model LM-530 (Scilab Instrument Co., Ltd., Taiwan) 
incubator at 250rpm overnight. The following day the cultures were centrifuged for 10 minutes at 
1250 x g (2500rpm) in an Eppendorf model 5810/5810R centrifuge (Eppendorf, United States) and the 
supernatant discarded. The plasmid DNA was extracted from the pellets using the PureYield™ Plasmid 
Miniprep system (Gene Tech Co., Ltd., Hong Kong) as indicated by the manufacturer’s instructions. 
After purification, 2µl of the plasmid preparation was used to determine the purity and concentration 
of the sample by using a Nanodrop Spectrophotometer (Thermo Fisher Scientific, United States) and 
the 260/280 (>1.8) and 260/230 (>2.0) ratios. The remainder of the product used for transfection into 
the HEK293, SHSY5Y or COS7 cell line. 
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2.5.2 Bacterial plasmid purification using NucleoBond® PC 100 Xtra Midiprep system 
In order to isolate endotoxin free plasmids from bacterial culture for transfection into the desired cell 
lines, the NucleoBond® PC100 Xtra Midiprep kit was used (MACHEREY-NAGEL GmbH and Co., 
Germany). A 10ml LB culture containing 100µl of the bacterial glycerol stock was incubated at 37°C 
shaking in a YIH DER model LM-530 (Scilab Instrument Co., Ltd., Taiwan) incubator at 250rpm 
overnight. The following day, 100µl of the start-up culture was inoculated in 200ml LB media 
containing the appropriate selection antibiotic. This 200ml culture was then incubated overnight 
shaking at 37°C in a YIH DER model LM-530 (Scilab Instrument Co., Ltd., Taiwan) incubator at 250rpm.  
The 200ml culture was subsequently centrifuged for 10 minutes at 1250 x g (2500rpm) in an Eppendorf 
model 5810/5810R centrifuge (Eppendorf, United States) and the supernatant discarded. The plasmid 
was extracted from the bacterial pellet using the NucleoBond® PC100 Xtra Midiprep kit according to 
the manufacturer’s instructions. The DNA was resuspended in 100-150µl ddH2O and the concentration 
and plasmid purity was determined by a Nanodrop Spectrophotometer (Thermo Fisher Scientific, 
United States) and the 260/280 (>1.8) and 260/230 (>2.0) ratios. The remainder of the product was 
used for transfection into the SHSY5Y, HEK293 or COS7 cell line. 
 
2.5.3 Genomic DNA extraction from biological samples 
2.5.3.1 DNA from blood 
Peripheral blood samples were collected from control and PD-affected individuals and gDNA was 
extracted using the NucleoSpin® Blood XL kit (MACHEREY-NAGEL GmbH and Co., Germany), following 
the manufacturer’s recommendations. 
 
2.5.3.2 DNA from fibroblasts 
Fibroblasts were cultured in a T25 culture flasks until the confluency of cells reached 80-100%. Cells 
were detached from the growth surface with trypsin (Appendix VII) and transferred to 2ml microfuge 
tubes. Thereafter, the Quick-gDNA™ MiniPrep kit (Zymo Research Corp., United States) was used 
according to the manufacturer’s instructions to isolate gDNA from cultured fibroblasts. The gDNA was 
eluted in ddH2O and the concentration and DNA integrity was determined by the Nanodrop 
Spectrophotometer (Thermo Fisher Scientific, United States). 
 
2.6 RNA extraction and cDNA synthesis 
Dermal fibroblasts were cultured in a T25 culture flasks until the confluency of cells reached 80-100%. 
Cells were trypsinized (Appendix VII) and transferred to 2ml microfuge tubes. Thereafter, the RNeasy 
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Mini kit (Qiagen, Germany) was used according to the manufacturer’s instructions to isolate and purify 
intracellular RNA from cultured fibroblasts.  
RNA conversion into cDNA was subsequently carried out using the Quantitect Reverse Transcription 
Kit (Qiagen, Germany). This kit provides a convenient procedure for effective reverse transcription as 
well as effective gDNA removal. The first reaction allows the elimination of gDNA by the gDNA wipeout 
buffer, and the second step consist of a reverse transcription reaction prepared by the addition of 
reverse transcriptase, RT buffer and RT primer mix (Qiagen, Germany). The resulting cDNA templates 
were used in subsequent verification PCR reactions. 
 
2.7 Polymerase chain reaction (PCR)     
2.7.1 Oligonucleotide primer design and synthesis    
All gene reference sequences for which primers were designed were obtained from the National 
Centre for Biotechnology Information (NBCI) Entrez Nucleotides Database 
(http://www.ncbi.nlm.nih.gov/nucleotide/). Primers were designed using Integrated DNA 
Technologies Software, OligoAnalyzer (http://eu.idtdna.com/calc/analyzer) and Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/). The NCBI Basic Local Alignment Search Tool (BLAST) 
(http://www.ncbi.nlm.nih.gov/Blast/) was used to examine primer specificity. Oligonucleotide 
primers were synthesized either by Inqaba Biotech (South Africa) or Whitehead Scientific Pty. Ltd. 
(South Africa). 
 
  2.7.1.1 Primers for sequencing constructs 
In order to verify WT and G2019S sequences from plasmids (Addgene plasmids #25044 and #25045) 
as well as Q5® Site-directed mutagenesis generated vectors, sequencing primers were designed and 
used for sequencing analysis (Appendix IV, Table 4). Additionally, universal primers were used to 
confirm the correct open reading fame of plasmid sequences (Appendix IV, Table 5). 
 
2.7.1.2 Primers for variant verification  
Primers were designed and synthesized to PCR amplify selected exons of LRRK2 from gDNA, cDNA and 
plasmid DNA (Table 2.4). These primers were used to verify the presence or absence of mutations 
(G2019S in exon 41) or variants (Q2089R in exon 42) in specified DNA samples. Exonic primers were 
used to amplify exons from cDNA and plasmid DNA samples. In brief, PCR was performed in 25µl 
reactions in a Mastercycler® ep PCR system (Eppendorf, United States), with each reaction mixture 
containing 10 - 200ng template DNA, 20pmol of each primer (Table 2.4), 1.5mM MgCl2, 75µM dNTPs 
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(Promega, United States), 1X NH4 reaction buffer (Bioline, United Kingdom) and 0.5 U BIOTAQ DNA 
polymerase (Bioline, United Kingdom). 
Table 2.4 Primers designed for SNP verification in the LRRK2 gene 
Exon Sequence (5’-3’) Tm (°C) Ta (°C) 
41 
Forward: GCA CAG AAT TTT TGA TGC TTG 51.1 
55 
Reverse: GAG GTC AGT GGT TAT CCA TCC 54.7 
41 
(Exonic 
primers) 
Froward: CCT CCA CTC AGC CAT GAT TAT ATA C 54.7 
60 Reverse: GTG TGC CCT CTG ATG TTT TT 53.5 
42 
Forward: GCC TCC TTG GAT GTA TGA GC 55.5 
55 Reverse: TGA AGC TGC TGA TAT TAA GAA AA 50.4 
42 
(Exonic 
primers) 
Forward: GGT TTC GTG CAC CTG AAG 54.0 
57 Reverse: CAT ATT CTT TAA CTG GAT CAG GTA ATT TTC 52.9 
Abbreviation: Tm, melting temperature; Ta, annealing temperature; °C, degree Celsius; A, adenine; 
C, cytosine; G, guanine; T, thymine 
 
PCR cycling conditions were as follows: an initial denaturation step at 94°C for 5 minutes, 30 cycles 
consisting of denaturation at 94°C for 30 seconds, annealing at Ta (Table 2.4) for 30 seconds and 
extension at 72°C for 45 seconds, and a final extension at 72°C for 10 minutes. 
 
2.8 Gel electrophoresis         
2.8.1 Agarose gel electrophoresis  
In the present study, agarose gel electrophoresis was used either to visualize fragments that have 
been amplified by PCR or for plasmid preparation integrity. Approximately 7µl of the PCR product or 
plasmid preparation were mixed with 3µl of cresol loading dye (Appendix II) before loading the total 
10µl into a separate well of a 1% (w/v) agarose gel (Appendix II). All agarose gels contained 1µg/ml 
ethidium bromide (Sigma-Aldrich., United States) and 1X sodium borate (SB) buffer (Appendix II). To 
calculate the size of each fragment, 5µl Kapa Universal Ladder (Kapa Biosystems, United States) was 
subjected to electrophoresis simultaneously. The products were resolved for 30 minutes at 100V in 
1X SB running buffer (Appendix II). Gels were subsequently viewed under UV light and photographed 
with the Multigenius Bio Imaging System (Syngene, United Kingdom).    
    
2.8.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)   
Proteins from co-immunoprecipitation (Co-IP) reactions as well as Western blot analyses were 
subjected to electrophoresis in Mini-PROTEAN® TGX™ precast polyacrylamide gels (Bio-Rad 
Laboratories Inc., United States), containing 1% Sodium dodecyl sulfate (SDS), ranging from 4% to 25% 
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depending on the size of the proteins. Typically, 10μl - 35μl SDS loading dye (Appendix II) was mixed 
with 150μg of Co-IP reaction product or 30-50μg whole cell lysate for Western blot analysis and 
incubated at 95°C for 10 minutes.  
Five microliters of molecular weight marker (Precision Plus Protein™ Kaleidoscope™ Prestained 
Protein Standard, Bio-Rad Laboratories Inc., United States) was also subjected to electrophoresis with 
the protein products. The samples were loaded onto the vertical gel and subjected to electrophoresis 
at 120V for approximately one hour in 1x SDS-PAGE running buffer (Appendix II).  
 
2.8.3 Transfer of proteins from SDS-PAGE gels to Polyvinylidene difluoride (PVDF) 
membrane 
In order to visualize the protein bands separated on SDS-PAGE gels for Western blot and Co-IP 
experiments, proteins were transferred to PVDF membranes. SDS-PAGE gels were rinsed in TBST 
(Appendix II) and placed on the PVDF membrane which is attached to the bottom stack of the IBLOT® 
transfer pack (Invitrogen™, United States). The transfer stack was further assembled according to the 
manufacturer’s instructions and the proteins were transferred to the PVDF membrane using the 
IBLOT® transfer system (Invitrogen™, United States) at program setting P3 (20V, 8-10 minutes). 
 
2.9 Automated DNA sequencing  
A volume of 8µl of each PCR product was transferred to a 0.2ml micro-centrifuge PCR epi (Sigma-
Aldrich, United States), and this was purified with 5U of each of the following enzymes: Exonuclease I 
(USN Corporation, United States) and SAP (Shrimp Alkaline Phosphatase; Promega, United States). The 
samples were incubated at 37°C for 15 minutes followed by 80°C for 10 minutes to deactivate the 
enzymes. Each product was diluted to 20ng/µl for the sequencing reaction.  The primers used for 
sequencing were the same primers used during the PCR amplification diluted to 1.1µM. Extracted 
plasmid DNA was sent for sequencing at a minimum concentration of 100ng/µl. All automated 
sequencing reactions of the PCR products and plasmid DNA were performed at the Central Analytical 
Facility (CAF) of Stellenbosch University using the BigDye terminator V3.1 Ready reaction kit on the 
ABI 3130xl® Genetic analyser (Applied Biosystems, United States). All sequenced data was analyzed 
using the BioEdit Sequence Alignment Editor Software system (Ibis Biosciences, United States) to 
verify the sequence integrity and identity of the fragments generated. The generated fragments were 
compared to their reference sequences obtained from the GenBank database 
(www.ncbi.nlm.nih.gov/Entrez).  
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2.10 In silico prediction and genetic analysis of Q2089R 
In a previous study by our group, selected exons of LRRK2 were screened for pathogenic mutations in 
South African patients (R Keyser, PhD thesis, 2011).  Exon 42 was screened, as a putative pathogenic 
variant in this exon, Q2089R, had previously been identified in one Afrikaner PD patient using the exon 
42 primer set in Table 2.4. Bioinformatics tools including SIFT (http://sift.jcvi.org/), Polyphen 
(http://genetics.bwh.harvard.edu/pph2/), Mutation Taster (http://www.mutationtaster.org/) and 
the Combined Annotation Dependent Depletion (CADD) score (http://cadd.gs.washington.edu/score) 
was determined for Q2089R by using a Variant Effect Predictor (VEP) algorithm 
(http://www.ensembl.org/Homo_sapiens/Tools/VEP). Project Hope 
(http://www.cmbi.ru.nl/hope/method) was used to predict the effect of Q2089R on protein folding 
and function. In order to assess the evolutionary conservation of Q2089, protein sequences of LRRK2 
from a variety of species were selected from UniProt and aligned to each other using UniProt 
(http://www.uniprot.org/align/).  
 
2.10.1 TaqMan® SNP genotyping 
Genotyping was performed in patient and control samples in order to determine the frequency of 
candidate variants in both patients and controls.  A total of 1269 individuals, 493 patients (all the PD 
probands available at the time of the study) and 776 controls were included for genotyping.  The 
controls were ethnically matched and were divided into a total of 415 white individuals (of which 245 
were Afrikaners), 181 mixed ancestry individuals and 180 black individuals (Table 2.5). White 
Afrikaners are Afrikaans speaking South African individuals mainly of Dutch decent, but may also 
contain German and French ancestry (Greeff, 2007).  
Mixed ancestry refers to an admixed population or combination of different ethnic groups, including 
Western European and Indian as well as ethnic groups indigenous to South Africa such as the San and 
Khoi-Khoi (Patterson et al., 2010). 
 
Table 2.5 Study group selected for Q2089R Taqman® genotyping. 
Probands Controls 
Ancestry Number of individuals Ancestry Number of individuals 
Afrikaner 190 Afrikaner 245 
Black 23 Black 180 
Mixed ancestry 109 Mixed ancestry 181 
White 171 White 170 
TOTAL 493 TOTAL 776 
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The DNA samples were subjected to TaqMan® allelic discrimination technology using the ABI TaqMan® 
Custom SNP Genotyping Assay (Applied Biosystems, United States).  The genotyping was outsourced 
to a commercial company, IKMB (Institut für Klinische Molekularbiologie – Institute for Clinical 
Molecular Biology) in Kiel, Germany. 
Each ABI TaqMan® Custom SNP Genotyping Assay consists of two primers in order to amplify the 
sequence of interest, as well as two TaqMan® minor groove binding (MGB) probes for allele 
detection.  Each probe contains a reporter dye at the 5’ end of each allele specific probe (the first 
allele contains the VIC reporter dye and the second allele probe contains the FAM reporter dye). Each 
probe also contains the MGB as well as a non-fluorescent quencher (NQF) at the 3’ end of the probe. 
The MGB will increase the probe’s melting temperature (Tm) without increasing the length of the 
probe, thereby generating greater differences in Tm values between matched and mismatched 
probes, thus improving allelic discrimination.   
 
2.10.2 Whole exome sequencing (WES) analysis 
Whole exome sequencing (WES) was performed using gDNA from the affected proband (Figure 3.2, 
Individual II:1) and his unaffected sibling (Figure 3.2, Individual II:3) as a means to exclude all other 
known mutations as a cause of the disorder. WES was performed at Otogenetics Corporation (United 
States) using in-solution capturing (Agilent Human V5 (51Mb); Agilent Technologies, United States) 
and Illumina HiSeq2500, 100 paired-end sequencing. Reads were aligned to the human reference 
genome hg19 (build 37) using NovoAlign (Selangor, Malaysia) while GATK (Genome-Analysis-Toolkit) 
was used for the detection of indels. Data was filtered using an in-house custom designed 
bioinformatics pipeline. 
 
2.11 Metabolic activity measured by MTT assay        
The metabolic activity of WT and mutant fibroblasts as well as transfected HEK293 cells were 
investigated using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) (Sigma-
Aldrich, United States) assay according to the manufacturer’s instructions. An MTT assay measures 
cell metabolic activity by measuring NADPH-dependent cellular oxidoreductase enzymes. During 
incubation of the cells in the MTT solution, the presence of these enzymes reduce the yellow 
tetrazolium MTT dye to its insoluble form formazan, which is purple. This is an indication of living and 
viable cells. 
A total of 1 x 105 HEK293 cells were seeded in a 24-well plate in triplicate and transfected with the 
LRRK2 WT, G2019S, Q2089R or empty vector plasmids for 24 hours. Supplemented medium was 
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removed, replaced with 200µl 10mg/ml MTT diluted in phosphate buffed saline (PBS) (Lonza, 
Switzerland) and incubated at 37°C for 4 hours in a Farma thermosteri-cycle 5% CO2 humidified 
incubator (Farma International, United States). After four hours, an equal amount of acidified 
isopropanol (a 50:1 ration of 1% isopropanol: HCL) and 0.1% Triton-x solution was added to each well 
to dissolve the crystals. Absorbance was read at 595nm with background subtraction at 650nm using 
a microplate reader (BioTek, Synergy HT, United States) and the KC4™ software. All values were 
calculated from three independent experiments with each experiment containing three replicates.  
Additionally, for ex vivo analysis, 1 x 104 WT, G2019S- and Q2089R-carrying fibroblasts were plated 
per well of a 96-well plate in quadruplicate and allowed to proliferate either for 24 hours, 48 hours, 
72 hours, 96 hours or 120 hours. Culture media was subsequently removed, replaced with 100µl 
10mg/ml MTT diluted in PBS and incubated at 37°C for four hours in a Farma thermosteri-cycle 5% 
CO2 humidified incubator (Farma International, United States). Thereafter, an equal amount of 
acidified isopropanol and 0.1% Triton-x solution was added to each well to dissolve the crystals. 
Absorbance was read at 595nm with background subtraction at 650nm using a microplate reader 
(BioTek, Synergy HT, United States).  
To quantify the number of fibroblast cells plated per sample, the CyQUANT® NF Cell Proliferation assay 
(Thermo Fisher Scientific, United States) was used according to the manufacturer’s instructions. In 
brief, the culture media was removed from the cells and all wells gently rinsed with pre-warmed PBS. 
A volume of 100μl 1X dye binding solution was added to each well. The plate was incubated in the 
dark at 37°C in a Farma thermosteri-cycle 5% CO2 humidified incubator for one hour. The subsequent 
fluorescence intensity was measured in a Synergy HT luminometer using KC4™ software, with 
excitation at 480nm and emission detection at 530nm.  
 
2.12 Measuring mitochondrial membrane potential (MMP)      
The MMP was determined by staining the cells with the tetraethyl benzimidazolyl carbocyanine iodide 
(JC-1) fluorochrome. The fluorescent signals were determined using flow cytometric analysis. JC-1 
exhibits a potential-dependent accumulation of aggregates in mitochondria. The JC-1 dye is present 
in its monomeric form at low concentrations and emits a fluorescent signal at 525nm (green). At higher 
concentrations, i.e. upon accumulation of the J-aggregates which is a specific type of dye, the 
fluorescent signal shifts to 590nm (red). Thus, the loss of MMP is monitored by a decrease in the 
red:green fluorescence emission ratio (Reers et al., 1995).  
 
 
Stellenbosch University  https://scholar.sun.ac.za
46 
 
2.12.1 Staining cells with JC-1        
HEK293 cells (LRRK2 WT, G2019S, Q2089R and pDEST53-GUS), transfected in 6-well culture plates, 
were incubated for 24 hours at 37°C after which 5mg/ml stock solution of JC-1 (Appendix II) was 
diluted to 10µg/ml in 2ml complete media and added to the cells. A volume of 2ml clean culture media 
was added to the untransfected, unstained control and media containing DMSO was added to the 
negative (vehicle) control in each experimental run. Cells were incubated for 30 minutes at 37°C in a 
Farma thermosteri-cycle 5% CO2 humidified incubator. Subsequently, cells were gently rinsed with 
pre-warmed PBS and removed from the growth surface of the culture plates using trypsin. The 
suspended cells were transferred to 15ml tubes and centrifuged for three minutes at 450 x g 
(1500rpm). The supernatant was discarded and the pellet resuspended in 500µl PBS to be analyzed 
using flow cytometry. Alternatively, to interrogate MMP under stress induced conditions, transfected 
HEK293 cells were treated with 10µM Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), a potent 
mitochondrial uncoupler, or DMSO (vehicle control) or 50µM CCCP (positive control) and incubated at 
37°C for 30 minutes in a Farma thermosteri-cycle 5% CO2 humidified incubator before being stained 
with 10µg/ml JC-1 solution as described above.  
Differences in MMP were also assessed for WT and patient-derived fibroblasts (G2019S and Q2089R) 
as follows: Fibroblasts were cultured in 6-well plates until 70-80% confluent. Two additional WT 
fibroblasts were cultured for use as positive and unstained controls. The culture media was removed 
and the monolayer stained with 1µg/ml JC-1 solution diluted in 2ml pre-warmed culture media. The 
positive control sample was treated with 50µM CCCP and 2ml of clean culture media containing only 
DMSO was added to the unstained control. Samples were incubated for one hour at 37°C in a Farma 
thermosteri-cycle 5% CO2 humidified incubator. The staining solution was subsequently removed and 
the monolayer briefly rinsed with pre-warmed PBS. The cells were detached form the culture flasks 
using trypsin and transferred to 15ml tubes. The suspended cells were centrifuged for three minutes 
at 450 x g (1500rpm). The supernatant was discarded and the pellet resuspended in 500µl PBS to be 
analyzed using flow cytometry. Alternatively, to interrogate the MMP of fibroblasts under stress 
induced conditions, WT and mutant fibroblasts were treated with 10µM CCCP or DMSO (vehicle 
control) or 50µM CCCP (positive control) and incubated at 37°C for one hour in a Farma thermosteri-
cycle 5% CO2 humidified incubator before being stained with 1µg/ml JC-1 solution as described above.  
 
2.12.2 Flow cytometric analysis        
All flow cytometric analyses were performed on a FACSAria flow cytometer (Becton Dickinson 
Biosciences, United States) equipped with a 488nm Coherent Sapphire solid state laser (13-20mW), 
633nm JDS Uniphase HeNe air-cooled laser (10-20mW) and 407nm Point Source Violet solid state laser 
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(1025mW). The FACSAria is able to sort a mixture of cells based on the fluorescent signal from each 
cells. Cells for this assay were sorted based on polarization. This was done at CAF at Stellenbosch 
University, with the help of Miss. Rozanne Adams.  
Samples were analyzed on the flow cytometer and a minimum of 10 000 events were collected per 
sample. Fluorescence signal intensity was measured using the geometric mean on the intensity 
histogram. JC-1 aggregates in red, indicative of healthy mitochondria and a high MMP, were measured 
with the PE (Phycoerythrin) fluorochrome, whereas JC1 monomers in green, indicative of lowered 
MMP were measured with the FITC (Fluorescein isothiocyanate) fluorochrome. Thereafter, the 
PE/FITC ratio could be used as a measure of the ratio of healthy mitochondria to depolarized 
mitochondria.   
 
2.13 Measuring mitochondrial and glycolytic respiration     
Cellular metabolism and mitochondrial respiration of cells were measured using the XFe96 Analyzer 
(Seahorse Bioscience, United States). This was achieved by measuring the oxygen consumption rate 
(OCR) of transfected HEK293 cells (WT and mutant) and fibroblasts (patient and control).  
Additionally, glycolytic respiration was measured by recording lactic acid production through protons 
released into the media surrounding the cells. This was achieved by measuring extracellular 
acidification rate (ECAR). The XFe96 Analyzer has a cartridge that enters each well of a 96-well plate. 
At the bottom of each cartridge two fluorophores are situated. The one is quenched by oxygen and 
thus measures the mitochondrial component of respiration (OCR) while the rate of extracellular 
acidification (ECAR), through the extrusion of protons, is proportional to glycolysis and quenches the 
other fluorophore. A change in fluorophore emission represents a change in the levels of oxygen or 
hydrogen in the cells. 
All Seahorse cell culture plates that had been analyzed in sections 2.13.1 – 2.13.2, were normalized 
according to the DNA content per well in order to account for any differences in cell seeding density 
between wells using the CyQUANT Cell Proliferation Assay (Thermo Fisher Scientific, United States) 
according to the manufacturer’s instructions. One plate was used for both the XF Mito Stress Test and 
XF Glycolysis Stress Test for the HEK293 cells (Appendix VI, Figure 1) whereas two separate plates were 
used for the fibroblasts (Appendix VI, Figure 2). 
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2.13.1 The XF Cell Mito Stress Test        
Several measures of mitochondrial respiration were derived by the sequential addition of 
pharmacological agents to cells including basal respiration, ATP-linked respiration, proton leak 
respiration, maximal respiration and reserve capacity (Figure 2.3).  
 
Figure 2.3 Mitochondria respiration as measured by the Mito Stress test. Oxygen consumption rate 
(OCR) is measured before and after the addition of inhibitors to derive several parameters of 
mitochondrial respiration including basal respiration, ATP-linked, proton leak respiration, maximal 
respiration and spare respiratory capacity. With permission from www.seahorsebio.com. 
 
The kit includes three pharmacological agents that are injected into the media surrounding the cells. 
First, baseline cellular oxygen consumption is measured, from which basal respiration is derived. Next 
Oligomycin, a complex V inhibitor, is added and the resulting OCR is used to derive ATP-linked 
respiration (ATP production) and respiration due to proton leak across the inner membrane. The 
reduction in OCR after Oligomycin shows the OCR as a result of ATP synthesis.  
The ratio of ATP-linked respiration to basal OCR is indicated as ATP coupling efficiency. Subsequently, 
carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP), a protonophore, is added to collapse 
the inner membrane gradient, which causes the ETC to function at its maximal rate. Finally, Antimycin 
A, a complex III inhibitor, and Rotenone, a complex I inhibitor, are added to deplete ETC function and 
increase ECAR as the cells switch to glycolysis for energy production. This reveals the non-
mitochondrial respiration and allows mitochondrial reserve capacity to be calculated (Table 2.6). 
HEK293 cells were plated at a density of 12 500 cells per well of the 96-well XF Analyzer culture plate 
and underwent transfection for 24 hours as previously described. Fibroblasts were seeded at a density 
of 25 000 cells per well. Cells were counted using the Scepter Handheld Cell Sorter (Merck, Germany) 
and plate set-ups can be seen in Appendix VI, Figure 1 and Figure 2, respectively.   
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Table 2.6 Calculations of oxygen consumption rates 
Measure Calculation 
Non-mitochondrial respiration 
Minimum OCR measurement after Rotenone and Antimycin A 
injection. 
Basal respiration 
Last OCR measurement prior to Oligomycin injection – Non-
mitochondrial respiration 
ATP-linked respiration 
Last OCR measurement prior to Oligomycin injection – 
Minimum OCR measurement after Oligomycin injection 
Proton leak 
Minimum OCR measurement after Oligomycin injection – Non-
mitochondrial respiration 
Maximal respiration 
Maximum OCR measurement after FCCP injection – Non-
mitochondrial respiration 
Spare respiratory capacity Maximal respiration – Basal respiration 
ATP coupling efficiency (%) 
ATP − linked respiration x 100
Basal respiration
       
Abbreviations: ATP, adenosine tri-phosphate; FCCP, carbonyl cyanide-p-trifluoromethoxyphenyl-
hydrazon; OCR, Oxygen consumption rate; %, percentage. 
 
The following day the culture media was removed and replaced with 175µl Seahorse assay media 
supplemented with 5mM glucose and 1mM pyruvate (pH7.4). The plates were subsequently 
incubated for one hour at 37˚C without CO2. The final concentrations for each compounds for the 
HEK293 cells were as follows: 1µM Oligomycin, 0.5µM FCCP and 0.5µM Rotenone + Antimycin A. For 
the fibroblast run the concentrations were as follows: 1µM Oligomycin, 0.8µM FCCP and 0.5µM 
Rotenone + Antimycin A. The compounds were loaded in specific ports using the loading plate. 
Oligomycin was added to port A, FCCP to port B and Rotenone + Antimycin A to port C. The run was 
initiated and the XFe Wave software (Seahorse Biosciences, United States) was used to analyze results. 
   
2.13.2 The XF Glycolysis Stress Test  
The XF Glycolysis Stress Test is used to measure glycolysis in real-time and identify selected 
parameters of glycolytic flux including glycolysis, glycolytic capacity and glycolytic reserve (Figure 2.4). 
ECAR is primarily a measure of lactate production and can be compared to the glycolytic rate (i.e., 
glycolysis). The conversion of glucose to pyruvate, and then to lactate, results in the production and 
release of protons to the extracellular medium. The increase in the release of protons results in an 
increase in the measurable ECAR, which indicates an increase in glycolytic activity.  
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Figure 2.4 Glycolytic flux as measured by the Glycolysis Stress Test. Extracellular acidification rate is 
measured including glycolysis, glycolytic capacity and glycolytic reserve. With permission from 
www.seahorsebio.com. 
 
The XF Glycolysis Stress Test makes use of three compounds that are injected into the media 
surrounding the cells through the injection ports. Following basal ECAR measurements in glucose-free 
medium, a saturating concentration of glucose is injected to the cells (Figure 2.4). This causes an 
increase in ECAR as glycolysis increase. Subsequently, Oligomycin is injected; inhibiting oxidative 
phosphorylation. This results in maximal cellular glycolytic capacity. Finally, 2-deoxy-glucose (2-DG), a 
glucose analogue, is injected to the cells and inhibits glycolysis. Calculations are shown in Table 2.7. 
 
Table 2.7 Calculations of extracellular acidification rates  
Measure Calculation 
Glycolysis 
Maximum rate measurement before Oligomycin injection – Last 
rate measurement before Glucose injection. 
Glycolytic capacity 
Maximum rate measurement after Oligomycin injection – Last 
rate measurement before Glucose injection 
Glycolytic reserve Glycolytic capacity – Glycolysis 
Non-glycolytic acidification Last rate measurement before Glucose injection 
 
Cells were plated and plates prepared as described in section 2.13.1. The following day the culture 
media was removed and replaced with 175µl Seahorse assay media and the plates incubated for one 
hour at 37˚C without CO2. The final concentrations of compounds were as follows: 10mM Glucose, 
1µM Oligomycin and 50mM 2-DG prepared in glycolysis assay medium. The compounds were loaded 
in specific ports using the loading plate. Glucose was added to port A, Oligomycin to port B and 2-DG 
to port C. The run was initiated and the XFe Wave software (Seahorse Biosciences, United States) was 
used to analyze results.   
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2.14 Determination of Relative mtDNA Copy Number using real-time PCR 
Fibroblasts (WTs and mutant/variant) were cultured for at least one week prior to mitochondrial and 
glycolytic respiration experiments (section 2.13) to a confluency of approximately 90%. Cells were 
detached from the culture flasks and plated in Seahorse culture plates. The remaining cells were 
pelleted and frozen at -20°C. Fibroblast passage numbers were matched, ranging from passage four 
to seven. DNA was extracted from the frozen pelleted cells from control and patient derived 
fibroblasts to determine the relative mtDNA copy number (RMCN) using real-time PCR 24 hours prior 
to the Seahorse experiments. This was achieved by quantifying the nuclear gene Hemoglobin subunit 
beta or HBB (β-globin) and the mtDNA gene, MT-ND2 (Mitochondrial encoded NADH2), using real-time 
PCR and the 2-ΔΔCT method to calculate the RMCN. To obtain ΔΔCT values, CT values were acquired from 
the real-time PCR instrument (Applied Biosystems, United States). The average CT values were 
calculated for both β-globin and MT-ND2, and the average CT for β-globin was subtracted from the 
average CT MT-ND2. These values then represented the ΔΔCT value and could then be used to calculate 
the 2-ΔΔCT value.  The final value represents the number of mtDNA molecules relative to the number of 
each nuclear DNA (nDNA) molecule and since two copies of nDNA exists in every human cell, the final 
values were multiplied by two (Ye et al., 2014; Zandberg et al., 2016).  
TaqMan® Gene Expression Assays, containing the two primers (18µM per primer) and a 6-FAMTM 
dye-labelled TaqMan® MGB probe (5µM) were purchased from Thermo Fisher Scientific (United 
States) for the nuclear β-globin gene (Hs00758889_s1) and the mitochondrial ND2 gene 
(Hs02596874_g1). Each reaction mixture for the two genes was prepared separately as follows: 1x 
TaqMan® Gene Expression Assay, 1x TaqMan® Gene Expression Master Mix, 5µL PCR-grade H2O and 
4 µL DNA (2.5ng/µL). Samples were run in triplicate for each gene and analyzed in an ABI 7300 real-
time PCR system. The CT values were acquired using version 1.4 of the 7300 System Sequence 
Detection Software (Applied Biosystems, United States). The PCR cycling conditions were as follow: 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for one minute. The RMCN 
determination was executed by Ms. Hayley van Dyk. 
 
2.15 Western blotting  
2.15.1 Cell lysis    
Cells needed to be lysed in order to be used for subsequent co-immunoprecipitation and Western blot 
analysis. Lysis of cells was achieved as follows:  The growth media was removed and 3-5ml of trypsin 
was added to the flasks or culture plates. The cells with trypsin was incubated at 37°C for 10-15 
minutes to facilitate the detachment of the cells after which a cell scraper was used to scrape the 
remaining cells off from the growth surface. The detached cells were transferred to a 15ml tube to 
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which a volume of 3-5ml of growth media was added to deactivate the enzyme activity of the trypsin. 
The tubes were centrifuged at 4°C for three minutes at 1250 x g (2500rpm)in a Beckman model TJ-6 
centrifuge (Beckman Coulter, United Kingdom). The supernatant was discarded and the pellet 
resuspended in 1ml of PBS and the suspension transferred to 2ml microfuge tubes.  The cells were re-
pelleted at 7600 x g (9000rpm) for two minutes and the PBS removed with a pipette. Lysis buffer was 
prepared (Appendix II) and 50 to 250µl used to resuspend the pellet. The mixture was placed on ice 
for 30 minutes after which lysates were cleared by centrifugation at 20 000 x g (130 000rpm) at 4°C 
followed in a bench top centrifuge (Labnet International Inc., United States) for 30 minutes. The 
supernatant was subsequently transferred to fresh 1.5ml microfuge tubes and stored at -80°C until 
required.         
2.15.2 Bradford protein concentration determination  
Before storage of samples prepared in section 2.15.1, 1µl of each lysed sample was aliquoted and used 
to perform a Bradford assay in order to assess the protein concentration.  This was done as follows: 
In order to calculate the standard curve, 10µl of serial diluted bovine serum albumin (BSA) ranging 
from 0-1000µg/µl and 1µl of the lysate samples in duplicate was loaded into the wells of a 
luminometer plate. Two hundred microliters of Bradford reagent were added to all of the standard as 
well as the lysate samples. The plates were read on a Synergy HT luminometer (BioTek Instruments 
Inc., United States) and were used to determine the protein concentration of each well. The KC4™ v 
3.4 software (BioTek Instruments Inc., United States) was used to calculate and set up the standard 
curve, as well as each sample’s protein concentration at an absorbance of 595nm. 
 
2.15.3 Membrane blocking   
Following SDS-PAGE, the proteins were transferred to a membrane using the IBLOT® transfer system 
(Invitrogen™, United States). The transfer was not controlled for however, we used GAPDH as a 
loading control when carrying out Western blot analysis. After complete transfer of the proteins onto 
the membrane, the membranes were removed from the transfer apparatus and washed in TBST for 
approximately two minutes. Afterwards, the membrane was placed in 5% fat free powder milk in TBST 
supplemented with 0.01% Tween-20 to ensure the blockage of all not specific binding sites. The 
membrane was incubated at room temperature for one hour shaking on a Stuart® orbital shaker SSL1 
(Barloworld Scientific Ltd., United Kingdom).   
 
2.15.4 Addition of primary antibody  
After blocking of the membranes, the membranes were rinsed with TBST and the primary antibodies 
diluted in 5% fat free powder milk in TBST or 5% BSA in TBST supplemented with 0.01% Tween-20 
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(Appendix IV, Table 6). The membranes were placed in a container along with the appropriate primary 
antibody and incubated overnight shaking at 4°C on an Orbit 300 shaker (Labnet International Inc., 
United States). 
 
2.15.5 Addition of secondary antibody  
The membranes were washed in TBST (Appendix II) for approximately 15 minutes after which the 
membranes were placed in 5% fat free powder milk in TBST supplemented with 0.01% Tween-20 
containing the appropriate horseradish peroxidase (HRP) conjugated secondary antibodies (Santa 
Cruz Biotechnology Inc., United States, Appendix IV, Table 6). The membranes were placed on a shaker 
for one hour shaking at room temperature on a Stuart® orbital shaker SSL1 (Barloworld Scientific Ltd., 
United Kingdom).  Subsequently, the membranes were rinsed twice in TBST and then washed for 30 
minutes in TBST (Appendix II). 
 
2.15.6 Chemiluminescent visualization of membrane proteins  
Following sections 2.15.1-2.15.5, the membranes were taken to a dark room where the two 
components of the Clarity™ Western ECL Blotting Substrate (Bio-Rad Laboratories, United States), 
were mixed in a ratio of 1:1 and used to label the membranes for five minutes. After removing the 
excess chemiluminescent reagent, the membranes were placed in an autoradiography cassette and 
covered with a transparent plastic sheet after which they were exposed to CL-Xposure™ 
autoradiography film (Thermo Fisher Scientific, United States). The exposure time varied between 10 
seconds and 10 minutes, depending on the strength of the signal. Following adequate exposure, the 
film was developed in a Hyperprocessor™ automatic autoradiography film processor (Amersham 
Pharmacia Biotech Ltd., United Kingdom) and the protein bands visualized.  
 
2.15.7 Autophosphorylation assay 
Transfected HEK293 cells were lysed and subjected to Western blotting as described in section 2.15.1-
2.15.6.  To determine the autophosphorylation status of each sample, the membrane was probed with 
LRRK2 pSer1292 (ab203181) and GFP (ab290) (Appendix IV, Table 6) and quantified as described in 
section 2.15.8. These experiments were conducted in triplicate. 
 
2.15.8 Quantification of Western blot 
All Western blots were quantified using the Image J software (http://imagej.nih.gov/ij/). Image J is 
able to measure the pixel intensity of the band and obtain an arbitrary unit, which could be used as a 
measure of relative protein abundance on the Western blot. All blots were performed in biological 
and technical triplicates.  
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2.16 Co-localization   
COS7 and HEK293 cells were plated on glass slides (Lasec Pty Ltd., South Africa) in 24-well plates and 
transfected with LRRK2 WT constructs for 24 hours. The culture media was subsequently removed and 
replaced with media containing 10µM CCCP or DMSO (vehicle control) and incubated for six hours at 
37°C in a Farma thermosteri-cycle 5% CO2 humidified incubator. Co-localization was used to assess 
protein localization in a physical cellular environment. Overexpressed WT LRRK2 and the 
endogenously expressed subunits of the TOM protein complex were labelled with appropriate primary 
and secondary antibodies. For confocal co-localization using COS7 cells, single-plane images were 
acquired with an Olympus FluoView™ FV-1000 confocal microscope (Olympus Corp., Japan) driven by 
Olympus FV-1000 Software housed at the Brain and Spine Institute (ICM) (Paris, France). Super 
resolution structured illumination microscopy (SR-SIM) images of HEK293 cells were acquired using 
the Zeiss LSM 510 Meta confocal microscope housed at CAF at the Department of Anatomy imaging 
facility (University of Stellenbosch, South Africa). Optimized antibody concentrations are indicated in 
Appendix IV, Table 7. 
 
2.16.1 Co-localization assay  
Following transfection and treatment with either DMSO or CCCP, the media was removed and the 
cells briefly rinsed with pre-warmed sterile PBS. The cells were fixed for 20 minutes at 37°C in 4% 
Formaldehyde diluted in culture media (Appendix II). Subsequently, the cells were washed in PBS three 
times for 10 minutes. The cells were then incubated in 1% BSA for one hour at room temperature.  
The 1% BSA solution acts as the blocking solution to ensure blockage of all non-specific binding sites. 
Following this incubation period, the cells were incubated with the appropriate pair of primary 
antibodies (Appendix IV, Table 7) diluted in 1% BSA (Blocking solution). The slides were transferred to 
a sealed container and incubated at 4°C overnight. The following day the cells were washed with PBS 
for 10 minutes, repeating the wash step three times. The cells were labelled with the appropriate 
secondary antibodies diluted in PBS (Appendix IV, Table 7) and incubated at room temperature for 90 
minutes in the dark.  With every experiment, negative controls were included that consisted of COS7 
or HEK293 cells labelled with secondary antibodies only. This was necessary for constructing baseline 
values for each fluorochrome (secondary antibodies) before acquiring the single and z-stacks images.  
Cells were washed with PBS for 10 minutes, repeating the wash step three times. A 1:200 dilution of 
the nucleic acid stain Hoechst H-33342 (Sigma-Aldrich, United States) was made for staining the 
nuclear material. The cells were incubated with Hoechst at room temperature for 10 minutes after 
which a brief 10-minute wash step with PBS followed.   
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ProLong® Gold Antifade Mountant (Thermo Fisher Scientific, United States), was used to mount the 
cells onto glass slides. The slides were stored at 4°C in the dark until viewing. After viewing and 
acquisition of a minimum of three single images, three overlay images as well as three z-stacked 
images from the appropriately labelled cells, co-localization analysis followed.   
Olympus images of COS7 cells were processed for co-localization using ImageJ software 
(http://imagej.nih.gov/ij/) and SR-SIM images of HEK293 cells were processed using the ZEN 2009 light 
edition software package (http://www.zeiss.com/microscopy/en_de/downloads/zen.html)  in 
combination with co-localization coefficients in Appendix IV, Table 8. 
For SR-SIM images, scatter diagrams were generated using the ZEN 2009 light edition software. For 
each pair the signal intensity of pixels from the red channel (TV2-T2-SR) were interpreted as x-axis 
coordinates and the signal intensity of pixels from the green channel (TV2-T1-SR) as y-axis coordinates. 
The crosshair in each diagram corresponds to the threshold values determined by the pixel intensity 
of the single images acquired for LRRK2 (TV2-T1-SR, green) and the subunits of the TOM complex; 
TOM20 (TV2-T2-SR), TOM22 (TV2-T2-SR), TOM40 (TV2-T2-SR) and TOM70 (TV2-T2-SR). Z-stack images 
(11 slices) were acquired from three to four cells per condition. The z-stacks were processed by 
combining slice 1 and 2, slice 3-5, slice 6-8 and slice 9-11 and creating maximum intensity projections 
from these images for each cell. These images were then used to generate the desired coefficients 
and to interpret the data. 
 
2.17 Co-immunoprecipitation (Co-IP)  
HEK293 cells were seeded in 6-well culture plates and transfected with LRRK2 WT constructs for 24 
hours as previously described. Subsequently, culture media was removed and replaced with media 
containing 10µM CCCP or DMSO and incubated for six hours at 37°C in a Farma thermosteri-cycle 5% 
CO2 humidified incubator. Cells were then harvested, lysed and the protein concentration determined 
by a Bradford assay. A final concentration of 150µg protein lysate was pre-cleared by adding 30µl 
Protein G agarose beads (KPL Inc., United States) to each sample and incubating it at 4°C on a rotating 
wheel for 30 minutes. Following incubation, the samples were centrifuged at 7600 x g (9000rpm) for 
30 seconds in a bench top centrifuge (Labnet International Inc., United States) and the supernatant 
transferred to fresh 1.5ml microfuge tubes. One microgram of the appropriate primary antibody was 
added to each lysate samples and the volume made up to 100µl by adding lysis buffer (Appendix II). 
Negative controls included a sample incubated with only Protein G agarose and a sample incubated 
with the negative control antibody, anti-Hemaglutinin (anti-HA antibody) which is a synthetic peptide. 
This mixture was incubated overnight at 4°C on a rotating wheel. 
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The following morning, 60µl of Protein G agarose was added to each sample after which an incubation 
period of one hour followed at 4°C rotating. Afterwards, the beads were collected by centrifugation 
at 7600 x g (9000rpm) for 30 seconds in a bench top centrifuge (Labnet International Inc., United 
States). The beads were washed four times with ice cold prepared lysis buffer (Appendix II) by mixing 
it and collecting it again by means of centrifugation at 9000rpm for 30 seconds in a bench top 
centrifuge (Labnet International Inc., United States). After completion of all the wash steps, 35µl of 
SDS loading dye (Appendix II) was added to each sample and denatured at 95°C for 10 minutes after 
which the beads were pelleted again and the supernatant loaded onto SDS-PAGE gel. Co-
immunoprecipitation (Co-IP) analysis was performed in order to verify the association of LRRK2 and 
the selected TOM proteins within the same complex. 
 
2.18 Autophagic flux measurement and calculation       
For analysis of cellular autophagy, the detection of autophagic proteins through Western blot analysis 
were achieved with the P62 and LC3 II antibodies. The LC3 II antibody was used to measure both 
lipidated and unlipidated LC3 II proteins. These proteins are incorporated within the inner and outer 
membrane of the autophagic vacuole (AV), and therefore detection of LC3 II is an indicator for the 
presence of autophagosomes (Figure 2.5). Additionally, p62 is also used to measure autophagic flux, 
as it binds to LC3 II in the autophagosome and is rapidly degraded during autophagy. Autophagic flux 
was calculated by measuring both LC3 II and p62 after activation of basal autophagy in a starvation 
state, as well as after the addition of Bafilomycin A1 (BafA1), which acts as an autophagosome-
lysosome fusion inhibitor (Figure 2.5). The difference in protein levels before and after BafA1 
treatment was used to define autophagic flux. A 20µg/ml stock solution of BafA1 was made up in 
ethanol (Appendix II) and stored at -20°C for future use.           
HEK293 cells were plated in 6-well plates and transfected with WT, G2019S and Q2089R constructs in 
duplicate for 24 hours. Additionally, WT and mutant/variant fibroblasts were plated in 6-well plates in 
duplicate and allowed to proliferate to a confluency of 70-80%. The media was removed and one 
duplicate well of each sample was replaced with 3ml HBSS media. HBSS is a saline solution that 
contains 1g/L glucose and no amino acids and is therefore capable of inducing nutrient starvation to 
the cells and a successive increase in autophagy. Alternatively, the second duplicate well was treated 
with 3ml HBSS media containing 100nM BafA1 (9.7µl BafA1 in 3ml HBSS media). Both groups were 
incubated at 37°C for two hours. 
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Figure 2.5 The effect of Bafilomycin A1 on autophagy. Bafilomycin A1 inhibits vacuolar-ATPase and 
prevents lysosomal fusion with the autophagosomes. Bafilomycin A1 ultimately inhibits the 
degradation of autophagosome content.  Reprinted with permission by MBL 
http://www.caltagmedsystems.co.uk/information/autophagy-watch/  
 
Following incubation, the cells were lysed and protein concentration was determined by the Bradford 
assay. Both groups of samples (HBSS-BafA1 and HBSS+BafA1) were simultaneously run on gels and 
detected by Western blot analysis. Antibodies for LC3 II, p62 and GAPDH (the loading control) were 
used at optimal concentrations (Appendix IV, Table 6). Intensity of the bands for each protein was 
quantified by Image J software (http://imagej.nih.gov/ij/), and band intensities of LC3 II and p62 were 
each normalized to the corresponding band intensities of LRRK2 and GAPDH. Autophagic flux was then 
calculated by comparing the normalized LC3 II and p62 in BafA1 treated versus untreated samples. 
These results were technically repeated three times, and replicated in three independent 
experiments.  
 
2.19 Statistical analysis 
All statistical analyses were performed using GraphPad Prism Software V5 
(http://www.graphpad.com/scientific-software/prism/). Column and line graphs were generated 
indicating the mean with standard error of the mean (SEM). Either one-way analysis of variance 
(ANOVA) with Bonferroni’s posttest, two-way ANOVA with Bonferroni’s posttest or unpaired t-tests 
were performed to determine p-values. P-values of < 0.05 were considered statistically significant. 
Statistical analyses were conducted with the assistance of Ms. Tonya Esterhuizen (Centre for Evidence 
Based Health Care, Biostatistics Unit, Stellenbosch University, South Africa) and Ms. Hayley van Dyk 
(North West University, Potchefstroom, South Africa). 
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3.1 LRRK2 p.Q2089R identification, verification and frequency determination 
This study was approved by the Health Research Ethics Committee at Stellenbosch University 
(Protocol number: S14/03/072). Renewed ethics approval was obtained annually. All study 
participants were recruited with written informed consent. 
In a previous study in our laboratory, 13 exons encoding the functional domains of LRRK2 were 
selected and screened in 30 unrelated patients diagnosed with autosomal dominant (AD) PD using 
Sanger sequencing. These exons included exons 29-31 (Roc domain), exon 35 (COR domain), exons 
38-44 (kinase domain) and exons 45-46 (WD40 domain). A novel variant, p.Q2089R, (on chromosome 
12: 40346909; c.A6267G) was identified in one of the 30 PD probands (Dr. R Keyser, PhD thesis 2011) 
and later in one control individual out of 132 controls screened (B Glanzmann, MSc thesis 2013). In 
the present study, these findings were independently confirmed by Sanger sequencing (Figure 3.1). 
 
Figure 3.1 Sequence chromatogram indicating the position of LRRK2 Q2089R. The variant is absent 
in the wild type (A) and present in a proband (B) as well as one Afrikaner control (C). Abbreviations: 
A, Adenine; C, Cytosine; G, Guanine; R, either A or G; T, Thymine. 
 
3.1.1 Pedigree of p.Q2089R-positive proband 
The Q2089R variant is in the kinase domain of LRRK2 and is located in exon 42. This variant was found 
in a single PD patient of white Afrikaner ancestry with an AAO of 50 years and an AD family history of 
the disorder (individual II:1; Figure 3.2 A). The patient had, at age 64, developed marked motor 
fluctuations with dyskinesia, and subsequently underwent bilateral globus pallidus internus (GPi) deep 
brain stimulation (DBS) with excellent results, at which time he was cognitively normal. The father of 
the proband (individual I:1, Figure 3.2 A) had also been diagnosed with definite PD prior to his demise.  
The family members of the proband were screened in order to possibly identify additional carriers of 
the variant. Q2089R was found to be present in both of his asymptomatic children (individuals III:1 
and III:2, aged 47 and 50, respectively; Figure 3.2 A) and was absent in his unaffected 79-year old 
sibling (individual II:3). In addition, we performed WES on the proband which excluded the presence 
of any other known PD-causing mutations or any other possibly pathogenic mutations in LRRK2. 
A B C 
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Protein alignment results showed that the Q2089 amino acid is evolutionarily well-conserved across 
various species from zebrafish to human (Figure 3.2 C). 
 
Figure 3.2 Sequencing results and pedigree of the family with the LRRK2 Q2089R variant. A) Q2089R 
is present in both children (III:1 and III:2) of the proband, but it is absent in his unaffected sibling (II:3). 
The small black arrow indicates the proband and the large downward pointing arrows shows the 
position where the Q2089R variant is present or absent in the sequence chromatograms. B) The 
sequence alignment of LRRK2 exon 42 indicating the absence and presence of the variant is indicated 
by the back arrow. C) UniProt protein sequence alignments show the evolutionarily well-conserved 
LRRK2 Q2089 amino acid indicated by the black arrow at the top of the figure. The conserved regions 
(where there are no amino acid changes) have been indicated with asterisks at the bottom of the 
figure. Abbreviations: AAO, age at onset; A, adenine; C, cytosine; G, guanine; N/A, not applicable; T, 
thymine. 
 
3.1.2 Frequency of Q2089R 
To our knowledge, Q2089R has not previously been reported in the literature and it is not present in 
any of the online databases searched on 17 October 2016. These databases include dbSNP 
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(http://www.ncbi.nlm.nih.gov/projects/SNP/), Ensembl http://www.ensembl.org/),  NHLBI Grand 
Opportunity Exome Sequencing Project (ESP, https://esp.gs.washington.edu/drupal/), 1000 Genomes 
project (http://www.1000genomes.org/),  PDmutDB (http://www.molgen.vib-ua.be/PDMutDB/), as 
well as the Exome Aggregation Consortium database (ExAC, http://exac.broadinstitute.org/). 
In order to determine the frequency in the South African PD patients and controls, a total of 1,269 
individuals were screened using TaqMan SNP genotyping. These included 493 unrelated SA PD 
probands and 776 controls of various ethnicities including 245 white Afrikaners, 170 white individuals, 
181 mixed ancestry individuals and 180 black individuals (Table 2.5).  Figure 3.3 shows the genotyping 
results as a representation of the allelic discrimination plots obtained with the Sequence Detection 
System (SDS) software package. 
 
Figure 3.3 Representative results for Taqman® allelic discrimination. Genotyping results for the 
Q2089R variant as a representation of the allelic discrimination plots obtained with the SDS software 
during analysis. Allele X = G (variant); Allele Y = A (WT). WT, wild-type; NTC, non-template control. 
 
The wild type allele (A) was plotted on the y-axis and the variant allele (G) was plotted on the x-axis. 
No amplification was observed in the non-template control samples which indicated that there was 
no contamination. All samples of ‘undetermined genotyping status’ and samples that were labelled as 
heterozygote mutants were selected for Sanger sequencing to confirm their genotype. Genotyping of 
the Q2089R variant in PD patients and controls revealed that it was absent in all of the other PD 
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probands and controls screened. Therefore, in South African patients and controls, this variant is 
present at an overall frequency of 0.2% (1/493) in PD patients and 0.1% (1/776) in controls. 
The control individual in whom the Q2089R variant was present is also of white Afrikaner ancestry and 
she had been recruited from the Geriatric Clinic at Tygerberg Hospital in Cape Town. She was 82 years 
old at recruitment and at the time of her death at the age of 83 years, she had apparently not exhibited 
any signs of PD. There was no information available on her family history of PD. 
 
3.2 In-silico analysis 
3.2.1 Functional predictions 
Bioinformatics tools including SIFT, Polyphen, Mutation Taster and the Combined Annotation 
Dependent Depletion (CADD) score were employed to predict the effect of the Q2089R variant on 
protein function.  SIFT predicted that the Q to R substitution was ‘deleterious’ (score = 0.02) and that 
it would affect likely protein function. Polyphen predicted the variant to be ‘possibly damaging’ with 
a score of 0.689 (1.0 being the highest possible score) and Mutation Taster predicted the variant to be 
disease-causing with a score of 0.95; 1.0 being the highest possible score. A CADD score of 24.1 was 
predicted for Q2089R providing further evidence of the deleteriousness of this variant, while G2019S 
has a CADD score of 35 (CADD scores range from 1 – 99 with 1 being the lowest and 99 the highest 
score of deleteriousness) (Kircher et al., 2014). Scores of >20 indicate that the substitution is in the 
upper 1% of substitutions least likely to be observed, thus indicating that the variant could have 
functional implications. 
 
3.2.2 Protein modeling  
Project Hope reported that the 2089R amino acid has different properties to the WT allele, which 
could affect and possibly abolish the protein function (Venselaar et al., 2010). Although the exact 
crystal structure of the LRRK2 protein is still unknown, a model of LRRK2 was generated based on the 
Mixed-lineage kinase 1 (MLK1) kinase domain (PDB ID: 4UY9)(West et al., 2007) using SWISS-MODEL 
(https://swissmodel.expasy.org) and Modeller (https://salilab.org/modeller/). The sequence identity 
of MLK1 with LRRK2 was 35.10% and the coverage was 100%. However, it is important to bear in mind 
that Q2089 is on a large loop in the protein structure, and disordered structures like loops are 
extremely difficult to model with any degree of accuracy.  This is due to the fact that they do not have 
definite conformations like helices or sheets and are also very flexible, with the component residues 
being able to move more easily relative to each other as well as to the rest of the protein. Figure 3.4 
Stellenbosch University  https://scholar.sun.ac.za
63 
 
shows the amino acid structures of the glutamine (Q) (left) and Arginine (R) (right) amino acids. The 
backbone, which is the same for all amino acids, is colored red, and the side chain, unique for each 
amino acid, is shown in black.  
 
Figure 3.4 Residue change from LRRK2 WT to LRRK2 Q2089R.  The illustration shows the change in 
the residue side chain when the Glutamine (Q) at position 2089 in LRRK2 changes to an Arginine (R). 
(Venselaar et al., 2010). 
 
The variant residue is much larger than the WT residue (Figure 3.4). Also, the WT (Q) residue is a 
neutral polar amino acid while the variant introduces a charged aliphatic amino acid which could cause 
repulsion between variant and neighboring residues. Additionally, this residue is located on the 
surface of the protein (Figure 3.5) and is located in the central catalytic core of LRRK2, and this region 
is speculated to be important for binding of other proteins or molecules (Cookson, 2010). We 
therefore hypothesize that when Q is mutated to R in LRRK2, possible protein-protein interactions 
could be disturbed and that this substitution could possibly affect the function and activity of the 
protein. 
 
Figure 3.5 Visual representation of the substitution from Glutamine to Arginine at position 2089 in 
a model of LRRK2’s kinase domain. Homology model of the LRRK2 kinase domain with the wild type 
(WT) residue, Glutamine (Q), shown in green and the mutant residue, Arginine (R), shown in red. The 
variant results in a significant change in the protein structure as seen in this representation (Venselaar 
et al., 2010). 
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3.3 Generation of cellular models to study LRRK2 Q2089R 
We attempted to study the functional effect of Q2089R in comparison to WT and the common G2019S 
mutation using various cellular models. In order to generate these models, we used different 
approaches including the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas9 
system, site-directed mutagenesis and collection of patient-derived dermal fibroblasts. In all 
experiments, G2019S was used as a control for comparison purposes as the effect of this mutation 
has been well-studied in previous studies. 
 
3.3.1 CRISPR-Cas9  
Firstly, in order to generate a suitable model to study LRRK2 WT and mutants, the (CRISPR)-Cas9 
system was considered. This is an RNA-guided gene-editing platform derived from Streptococcus 
pyogenes that makes use of an endonuclease (Cas9) and a synthetic guide RNA to introduce a double 
strand break at a specific location within the genome. The human neuroblastoma cell line, SHSY5Y, 
was selected for these experiments as they are adrenergic in phenotype but also express 
dopaminergic markers and have previously been used to study PD (Lopes et al., 2010; Xie et al., 2010). 
Target sequences were carefully selected based on GeneArt® CRISPR Nuclease Vector Kit guidelines 
directly upstream of proto-spacer adjacent motif (PAM) sequences (Appendix III, Figure 3). 
Two single-stranded DNA oligonucleotides with overhangs complementing the linearized GeneArt® 
CRISPR Nuclease Vector were designed (Appendix III, Table 1). The top strand targets the CRISPR RNA 
(crRNA) and the bottom strand is its complement. Also, long DNA templates, carrying the mutated 
sequences, were designed to be co-transfected into SHSY5Y cells and to serve as the template to be 
incorporated into the cellular genome during DNA repair (Appendix III, Table 1). The strands were 
annealed and ligated into the linearized Orange Fluorescent Protein (OFP) reporter vector. Sanger 
sequencing of the resulting plasmids show that the guide sequences were successfully ligated into the 
reporter vectors (Figure 3.6). 
However, it was then discovered that the SHSY5Y cell line is not compatible with the CRISPR-Cas9 
system, since the CRISPR-Cas9 system requires that cells are able to generate a new cell line from a 
single cell, which SHSY5Y cells are not able to do (personal communication, Dr Sally Cowley, James 
Martin Stem Cell Facility, Sir William Dunn School of Pathology, United Kingdom and Ms. Liesl Brand, 
Sales Specialist, Sigma-Aldrich (Pty) LTD, South Africa). 
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Figure 3.6 Sanger sequencing of CRISPR reporter vectors. A) The guide sequence of LRRK2 exon 41 
was successfully ligated into the GeneArt® CRISPR Nuclease OFP reporter vector. B) The guide 
sequence of LRRK2 exon 42 was successfully ligated into the GeneArt® CRISPR Nuclease OFP reporter 
vector. 
 
This is a requirement of this system because CRISPR theoretically randomly mutates every allele 
differently, and because the pool of positively transfected/edited cells will always contain a 
percentage of WT background. Subsequently, we also learnt that off-target effects are a major 
problem of the CRISPR genome editing system especially with the system that we were using. These 
off-target effects can be difficult to identify and require whole genome sequencing to determine 
whether mutations have been introduced at sites with sequence similarity to that of the gRNA target 
sequence. Furthermore, DNA repair through non-homologous end joining (NHEJ) can also produce 
different mutations from the same targeting constructs, thus also creating the need for whole genome 
sequencing before conducting any downstream laboratory experiments. This makes the CRISPR-Cas9 
technique rather labor intensive, time-consuming and expensive. Therefore, the CRISPR-Cas9 genome 
editing approach was abandoned and we considered alternative techniques to create cellular models 
to study the effect of Q2089R. 
 
3.3.2 LRRK2 Q2089R construct generated using site-directed mutagenesis 
Two commercially available plasmids namely pDEST53 LRRK2 WT and (LRRK2 WT) and pDEST53 LRRK2 
G2019S (LRRK2 G2019S) (Appendix I) which encode N-terminally tagged GFP-LRRK2 fusion proteins 
Vector backbone 
LRRK2 exon 41 guide 
LRRK2 exon 42 guide 
A 
B 
LRRK2 exon 41 
guide insert 
LRRK2 exon 42 
guide insert 
Vector backbone 
Vector backbone 
Vector backbone 
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were used for transfections. The WT plasmid was used to generate a LRRK2 Q2089R construct. These 
plasmids were purified from E. coli and sequenced using specific primer sets (Table 2.7) to confirm the 
absence and presence of the G2019S mutation in the LRRK2 WT sample (WT codon GGC) and LRRK2 
G2019S plasmid sample (G2019S codon AGC), respectively (Figure 3.7). Additionally, the GUS insert (a 
gift from Mr. J Gallant, Stellenbosch University, South Africa) was cloned into the pDEST53 empty 
vector, and used as a negative control in subsequent experiments. 
 
 
Figure 3.7 Sequence alignments of LRRK2 WT and LRRK2 G2019S plasmid sequences. The black arrow 
indicates the position of the G2019S mutation which was present in the LRRK2 G2019S plasmid 
sequence (AGC) and absent in the LRRK2 WT plasmid sequence (GGC). Abbreviations: A, adenine; C, 
cytosine; G, guanine; T, thymine. 
 
The Q5® Site-Directed Mutagenesis Kit was used to generate a pDEST53 LRRK2 Q2089R plasmid using 
the pDEST53 LRRK2 WT construct as a template.  Specific primers were designed to synthesize the full-
length plasmid (Table 2.1) and these plasmids were transformed into E. coli and purified for 
sequencing. The purified plasmid was sequenced using specific exonic primers (Table 2.4) to confirm 
the presence of the Q2089R variant in the correct position, to confirm the open reading frame and to 
verify the absence of any other variants that might have been introduced during site-directed 
mutagenesis.  
 
Figure 3.8 Sequence alignments of LRRK2 WT and LRRK2 Q2089R sequences. Sequencing results 
validated the presence of the Q2089R variant at the correct position in the newly generated LRRK2 
Q2089R construct. The LRRK2 WT codon, CAA, was successfully mutated to CGA with no other SNPs 
being introduced into the sequence.  The black arrow indicates the position of the Q2089R variant 
present in the LRRK2 Q2089R sequence (CGA) and absent in the LRRK2 WT sequence (CAA). 
 
Figure 3.8 shows the alignment between the LRRK2 WT construct (CAA) and the LRRK2 Q2089R 
construct (CGA). Therefore, we had successfully generated a construct containing Q2089R.  
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3.3.3 Patient-derived fibroblasts  
Skin biopsies were obtained from individuals with WT, G2019S or Q2089R LRRK2 genotypes to study 
the functional effects of the variants in an ex vivo model. These individuals included five with no 
mutations in LRRK2, one individual carrying the G2019S mutation [Appendix V, Figure 1, individual 
III:2), (Bardien et al., 2010)], and one individual carrying the Q2089R variant (Figure 3.2 A, individual 
III:1) (Table 2.3). We were not able to obtain a skin biopsy from the Q2089R-positive proband as he 
was deceased at the time of biopsy sampling.   
The dermal fibroblasts were successfully cultured from all of these biopsies.  RNA was extracted from 
the patient fibroblasts, converted to cDNA and exons 41 and 42 were PCR-amplified. The resulting 
fragments were sequenced to confirm the presence of the G2019S mutation and the Q2089R variant 
in the respective exons (Figure 3.9).  
 
 
Figure 3.9 Sequence chromatograms of exons 41 and 42 of patient derived fibroblasts A) Sequence 
of exon 41 of cDNA extracted from fibroblasts carrying the G2019S mutation (as indicated by the black 
arrow). B) Sequence of exon 42 of cDNA from fibroblasts carrying the Q2089R variant (as indicated by 
the black arrow) Abbreviations: A, adenine; C, cytosine; G, guanine; R, purine (either a G or an A); T, 
thymine. 
 
Therefore, in summary we had successfully generated two cellular models to study the effect of 
Q2089R in comparison to WT and G2019S. The WT, G2019S and Q2089R constructs were used to 
transfect either HEK293 or COS7 cells, and this represented the ‘overexpression’ model in our study 
to investigate the functional effect of G2019S and Q2089R in vitro. The dermal fibroblasts served as 
an ex vivo model and were used to compare the findings from the overexpression model. 
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3.4 Q2089R exhibits reduced autophosphorylation 
As Q2089R is located within the kinase domain of LRRK2, 70 amino acids downstream of G2019S, we 
postulated that is could affect the kinase activity of LRRK2. HEK293 cells were transfected with LRRK2 
WT, G2019S, Q2089R or the pDEST53-GUS control vector. Western blot analysis was performed using 
the anti-LRRK2 phospho-Ser1292 autophosphorylation antibody as an indirect indicator of kinase 
activity. Results from three biological replicate experiments indicated that HEK293 cells transfected 
with G2019S exhibited a significant increase in autophosphorylation (p=0.019) (Figure 3.10). 
       Transfected HEK293 cells 
 
Figure 3.10 Phospho-Ser1292 autophosphorylation of LRRK2 in transfected HEK293 cells. A) A 
representative western blot probed with anti-LRRK2 (pSer1292) antibody which was used to determine 
the autophosphorylation status of untransfected (Negative), LRRK2 WT, G2019S and Q2089R. B) A 
representative western blot probed with anti-GFP antibody. This value approximates total LRRK2 since 
levels of endogenous LRRK2 was negligible relative to the levels of the GFP-fusion proteins. C) Three 
independent western blots were quantified to indicate LRRK2 (pSer1292) autophosphorylation relative 
to GFP-LRRK2 levels. LRRK2 G2019S showed significant higher levels of autophosphorylation while 
LRRK2 Q2089R exhibited nearly undetectable autophosphorylation levels (Unpaired t-test, *p<0.05). 
 
Notably, Q2089R exhibited almost completely abolished autophosphorylation activity (p=0.026), 
(Figure 3.10). These results suggest that the novel variant may eliminate the kinase activity of LRRK2 
and this finding correlates with in silico protein prediction results which indicated that Q2089R could 
affect protein function.  
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3.5 Q2089R decreases metabolic activity  
Next, we decided to investigate whether Q2089R affects the cells’ metabolic activity. HEK293 cells 
were transfected with plasmids expressing WT, G2019S or Q2089R, and the effect on metabolic 
activity was assessed using the MTT assay. A significant decrease in metabolic activity was observed 
in cells overexpressing G2019S (p=0.021) (Figure 3.11 A). Interestingly, Q2089R also significantly 
decreased the cellular metabolic activity (p=0.016) (Figure 3.11 A). The control vector did not have 
any effect on metabolic activity (p=0.078) and the transfection efficiencies were comparable between 
all samples (Figure 3.11 B). 
Transfected HEK293 cells  
 
Figure 3.11 Metabolic activity of LRRK2 WT and mutants transfected into HEK293 cells. A) A decrease 
in metabolic activity was observed in HEK293 cells expressing LRRK2 G2019S and LRRK2 Q2089R 
compared to LRRK2 WT. The control vector did not have any effect on metabolic activity when 
compared to WT cells. Data is represented as percentage (%) cell viability. B) The transfection 
efficiencies were statistically comparable between constructs (One-way ANOVA, Bonferroni’s 
posttest, *p<0.05). Data is represented as the % of cells expressing the GFP tagged LRRK2 (WT, G2019S 
or Q2089R) or GFP control constructs (pDEST53-GUS) after transfection. 
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To further investigate and validate these findings, the experiment was also conducted on dermal 
fibroblasts. The metabolic activity of the individual fibroblasts were investigated over a period of five 
days at 24 hourly intervals.  
At 24 and 48 hours, no significant differences were observed between the WT and mutant fibroblasts 
however, after 72 hours the metabolic activity of Q2089R positive fibroblasts significantly declined 
(p=0.003) (Figure 3.12). This reduced metabolic activity continued through 96 hours (p=0.004) and 120 
hours (p=0.001). The G2019S fibroblasts also showed a significant decline in metabolic activity rate at 
72 hours (p=0.03), 96 hours (p=0.01) and 120 hours (p=0.001) (Figure 3.12). 
 
Fibroblasts 
 
Figure 3.12 Metabolic activity of WT and mutant LRRK2 fibroblasts. A decrease in metabolic activity 
was observed in G2019S and Q2089R-positive fibroblasts compared to WT fibroblasts. Values were 
calculated from four replicates per group and normalized using the CyQUANT® NF cell proliferation 
assay. Significant differences were observed between the mutant and WT cells at 72 hours, 96 hours 
and 120 hours (two-way ANOVA, Bonferroni’s posttest, *p<0.05, **p<0.01 and ***p<0.001). 
 
This indicates that mutant LRRK2 fibroblasts exhibit lower metabolic activity than cells containing WT 
LRRK2. At this stage, we are unsure of the reason(s) for these differences in metabolic activity for both 
HEK293 cells and primary cell lines since the reduction in metabolic activity may be due to a decrease 
in enzyme activity, cell viability or cytostatic activity which means that the cells shift from proliferation 
to quiescence. 
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3.6 Q2089R reduces mitochondrial membrane potential  
Next, we evaluated the effect of WT and mutant LRRK2 on MMP in both transfected HEK293 cells as 
well as in patient derived fibroblasts using JC-1 dye. When MMP is maintained, JC-1 is able to 
permeabilize the mitochondrial membrane, aggregate inside mitochondria and emit a fluorescence 
signal in the red (PE) channel. When MMP is lost through the depolarization of cells, JC-1 diffuses into 
the cytoplasm and is converted into its monomeric form which emits fluorescence through the green 
(FITC) channel. Changes in MMP were determined by calculating the ratio of PE/FITC mean intensity 
values, and lower ratio values were associated with decreased MMP. 
Results from the flow cytometric analysis in HEK293 cells indicated that transfected LRRK2 WT did not 
have any effect on MMP compared to untransfected cells (Figure 3.13, A). However, treatment with 
CCCP (a potent mitochondrial uncoupler) significantly lowered the MMP of treated cells (p=0.0065) 
(Figure 3.13 B).  
Transfected HEK293 cells 
 
Figure 3.13 Mitochondrial membrane potential of transfected HEK293 cells. A) LRRK2 WT did not 
affect mitochondrial membrane potential (MMP) compared to untransfected (control) cells. B) 
Treatment with the mitochondrial uncoupler, CCCP, caused a significant decrease in MMP, as 
expected. C) Both G2019S and Q2089R showed significantly lower MMP compared to WT cells under 
basal conditions. Transfection with pDEST53-GUS (the negative control vector) did not have any effect 
on MMP. D) When cellular stress was induced by CCCP treatment (10µM) the MMP was comparable 
between all groups (One-way ANOVA, Bonferroni’s posttest, *p<0.05). 
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Both G2019S and Q2089R, significantly reduced MMP compared to WT cells (p=0.038 and p=0.043, 
respectively; Figure 3.13 C). The negative control vector (pDEST53-GUS) did not have any effect on 
MMP. These findings suggested that both G2019S and Q2089R could induce mitochondrial 
dysfunction by depolarizing the mitochondrial membrane. Once MMP is lost, mitochondria cannot 
function normally which could lead to cell death. To interrogate the MMP of these cells under stress 
conditions, cells were treated with CCCP. However, interestingly, no significant changes were 
observed between the different groups under stress-induced conditions (Figure 3.13, D). 
Next, the effect of MMP on patient derived fibroblasts was investigated. A notable difference between 
WT cells was detected when treating the cells with CCCP, significantly decreasing the MMP of the 
fibroblasts as expected (p<0.0001) (Figure 3.14 A). Interestingly, results showed that G2019S and 
Q2089R carrying fibroblasts did not display any difference in PE/FITC ratios compared to control 
fibroblasts under basal conditions (Figure 3.14 B). After treatment with CCCP, flow cytometric results 
revealed that the MMP of Q2089R fibroblasts were significantly reduced (p=0.009, Figure 3.14 C). 
G2019S fibroblasts also exhibited reduced MMP although it did not reach statistical significance 
(p=0.057, Figure 3.14 C).  
              Fibroblasts       
      
Figure 3.14 Mitochondrial membrane potential of patient derived fibroblasts. A) Treatment of WT 
LRRK2 fibroblasts with the mitochondrial uncoupler, CCCP, caused a significant decrease in 
mitochondrial membrane potential (MMP), as expected. B) Under basal conditions G2019S and 
Q2089R carrying fibroblast did not affect MMP. C) Induction of cellular stress using CCCP treatment 
(10µM) caused Q2089R cells to display significantly lower MMP compared to WT cells (Unpaired t-
test, **p<0.01, ****p<0.0001). 
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These findings suggest that the G2019S fibroblasts in our study are less susceptible to extracellular 
stress and can maintain their MMP even under stressed conditions. Our results also indicate that 
fibroblasts carrying Q2089R are more vulnerable to extracellular stressors which could indicate that 
mitochondria in Q2089R carrying fibroblasts are not functioning optimally. 
 
3.7 Q2089R affects mitochondrial and glycolytic respiration  
The fact that Q2089R cells exhibit reduced MMP was interesting, and we therefore investigated 
whether Q2089R could affect mitochondrial respiration and glycolysis. These experiments were done 
in both transfected HEK293 cells and patient derived fibroblasts, on the Seahorse XF Analyzer. This 
instrument measures oxygen consumption rates (OCR) as well as the protons released during 
glycolysis, also known as extracellular acidification rate (ECAR) of the media surrounding the cells. This 
was used to determine the bioenergetic status of cells. For the HEK293 cells an average of 20 replicate 
measurements for each group (n=20) was performed, and for the fibroblasts there were an average 
of 10 replicate measurements for each patient and control sample (n=10). The results from four 
control fibroblasts were grouped together for analysis of OCR and ECAR. 
 
3.7.1 Mitochondrial Stress Test 
A series of OCR measurements were taken for each group. Respiration was first measured at baseline 
(basal respiration) followed by three measurements after the addition of Oligomycin, a potent 
complex V inhibitor of the ETC, which causes inhibition of ATP synthesis.  
The ATP-linked respiration was calculated by measuring the difference between basal respiration and 
the minimum OCR measurement after Oligomycin injection. OCR measured here was due to the 
proton leak across the IMM. Carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP) was 
subsequently added to uncouple the mitochondria in order to measure the maximum rate at which 
mitochondria respire, known as maximal respiration. This also allows for the calculation of spare 
respiratory capacity (taken as the difference between OCR of maximal respiration and basal 
respiration). Finally, Rotenone and Antimycin A, the complex I and III inhibitors, respectively were 
added to completely deplete mitochondrial respiration. This was necessary to measure non-
mitochondrial OCR. The ratio of ATP-linked respiration over basal OCR was used in order to calculate 
the ATP-coupling efficiency. 
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The point-by-point data of OCR, indicative of oxidative phosphorylation, for transfected HEK293 cells 
and the fibroblasts are shown in Figure 3.15 A and B, respectively. After analysis of the data, the values 
were plotted as bar graphs for the various parameters measured to facilitate statistical comparisons 
between the groups (Figure 3.16 and 3.17).  
 
Figure 3.15 Oxygen consumption rate (OCR) profiles of transfected HEK293 cells and patient derived 
fibroblasts. The graphs represent the OCR for each group of the transfected HEK293 cells (A) and 
patient derived fibroblasts (B) after the addition of drug compounds. Abbreviations: Oligo, 
Oligomycin; FCCP, carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon; Rot, Rotenone; Anti A, 
Antimycin A. 
 
As shown in Figure 3.16, in transfected HEK293 cells, the only difference observed was that Q2089R 
had significantly reduced mitochondrial respiration under basal conditions compared to WT cells 
(Figure 3.16 A, p=0.044). Q2089R did not exhibit any additional changes in OCR (Figure 3.16 B-F). 
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G2019S and the negative control vector (pDEST53-GUS) did not show significant differences for any of 
the OCR parameters investigated (Figure 3.16 A-F). 
 
Transfected HEK293 cells 
 
Figure 3.16 Parameters of mitochondrial respiration in transfected HEK293 cells. Q2089R reduced 
basal respiration (A) but did not affect ATP production (B), Proton leak (C), ATP coupling efficiency (D), 
Maximal respiration (E) or Spare respiratory capacity (F) in HEK293 cells. G2019S and pDEST53-GUS 
did not result in any changes of OCR compared to WT cells (A-F) (One-way ANOVA, Bonferroni’s 
posttest, *p<0.05). 
 
Next, we determined the OCR of the fibroblasts. Raw data showed that, at basal respiration, the 
Seahorse profiles were near identical for each of the control fibroblasts (Figure 3.15 B, measurement 
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one to three). It was subsequently decided to conduct grouped analysis with these cell lines. 
Interestingly, the basal respiration of both G2019S and Q2089R fibroblasts were significantly increased 
when compared to WT cells (p=0.029 and p=0.012, Figure 3.17 A) but only G2019S fibroblasts 
exhibited increased ATP-linked respiration (p=0.029, Figure 3.17 B).  
Furthermore, Q2089R showed a pronounced increase in proton leak (p=0.0001, Figure 3.17 C) and 
significantly reduced ATP coupling efficiency compared to WT fibroblasts (p=0.0014, Figure 3.17 D). 
Maximal respiration was induced by the addition of FCCP, causing the direct transport of protons 
across the IMM instead of through the ATP synthase proton channel which results in rapid oxygen 
consumption without the generation of ATP.  
The difference between maximal respiration and basal respiration represents spare respiratory 
capacity which is a feature indicative of cellular health and survival during times of high energy 
demand in the cell. In our study, Q2089R fibroblasts exhibited a considerably higher rate of maximal 
respiration and spare respiratory capacity compared to healthy control cells (p<0.001 and p<0.001, 
Figure 3.17 E and F). G2019S fibroblasts did not exhibit any effect on proton leak, ATP coupling 
efficiency, maximal respiration or spare respiratory capacity (Figure 3.17 D-F).  
Fibroblasts 
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Figure 3.17 Parameters of mitochondrial respiration in control and patient derived fibroblasts. A) 
G2019S and Q2089R exhibit increased basal mitochondrial OCR. B) G2019S shows increased ATP-
linked respiration while Q2089R did not have any effect. Q2089R increased OCR due to increased 
proton leak respiration (C) and decreased ATP coupling efficiency (D). Q2089R increased Maximal 
respiration (E) and Spare respiratory capacity (F). (Unpaired t-test, *p<0.05, **p<0.01 and 
***p<0.001). 
 
Taken together, our findings indicate that the G2019S fibroblasts used in our study do not exhibit 
major mitochondrial deficits whereas the Q2089R fibroblasts show clear signs of mitochondrial 
dysfunction. Thus, although maximal respiration and spare respiratory capacity was significantly 
increased for Q2089R fibroblasts, the concurrent increase in ‘proton leak respiration’ and the reduced 
ATP-coupling efficiency leads us to speculate that the mitochondria in Q2089R fibroblasts cannot fulfil 
the energy requirements of the cells. Additionally, the marked increase in maximal respiration and 
spare respiratory capacity could be ascribed to a possible compensatory mechanism exhibited by 
these cells.  
 
3.7.2 Glycolysis Stress Test 
When the oxidative phosphorylation system becomes damaged or is inhibited, glycolysis can become 
the main producer of ATP in the cell. Therefore, it is essential to investigate glycolytic function to 
understand the complete effect of mutations or variants on cellular function and energy demands. 
The point-by-point data of ECAR, indicative of glycolysis, for transfected HEK293 cells and fibroblasts 
are shown in Figure 3.18 A and B, respectively. Individual reagents were sequentially added to the 
cells to investigate the glycolytic function for each group. 
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Figure 3.18 Extracellular acidification rate (ECAR) profiles of transfected HEK293 cells and patient 
derived fibroblasts. The graphs represent the ECAR for each group of the transfected HEK293 cells (A) 
and patient derived fibroblasts (B) in glucose-free medium after the addition of compounds. 
Abbreviations: Oligo, Oligomycin; 2-DG, 2-deoxy-D-glucose. 
 
The ECAR of basal (non-glycolytic acidification) rate was determined in glucose-free medium. 
Subsequently, a saturating concentration of glucose was added to the medium to measure the rate of 
glycolysis. Thereafter, the ATP synthase inhibitor Oligomycin was added to determine the glycolytic 
capacity of cells. This was calculated by the difference between ECAR at basal levels and after the 
Stellenbosch University  https://scholar.sun.ac.za
79 
 
addition of Oligomycin. Lastly, 2-DG which inhibits glycolysis was added to the medium. Glycolytic 
reserve was determined by the difference between ECAR of glycolytic capacity and ECAR of glycolysis. 
Again, the individual data are plotted as bar graphs in Figures 3.19 and 3.20. 
 
Results for transfected HEK293 cells revealed that G2019S and the negative control vector did not 
have any effect on the parameters of ECAR (Figure 3.19, A-D). However, Q2089R showed significantly 
reduced glycolytic reserve ECAR when compared to WT cells (p=0.012, Figure 3.19, D).  
 
Transfected HEK293 cells 
 
Figure 3.19 Parameters of glycolysis measured in transfected HEK293 cells. Cells transfected with 
Q2089R and G2019S did not have any effect on Basal respiration (A), Glycolysis (B) or Glycolytic 
capacity rates (C). Q2089R significantly reduced ECAR of Glycolytic reserve, while G2019S showed no 
changes (D) (One-way ANOVA, Bonferroni’s posttest, *p<0.05). The negative control (pDEST53-GUS) 
did not affect any of the parameters measured. 
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Subsequently, glycolysis was investigated in control and patient derived fibroblasts. Again, at basal 
levels, virtually indistinguishable glycolysis profiles were recorded for the control fibroblasts cell lines 
(Figure 3.18 B, measurement four to six) and grouped analyses were performed. In this model, G2019S 
fibroblasts displayed an increase in ECAR of glycolysis, (p=0.001, Figure 3.20, B), but did not have any 
effect on non-glycolytic acidification (basal), glycolytic capacity or glycolytic reserve when compared 
to control fibroblasts (Figure 3.20 A, C, and D).  
Fibroblasts 
 
Figure 3.20 Parameters of glycolysis measured in control and patient derived fibroblasts. A) G2019S 
and Q2089R did not affect Basal ECAR. B) G2019S increased Glycolysis while Q2089R did not have any 
affect.  Q2089R decreased ECAR of Glycolytic capacity (C) and Glycolytic reserve (D) however G2019S 
did not have any effect (Unpaired t-test, *p<0.05 and **p<0.01). 
 
Similarly, Q2089R did not cause any changes in non-glycolytic acidification (Figure 3.20 A) or glycolysis, 
although a trend for an increase was observed in the latter but this was not significant (p=0.051, Figure 
3.20 B). Interestingly, however, Q2089R markedly reduced the ECAR of glycolytic capacity (p=0.007) 
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and the glycolytic reserve (p=0.006, Figure 3.20 C and D). This decrease (in both HEK293 cells and 
fibroblasts) implies that Q2089R containing cells are not able to supply sufficient energy when it is 
required. Thus, although compensatory mechanisms are at work to a certain extent, these results 
indicate that Q2089R cells exhibit significant energy demand deficiencies.  
 
3.8 Q2089R exhibits increased mitochondrial DNA (mtDNA) copy number  
Increased mitochondrial biogenesis has previously been implicated as a compensatory response of 
patient fibroblasts (Grünewald et al., 2010; Pacelli et al., 2011) and to investigate this possibility, we 
determined the relative mtDNA copy number (RMCN) of each patient and control fibroblast sample. 
DNA was isolated from the fibroblasts and used to determine the RMCN using real-time PCR. Triplicate 
∆∆CT values were obtained for the nuclear gene, β-globin and the mtDNA gene, MT-ND2, and the 2-
∆∆C
T formula was used to calculate RMCN. The WT and mutant/variant cell lines remained in culture 
for at least one week before isolating DNA for RMCN determination in order to allow stabilization of 
the mitochondrial load. Additionally, passage numbers were matched between individuals (passage 
five to seven). When comparing the RMCN between individual WT cell lines, no differences were 
detected (One-way ANOVA, Bonferroni’s posttest, p>0.05, data not shown). Subsequently, grouped 
analysis revealed that fibroblasts carrying Q2089R had a significantly higher number of mitochondrial 
copies compared to control fibroblasts (p=0.0006, Figure 3.21) and that there was no difference 
between G2019S and WT cells.   
                     Fibroblasts 
 
Figure 3.21 Relative mtDNA copy number of control and patient derived fibroblasts. Q2089R positive 
fibroblasts contained significantly more copies of mitochondria when compared to control fibroblasts 
(Unpaired t-test, ***p<0.001). Abbreviations: RMCN, Relative mtDNA Copy Number. 
 
L R R K 2  W T G 2 0 1 9 S Q 2 0 8 9 R
0
2 5 0
5 0 0
7 5 0
1 0 0 0
R
M
C
N
C
o
p
ie
s
 o
f 
m
it
o
c
h
o
n
d
ri
a
*** 
Stellenbosch University  https://scholar.sun.ac.za
82 
 
We believe that the increase in mitochondrial biogenesis could possibly be due to compensatory 
mechanisms previously described (Grünewald et al., 2010). 
 
3.9 Q2089R enhances autophagic flux 
Furthermore, we sought to investigate the effect of Q2089R on autophagic flux. Autophagic markers 
LC3 II and P62 were employed to investigate the effect of WT and mutant LRRK2 on the rate of protein 
degradation through macro-autophagy i.e. autophagic flux. For these experiments, both LC3 II and 
P62 were measured after activation of basal autophagy under starvation conditions, in the presence 
and absence of a autophagosome-lysosome fusion inhibitor, Bafilomycin A 1 (BafA1). BafA1 prevents 
the degradation of the autophagosome-lysosome by inhibiting acidification. This inhibition blocks the 
degradation of LC3 II and P62, resulting in the accumulation or increase in LC3 II and P62 expression 
(since LC3 II proteins are incorporated within the inner and outer membrane of the autophagic 
vacuoles (AVs) and P62 binds to LC3 II in the autophagosomal membrane) (Klionsky et al., 2008; Barth 
et al., 2010).  
Transfected HEK293 cells were starved (in amino acid-free media) in the absence or presence of BafA1 
and LC3 II and P62 (Figure 3.22 A) levels were determined with and without BafA1 treatment. When 
LC3 II and P62 levels are increased after BafA1 treatment, this indicates that an accumulation of 
autophagosomes has occurred; indicating an increase in autophagic flux and increased clearance rates 
through autophagy. Conversely, when these levels are decreased after BafA1 treatment, the opposite 
is true. 
In our study, we showed the expected elevation in LC3 II after BafA1 treatment in all sample groups,  
indicating that the mechanism of autophagy was not defective and functioning correctly (Mizushima 
and Yoshimori, 2007) (Figure 3.22 A). Our analysis showed that in transfected HEK293 cells, G2019S 
did not have any significant effect on either LC3 II (p=0.322) or P62 (p=0.206) levels when compared 
to WT cells (Figure 3.22 B and C). Interestingly, however, a significant increase in LC3 II (p=0.004) and 
in P62 (p=0.018) levels were observed for Q2089R compared to WT LRRK2 (Figure 3.22 B and C). The 
increase in the autophagic markers suggests that the pool size of autophagosomes in Q2089R cells 
significantly increased. This suggested that in Q2089R cells, an accumulation of (AVs) had occurred. 
This could suggest that autophagy increases or perhaps that the degradation of AVs decreases 
(Manzoni et al., 2013a; Schapansky et al., 2014).          
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Transfected HEK293 cells 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Detection and quantification of autophagic markers LC3 II and P62 for transfected 
HEK293 cells. A) Representative Western blot images of HEK293 cells transfected with LRRK2 WT, 
G2019S and Q2089R in the absence (-BafA1) and presence (+BafA1) of BafA1 (n=3). Western blots 
were quantified and the difference in LC3 II and P62 before (-BafA1) and after (+BafA1) treatment was 
calculated and standardized to GFP-LRRK2 and GAPDH. Q2089R exhibited increased LC3 II (B) and 
increased P62 levels (C) when compared to LRRK2 WT. No significant differences in LC3 II (B) and P62 
levels (C) were observed for G2019S (Unpaired t-test, *p<0.05, **p<0.01). The experiments were done 
in three independent experiments (i.e. three biological replicate experiments). 
 
Additionally, this experiment was conducted on the fibroblasts (Figure 3.23 A) which also showed 
autophagy working correctly (an increase in LC3 II following BafA1 treatment) in all groups.  
Furthermore, we detected significantly increased LC3 II levels in both G2019S and Q2089R carrying 
fibroblasts (p=0.022 and p=0.031, Figure 3.23 B). Interestingly, when quantifying P62 levels, both 
G2019S and Q2089R indicated an enhanced autophagosomal pool size, although only Q2089R reached 
statistical significance (p=0.131 and p=0.006, respectively, Figure 3.23 C).  
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 Fibroblasts 
 
 
 
Figure 3.23 Detection and quantification of autophagic markers LC3 II and P62 in control and patient 
derived fibroblasts. A) Representative Western blot images of individual fibroblasts in the absence (-
BafA1) and presence (+BafA1) of BafA1 (n=3). Western blots were quantified and the difference in LC3 
II and P62 before (-BafA1) and after (+BafA1) treatment was calculated and standardized to total 
LRRK2 and GAPDH. Q2089R exhibited increased LC3 II (B) and P62 levels (C). G2019S fibroblasts 
showed an increase LC3 II signal (B). The increase in P62 levels were not significant (C) (Unpaired t-
test, *p<0.05, **p<0.01). 
 
In conclusion, we observed an increase in autophagic flux in both transfected HEK293 cells and 
fibroblasts carrying Q2089R when compared to control cells. Therefore, we speculate that the 
increased autophagy observed in Q2089R cells could indicate that toxic products (such as 
dysfunctional mitochondria) are accumulating in the cell, triggering the upregulation of autophagy. 
 
3.10 Wild type LRRK2 interacts with the translocase of outer mitochondrial 
membrane (TOM) complex 
In our final experiment, as  LRRK2 has previously been associated with the OMM and with evidence 
implicating the TOM complex in PD (Bender et al., 2013; Bertolin et al., 2013), we investigated the 
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possible co-localization of WT LRRK2 and essential subunits of the TOM protein complex using 
confocal imaging and co-localization analysis. The co-localization experiments were performed on two 
commercial cell lines, COS7 cells and HEK293 cells. The confocal imaging was done on COS7 cells as 
these cells are large and therefore it is easier to visualize the cellular structures. Also, many previous 
co-localization experiments on LRRK2 had been done in these cells (Gloeckner et al., 2006; Greggio et 
al., 2006; Bertolin et al., 2013). The super-resolution imaging was done on HEK293 cells as the work 
on the COS7 cells had been done in Dr. Corti’s laboratory in France and were not available in our 
laboratory in South Africa.  
 
3.10.1 Co-localization of LRRK2 and TOM subunits using confocal microscopy  
Intracellular localization of LRRK2 and the subunits of the TOM complex (TOM20, TOM22, TOM40 and 
TOM70) in transfected COS7 cells showed co-localization between LRRK2 and all of subunits under 
normal physiological conditions (Figure 3.24). Visually, the co-localization output indicated that LRRK2 
occupies the same three-dimensional subcellular space as the proteins of the TOM complex (Figure 
3.24, D, H, L and P).  
Images were corrected for background noise by including negative control images with every 
experiment and image acquisition. The images were analyzed using ImageJ software 
(https://imagej.nih.gov/ij/) and the JaCoP plugin analysis. Both Mander’s coefficient and the overlap 
coefficient algorithms were used for the quantification of confocal co-localization images (Appendix 
IV, Table 8).  
According to Mander’s coefficients, approximately 20% of the total overexpressed LRRK2 (M1) co-
localizes with the proteins of the TOM complex (Table 3.1). Furthermore, roughly 25-60% of each 
individual TOM subunit (column labelled M2 in Table 3.1) co-localizes with LRRK2. In each co-
localization experiment, the overlap coefficient was equal to or higher than 0.9, i.e. close to 1, 
indicating a high degree of overlap between green and red pixels.  
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Figure 3.24 Fluorescent confocal imaging and co-localization analysis of LRRK2 and the subunits of 
the TOM complex in transfected COS7 cells. The fluorescent images of endogenous TOM proteins 
(Red): TOM20 labelled with donkey anti-mouse cy3 (A), TOM22 labelled with donkey anti-mouse cy3 
(E), TOM40 labelled with donkey anti-rabbit cy3 (I) and TOM70 labelled with donkey anti-mouse cy3 
(M) co-localized with exogenous LRRK2 (Green) labelled with donkey anti-rabbit Alexa 488 (B, F and 
N) and exogenous LRRK2 (Green) labelled with donkey anti-mouse Alexa 488 (J). Images C, G, K and O 
show the overlay of LRRK2 and the respective TOM proteins. Figures D, H, L and P represent the red 
and green pixels that co-localize (White). Scale bar 20µm. 
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Table 3.1 Quantification of co-localization between LRRK2 and the TOM protein complex in COS7 
cells 
Subunit Mander’s Coefficient Overlap coefficient 
 M1 M2  
TOM20 0.253 0.632 0.90 
TOM22 0.240 0.547 0.93 
TOM40 0.190 0.520 0.92 
TOM70 0.170 0.250 0.93 
Abbreviations: M1, Mander’s coefficient for the green channel; M2, Mander’s coefficient for the red 
channel. 
 
Taken together, in each of the co-localization experiments the visual outputs as well as the co-
localization coefficients, indicate that LRRK2 positively co-localizes with the subunits of the TOM 
complex. 
 
3.10.2 Co-localization of LRRK2 and TOM subunits using super-resolution 
microscopy 
To confirm the co-localization of LRRK2 with the TOM complex subunits, HEK293 cells were 
transfected with LRRK2 and investigated using super resolution microscopy (SR-SIM). SR-SIM allows 
the detection of co-localizing pixels with a resolution of 100-200nm, thus providing a more accurate 
measure of protein co-localization. The co-localization results for LRRK2 and TOM20 (Figure 3.25), 
TOM22 (Figure 3.26), TOM40 (Figure 3.27) and TOM70 (Figure 3.28) are shown.  
In each figure, panels A and E are overlay images of LRRK2 (green) and the respective TOM subunits 
(red), B and F show zoomed images to focus on specific pixels in A and E, respectively, and C and G 
represents scatter diagrams. These scatterplots are important as they provide a qualitative indication 
of the degree of co-localization in the third quadrant (Dunn et al., 2011). Panels D and H show the 
overlap of pixels from B and F, respectively, occupying the exact same subcellular space and thus 
signifies the co-localized pixels. 
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Figure 3.25 Super resolution images and co-localization analysis of LRRK2 and TOM20 under basal 
(DMSO) and stress conditions (CCCP) in transfected HEK293 cells. Overlay of LRRK2 labelled with 
donkey anti-rabbit Alexa 488 secondary antibody (Green) and TOM20 labelled with donkey anti-
mouse cy3 secondary antibody (Red) treated with DMSO (A) and CCCP (E). Enlarged images of overlays 
(B and F) and co-localized pixels (D and H). Scatter diagram generated by co-localization analysis of 
LRRK2 and TOM20 with DMSO (C) or CCCP (G) treatment. Scale bar: 5µm (A and E), 2 µm (B and F). 
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Figure 3.26 Super resolution images and co-localization analysis of LRRK2 and TOM22 under basal 
(DMSO) and stress conditions (CCCP) in transfected HEK293 cells. Overlay of LRRK2 labelled with 
donkey anti-rabbit Alexa 488 secondary antibody (Green) and TOM22 labelled with donkey anti-
mouse cy3 secondary antibody (Red) treated with DMSO (A) and CCCP (E). Enlarged images of overlays 
(B and F) and co-localized pixels (D and H). Scatter diagram generated by co-localization analysis of 
LRRK2 and TOM22 with DMSO (C) or CCCP (G) treatment.  Scale bar: 5µm (A and E), 2 µm (B and F). 
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Figure 3.27 Super resolution images and co-localization analysis of LRRK2 and TOM40 under basal 
(DMSO) and stress conditions (CCCP) in transfected HEK293 cells. Overlay of LRRK2 labelled with 
donkey anti-mouse Alexa 488 secondary antibody (Green) and TOM40 labelled with donkey anti-
rabbit cy3 secondary antibody (Red) treated with DMSO (A) and CCCP (E). Enlarged images of overlays 
(B and F) and co-localized pixels (D and H). Scatter diagram generated by co-localization analysis of 
LRRK2 and TOM40 with DMSO (C) or CCCP (G) treatment.  Scale bar: 5µm (A and E), 2 µm (B and F). 
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Figure 3.28 Super resolution images and co-localization analysis of LRRK2 and TOM70 under basal 
(DMSO) and stress conditions (CCCP) in transfected HEK293 cells. Overlay of LRRK2 labelled with 
donkey anti-rabbit Alexa 488 secondary antibody (Green) and TOM70 labelled with donkey anti-
mouse cy3 secondary antibody (Red) treated with DMSO (A) and CCCP (E). Enlarged images of overlays 
(B and F) and co-localized pixels (D and H). Scatter diagram generated by co-localization analysis of 
LRRK2 and TOM70 with DMSO (C) or CCCP (G) treatment.  Scale bar: 5µm (A and E), 2 µm (B and F). 
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Quantitative analysis of overlapping pixels and intensities using the Zeiss Zen black edition software 
package showed that LRRK2 did not co-localize with TOM20 under basal conditions (Figure 3.25 A-D). 
However, co-localization was confirmed between LRRK2 and the other subunits under these 
conditions (TOM22, Figure 3.26 A-D; TOM40, Figure 3.27 A-D; and TOM70, Figure 3.28 A-D).  
Next, we investigated the co-localization of LRRK2 and the TOM complex under stress induced 
conditions (using CCCP to induce damage to mitochondria) based on previous studies showing the 
accumulation of PINK1 on the OMM and the subsequent translocation of Parkin to the OMM during 
mitochondrial stress (Geisler et al., 2010; Narendra et al., 2010; Vives-Bauza et al., 2010; Kondapalli 
et al., 2012; Bertolin et al., 2013). Interestingly, we now observed co-localization between LRRK2 and 
TOM20 (Figure 3.25 E-H) and a marked increase in the co-localization between LRRK2 and TOM22 
(Figure 3.26 E-H) based on the coefficients (Table 3.2), the scatter diagrams as well as the visual 
outputs. However, the induction of cellular stress, marginally reduced the co-localization between 
LRRK2 and TOM40 (Figure 3.27, E-H) while the co-localization between LRRK2 and TOM70 remained 
unchanged (Figure 3.28 E-H). For all of the co-localization experiments the weighted co-localization 
coefficients, the overlap coefficients and the Pearson’s correlation coefficients were calculated and 
are shown in Table 3.2).  
 
Table 3.2 Quantification of co-localization parameters for the association between LRRK2 and the 
TOM complex under normal (DMSO) and stress induced (CCCP) growth conditions in HEK293 cells 
DMSO CCCP 
TOM 
subunit 
Weighted 
(TV2-T1-
SR) 
Weighted 
(TV2-T2-
SR) 
Overlap  
Pearson’s 
Correlation  
Weighted 
(TV2-T1-
SR) 
Weighted 
(TV2-T2-
SR) 
Overlap 
Pearson’s 
Correlation  
TOM20 0.170 0.007 0.5 -0.03 0.299 0.093 0.51 -0.02 
TOM22 0.255 0.049 0.49 -0.03 0.308 0.09 0.52 -0.06 
TOM40 0.192 0.09 0.54 -0.02 0.053 0.101 0.32 -0.19 
TOM70 0.203 0.052 0.54 -0.0 0.373 0.084 0.56 0.03 
 
In summary, our findings indicate that co-localization between LRRK2 and TOM20 occurred under 
stress conditions only, whereas the co-localization between LRRK2 and TOM22, TOM40 and TOM70 
occurred under both basal and stress conditions. Interestingly, the co-localization with TOM22 was 
increased when stress was induced whereas for TOM40 the co-localization was increased under basal 
conditions.  
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3.10.3 Co-immunoprecipitation of LRRK2 and TOM subunits 
Although, co-localization is a powerful tool to identify subcellular location of proteins at a specific time 
and under specific conditions it does not provide proof of an actual association between proteins 
within a complex. Therefore, co-immunoprecipitation (Co-IP) was used in our study to validate the 
confocal and SR-SIM findings.  
The Co-IP results for the association between LRRK2 and TOM subunits (Figure 3.29 A, C, E and G) and 
the reciprocal experiments (Figure 3.29 B, D, F and H) are shown. All negative controls (protein G 
agarose control and immunoprecipitation with the anti-HA negative control antibody), except the one 
for TOM40, did not produce any bands. Non-specific bands were present in the Co-IP assays with 
TOM40 (Figure 3.29 E) which were at the predicted size for antibody light chains (approximately 
35kDa), however these were observed in all the samples and could therefore be excluded from the 
analysis. It should also be noted that these Co-IP assays were completed in the context of whole 
protein lysate from a given cell population.  
As suggested by SR-SIM experiments, LRRK2 and TOM20 did not associate under basal conditions 
however, when stress was induced using CCCP, an association was detected (Figure 3.29 A). Reciprocal 
assays also corroborated the SR-SIM and initial Co-IP results, showing both LRRK2 and TOM20 within 
the same protein complex exclusively under CCCP conditions, and not under basal conditions (Figure 
3.29 B). These results confirm the co-localization findings (Figure 3.25). Furthermore, LRRK2 and 
TOM22 were moderately associated with the complex under basal conditions but this association 
increased during cellular stress (Figure 3.29 C). Reciprocal Co-IP analysis verified this increased 
association between LRRK2 and TOM22 upon CCCP treatment (Figure 3.29 D). This trend was also 
observed in SR-SIM co-localization analysis (Figure 3.26 A-H).  
Our results further showed that LRRK2 could immunoprecipitate with the protein complex containing 
both TOM40 (Figure 3.29 E) and TOM70 (Figure 3.29 G) under both DMSO and CCCP conditions. This 
was also confirmed by reciprocal immunoprecipitations, although to a lesser extent with TOM40 
under stress conditions (Figure 3.29 F and H). Again, these findings corroborated the SR-SIM results 
(Figure 3.27 E-H and Figure 3.28).  
We consequently propose that LRRK2 associates with several subunits of the TOM complex, possibly 
through the multiple potential protein-protein interaction domains surrounding the central core of 
LRRK2 or through its phosphorylation activity. 
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Figure 3.29 Western blots of co-immunoprecipitation analysis of LRRK2 with the subunits of the 
TOM complex under basal (DMSO) and stress induced (CCCP) conditions in transfected HEK293 cells. 
Reciprocal reactions were performed for each experiment. Abbreviations: CCCP, Carbonyl cyanide m-
chlorophenyl hydrazone; DMSO, Dimethyl sulfoxide; GFP, green fluorescent protein; IP, 
immunoprecipitation; IPneg, immunoprecipitation using a “non-relevant” antibody as negative 
control; kDa, kilo dalton; WB, Western blot; protG, protein G agarose control. 
 
In conclusion, both co-localization and Co-IP analysis revealed and confirmed that LRRK2 associates 
with a protein complex containing the subunits of the TOM complex. These associations were 
identified under both basal and stress conditions, and differing levels of associations were identified 
for the different subunits. Reasons for this are unclear at present and further validation studies are 
required. 
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4.1 Summary of the main findings 
The present study aimed to functionally characterize the novel Q2089R variant which is located in the 
kinase domain of LRRK2. To our knowledge, we are the first group to ever report on Q2089R, which 
was found in the unique South African population. G2019S was included in the functional analyses for 
comparison purposes. The presence of any other known PD-causing mutations or any other possibly 
pathogenic mutations in LRRK2 in the Q2089R-positive proband was excluded by WES analysis. 
Bioinformatics analysis indicated that the variant may significantly disrupt the structure and function 
of the protein and therefore may be pathogenic. Interestingly, Q2089R was found to significantly 
decrease autophosphorylation of LRRK2 in vitro and showed a reduction in metabolic activity and 
MMP when overexpressed in HEK293 cells. A decrease in glycolytic reserve and in basal respiration 
was detected when measuring extracellular acidification rate (ECAR) and oxygen consumption rate 
(OCR). Q2089R-positive fibroblasts showed significantly reduced cellular metabolic activity and MMP 
(under cellular stress) when compared to WT cells. Additionally, an increase in basal respiration, 
proton leak, maximal respiration and spare respiratory capacity was observed while ATP-coupling 
efficiency was significantly reduced. A non-significant trend for an increase in glycolysis was observed 
whereas both glycolytic reserve and glycolytic capacity were significantly reduced. In both models 
used in this study, Q2089R significantly increased the pool size of autophagosomes.  
In comparison, in the G2019S overexpression model a significant increase in autophosphorylation, 
reduced metabolic activity and reduced MMP was observed. However, no changes were detected in 
mitochondrial respiration and glycolysis. In the ex vivo model, G2019S-positive cells showed reduced 
cellular metabolic activity and increased basal respiration, ATP-linked respiration and autophagic flux. 
The MMP of these cells were not affected under basal conditions although a non-significant trend for 
a decrease was observed under stress conditions.  
Finally, we showed that WT LRRK2 co-localizes and associates with a protein complex containing 
TOM22, TOM40 and TOM70. Surprisingly, LRRK2 and TOM20 associated with the complex only when 
cells were stressed with CCCP. This induction of cellular stress also resulted in an increased association 
of LRRK2, TOM22 and TOM70 while the association of TOM40 with this complex was decreased.  
Our findings in comparison to the literature is summarized in Table 4.1. We found that the G2019S 
models in our study, for the most part, agreed with previous literature. Interestingly, however, we 
showed that Q2089R had a more severe effect on various cellular phenotypes. For example, Q2089R 
exhibited increased proton leak respiration and decreased ATP-coupling efficiency, glycolytic reserve, 
glycolytic capacity and MMP when compared to WT cells. 
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Table 4.1 Summary of findings from functional experiments for LRRK2 G2019S and Q2089R 
Assay Previous studies               Present study 
G2019S G2019S Q2089R 
Autophosphorylation using 
pSer1292  
Increase 
(Sheng et al., 
2012) 
Increase     
(Reynolds et 
al., 2014)   
Increase 
(Henry et 
al., 2015) 
Increase 
(Alcalay et 
al., 2015) 
Increase  
(Fraser et al., 
2016) 
- Increase 
(HEK293) 
Decrease 
(HEK293) 
Cell viability (Commercial cell 
line) 
Decrease 
(Smith et al., 
2006) 
Decrease 
(West et al., 
2007) 
Decrease 
(Liou et al., 
2008) 
Decrease 
(Heo et al., 
2010b) 
Decrease 
(Kondo et al., 
2011) 
Decrease 
(Wang et al., 
2012b) 
Decrease 
(HEK293) 
Decrease 
(HEK293) 
Cell viability (Neurite 
morphology) 
Decrease  
(MacLeod et al., 
2006) 
Decrease 
(Plowey et al., 
2008) 
Decrease 
(Parisiadou 
et al., 2009) 
Decrease  
(Heo et al., 
2010a) 
Decrease 
(Lavalley et al., 
2016) 
- ND ND 
Cell proliferation 
(Primary cells) 
Unchanged 
(Decrease with 
MPP+) 
(Yakhine-Diop et 
al., 2014) 
- - - - - Decrease 
(Fibroblasts) 
Decrease 
(Fibroblasts) 
Mitochondrial 
membrane 
potential 
Commercial 
cell line 
Decrease 
(Wang et al., 
2012b) 
Decrease 
(Papkovskaia 
et al., 2012) 
Decrease 
(Cherra et 
al., 2013) 
- - - Decrease 
(HEK293) 
Decrease 
(HEK293) 
Primary 
cells 
Decrease (Basal) 
(Mortiboys et al., 
2010) 
Decrease 
(Basal) 
(Papkovskaia 
et al., 2012) 
Decrease 
(Basal) 
(Grünewald 
et al., 2014) 
Decrease 
(Basal) 
(Su et al., 
2015) 
- - No change with DMSO 
(Fibroblasts) 
No change with CCCP 
(Fibroblasts) 
No change with DMSO 
(Fibroblasts) 
Decrease with CCCP 
(Fibroblasts) 
Mitochondrial 
respiration 
Commercial 
cell line 
Increase basal 
resp. 
(Papkovskaia et 
al., 2012) 
- - - - - No change 
(HEK293) 
Decrease in basal 
respiration 
(HEK293) 
Primary 
cells 
Decrease ATP 
production 
(Mortiboys et al., 
2010) 
Increase basal 
resp. 
Increase 
proton leak 
Decrease ATP 
production 
(Papkovskaia 
et al., 2012) 
Decrease 
basal resp. 
Decrease 
maximal 
resp. 
(Cooper et 
al., 2012) 
Increase 
proton leak 
(Grünewald 
et al., 2014) 
Decrease basal 
resp.  
Decrease maximal 
resp. 
Decrease ATP-
coupling 
(Mortiboys et al., 
2015) 
- Increase in basal resp. 
Increase in ATP-linked resp. 
(Fibroblasts) 
Increase in basal resp. 
Increase in proton leak 
Decrease in ATP-coupling 
Increase in maximal resp. 
Increase in spare resp. 
capacity 
(Fibroblasts) 
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Mitochondrial DNA copy 
number 
(Primary cells) 
Increase  
(G2019S carriers) 
Decrease  
(G2019S affected) 
(Grünewald et al., 
2014) 
No change 
(Sanders et 
al., 2014) 
Decrease 
(Su et al., 
2015) 
-  
 
- - No change 
(Fibroblasts) 
Increase 
(Fibroblasts) 
Glycolysis Commercial 
cell line Upregulation of 
glycolysis  
(Nikonova et al., 
2012) 
- - - - - No change 
(HEK293) 
Decrease in glycolytic 
reserve 
(HEK293) 
Primary 
cells 
- - - - - - Increase in glycolysis 
(Fibroblasts) 
Decrease in glycolytic 
reserve 
Decrease in glycolytic 
capacity 
(Fibroblasts) 
Autophagic flux Commercial 
cell line 
Increase 
(Plowey et al., 
2008) 
Increase  
(Su and Qi, 2013) 
No 
change 
in LC3  
(Orenst
ein et 
al., 
2013) 
- - - No change in LC3 II  
No change in P62 
(HEK293) 
Increase in LC3 II 
Increase in P62 
(HEK293) 
Primary 
cells 
Increase in LC3 II 
Increase in P62 
(Sánchez-Danés et 
al., 2012) 
Increase in 
LC3 II 
No change in 
P62 
(Manzoni et 
al., 2013b) 
Increase 
(Bravo-San 
Pedro et al., 
2013) 
Increase 
(Yakhine-
Diop et al., 
2014) 
Increase in LC3 II 
and P62 
(Su et al., 2015) 
- Increase in LC3 II 
No change in P62 
(Fibroblasts) 
Increase in LC3 II 
Increase in P62 
(Fibroblasts) 
resp., respiration; LC3 II, Microtubule Associated Protein 1 Light Chain 3; P62, Sequestosome 1; ND, not done 
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4.2 Identification of Q2089R 
LRRK2 Q2089R was present in only one of 493 PD patients and in one of the 776 controls screened. 
The Q2089R-positive patient had an age at onset (AAO) of 50 years and presented with typical features 
of PD. He developed marked motor fluctuations with dyskinesia including shaking of the legs and feet 
as well as speech impediments. He had undergone bilateral globus pallidus internus (GPi) deep brain 
stimulation (DBS) surgery with excellent results at the age of 64, and was cognitively normal. He 
passed away of pneumonia at the age of 74 years. LRRK2-associated PD patients typically present with 
features of motor symptoms including resting tremor and postural instability (Trinh et al., 1993), and 
while the AAO varies widely, individuals usually present with the first symptoms after the age of 60 
years (Paisán-Ruíz et al., 2005; Kay et al., 2006b; Trinh et al., 2014). These patients respond well to 
treatment (Schüpbach et al., 2007), have lower rates of developing dementia (Srivatsal et al., 2015) 
and mainly present with an AD family history of disease. Our patient presented with many of these 
features except that his AAO was younger (but again this is not uncommon) (Kay et al., 2006b). 
It is well-established that the penetrance of pathogenic PD-causing variants, especially LRRK2 
mutations, are variable and have been shown to be dependent on age, ethnicity as well as 
environmental factors (Trinh et al., 1993; Klein and Westenberger, 2012). In fact, the penetrance of 
G2019S in certain populations has been shown to be as low as 30% (Clark et al., 2006b; Ozelius et al., 
2006; Ferreira et al., 2007; Hentati et al., 2014). Also, G2019S has been found in numerous unaffected 
control individuals in various studies (Bonifati, 2006; Kay et al., 2006a; Change et al., 2008). Therefore, 
the finding of Q2089R in one unaffected female control individual cannot rule it out as being ‘disease-
causing’. The control had been recruited from the Geriatric clinic at Tygerberg Hospital (South Africa) 
and apparently did not exhibit any signs of PD at the time of her demise at 83 years of age. It is possible 
however that subtle clinical symptoms might have been overlooked, as she had not been assessed by 
a neurologist. She had already died by the time we identified that she harbored Q2089R. No family 
history of PD was reported by this individual. 
Modelling and in silico functional predictions of the 2089R amino acid, showed that its side chain 
introduces a significant difference which likely affects protein folding and function. Each amino acid 
has its own specific size, charge, and hydrophobicity value (Biro, 2006), and the WT (Q) and mutant 
(R) residues have distinct properties. For example, R is much larger than Q, and as Q is predicted to be 
buried in the core of the protein, the introduction of this larger, charged residue will most likely not 
fit into the core which could lead to a change in protein structure. Also, as this amino acid position is 
located in a loop structure that is predicted to be involved in protein-protein interactions, disruption 
of the loop by the R residue is likely to alter these interactions (Regad et al., 2010). Although, it is 
Stellenbosch University  https://scholar.sun.ac.za
100 
 
acknowledged that the template used to model the kinase domain of LRRK2 only has an approximately 
30% sequence homology with LRRK2, it does provide a reasonable estimate of how the amino acid 
change will affect protein function/folding in that specific domain. However, it would be interesting 
to investigate the protein modelling and folding using a structure with closer similarity to LRRK2, which 
is currently unavailable, or ideally to have the crystal structure of full-length LRRK2 available for 
modelling purposes.  
 
4.3 Overexpression of Q2089R reduces metabolic activity 
In the present study, our results revealed that the overexpression of Q2089R and G2019S substantially 
decreased the metabolic activity of the cells (Figure 3.11). The increase in cytotoxicity, attributed to 
the overexpression of G2019S, was in accordance with previous studies using similar techniques (Liou 
et al., 2008; Kondo et al., 2011).  
Commercial cell lines and mouse primary cortical neurons transfected with either R1441C or G2019S 
constructs only or co-transfected with both G2019S and kinase dead constructs (D1994N and K1906A), 
exhibited decrease cell viability (Smith et al., 2006; Wang et al., 2012b). Similarly, West and co-workers 
showed that the overexpression of G2019S, Y1699C, and I2020T reduce cell viability of transfected 
mouse cortical neurons compared to control cells (West et al., 2007). Likewise, the overexpression of 
the PD risk variant, G2385R, also significantly reduced the cell viability compared to control cells. In a 
recent study, five LRRK2 variants (L1165P, T1410M, M1646T, L2063X and Y2189) of unknown 
pathogenicity were analyzed for their possible involvement in PD using an overexpression model in 
HEK293 cells and cell viability assays (Refai et al., 2015). All of these variants significantly reduced cell 
viability. Interestingly, all variants also exhibited increased kinase activity, except L2063X which is 
located in the kinase domain of LRRK2.  
When investigating the viability of patient-derived fibroblasts in the present study, we did not detect 
any differences between WT and mutant (G2019S or Q2089R) cells after 24 hours of growth (Figure 
3.12). This was in agreement with a previous study showing similar cellular viability between control 
and G2019S carrying cells after 24 hours of growth under basal conditions (Yakhine-Diop et al., 2014). 
Furthermore, fibroblasts from patients carrying Parkin mutations were shown to have similar growth 
rates when compared to healthy control cells (Mortiboys et al., 2008). However, inconsistencies have 
been reported regarding the growth rate of Parkin mutant fibroblasts, with literature showing both 
increased and decreased cellular growth rates (Pacelli et al., 2011; Haylett et al., 2016). Interestingly, 
in the present study, we noted a significant decline in metabolic activity for both G2019S- and Q2089R-
carrying cells compared to control cells after three days of incubation. To our knowledge, this is the 
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first study to investigate the metabolic activity of human fibroblasts carrying LRRK2 
mutations/variants over an extended period (i.e. five days). Our findings thus highlight the advantages 
of investigating metabolic activity over time since important differences might be missed with short-
term growth assays.  
Although additional studies are required to further interrogate the effect of Q2089R on cytotoxicity, 
possibly by investigating neurite morphology, our findings suggest that Q2089R could have functional 
implications. Previous studies showed G2019S to reduce neurite length, branching and general 
complexity (MacLeod et al., 2006; Ramonet et al., 2011; Schwab and Ebert, 2015). However, it should 
be noted that neither the inhibition of LRRK2 kinase activity nor the expression of WT or G2019S LRRK2 
in human fibroblasts or transgenic mouse brains affected neurite complexity in a recent study (Garcia-
Miralles et al., 2015). Thus, we suggest that assays on neurite complexity in combination with 
alternative toxicity tests, for example the Image-iT® DEAD™ Green cytotoxicity assay (Smith et al., 
2015), should be used in future studies to determine the effect of mutations/variants on cell viability 
and metabolic activity over an extended period. 
 
4.4 Could decreased LRRK2 kinase activity be linked to PD? 
Increased kinase activity of LRRK2 is widely acknowledged to be implicated in PD pathogenesis 
(Cookson et al. 2007; Gloeckner et al. 2006; Greggio 2012; Henry et al. 2015; Smith et al. 2006). In the 
present study we used pSer1292 autophosphorylation as a measure of WT and mutant (G2019S and 
Q2089R) LRRK2 kinase activity in vitro. In earlier studies, autophosphorylation had been detected 
using radioactivity (Luzón-Toro et al., 2007; Webber et al., 2011; Lewis, 2012) or other kinase assays 
using purified protein (Nichols et al., 2009; Liu et al., 2014). But more recent advances made it possible 
to use a single autophosphorylation site (Ser1292) and Western blot analysis to measure the kinase 
activity of LRRK2.  
The use of the pSer1292 autophosphorylation method has been validated as an indicator of kinase 
activity in vitro as well as a potential biomarker for ex vivo studies (Sheng et al., 2012; Reynolds et al., 
2014; Alcalay et al., 2015; Fraser et al., 2016). Reynolds and colleagues showed that G2019S and 
R1441C augment autophosphorylation of the serine residue at position 1292 when compared to WT 
LRRK2 protein (Reynolds et al., 2014). Additionally, the kinase-dead mutant, D1994A, showed no 
autophosphorylation activity.  
In another study, abundant LRRK2 protein levels were found in urinary exosomes of PD patients 
(Fraser et al., 2013). Alcalay and colleagues subsequently proposed to measure pSer1292 LRRK2 levels 
in the exosomes of LRRK2 G2019S carriers with PD, non-carriers with PD and healthy individuals 
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without PD (Alcalay et al., 2015). They found that it was possible to distinguish between LRRK2 G2019S 
carriers (with PD) and non-carriers with and without PD using pSer1292. G2019S carriers with PD also 
had higher ratios of pSer1292 LRRK2 over total LRRK2 protein when compared to asymptomatic G2019S 
carriers (Fraser et al., 2016). Therefore, the G2019S mutation is not necessarily sufficient to cause PD. 
Finally, LRRK2 autophosphorylation and phosphorylation of LRRKtide, the proposed synthetic 
substrate of LRRK2, were found to be comparable (Reynolds et al., 2014). Thus, researchers identified 
autophosphorylation as a true biochemical readout of LRRK2 kinase activity in vitro (Reynolds et al., 
2014). Therefore, we believe that the use of pSer1292 autophosphorylation is a reliable and robust 
indicator of kinase activity for LRRK2. 
Unexpectedly, we observed a marked reduction in the autophosphorylation activity for Q2089R when 
compared to WT and G2019S, indicating that Q2089R almost totally abolishes autophosphorylation of 
LRRK2 (Figure 3.10). G2019S, in agreement with previous studies (West et al., 2005; Smith et al., 2006; 
Sheng et al., 2012; Reynolds et al., 2014; Fraser et al., 2016), exhibited significantly increased 
autophosphorylation activity (Figure 3.10). There have been many previous studies investigating the 
effect of other PD-causing mutations on the kinase activity of LRRK2, but they have produced 
conflicting findings. Some studies show that I2020T decreases kinase activity (Jaleel et al., 2007; Anand 
et al., 2009), while others show an increased or unchanged kinase activity for this mutation (Gloeckner 
et al., 2006; Sheng et al., 2012). G2385R (the PD risk factor), has been shown to decrease GTPase and 
kinase activity and was identified as a partial loss-of-function mutation (Rudenko et al., 2012b; 
Rudenko and Cookson, 2014; Ho et al., 2016). A variant of unknown pathogenicity (L2063X), also 
located in the kinase domain of LRRK2, was recently shown to decrease autophosphorylation activity 
although these findings were not statistically significant (Refai et al., 2015). These findings highlight 
the limitations of regarding increased kinase activity as the sole disease mechanism underlying LRRK2 
mutations. 
Kinase activity is an essential process involved in numerous pathways including cell signaling, protein 
regulation, mitochondrial homeostasis and autophagy (Manzoni et al., 2013a). PINK1 is a protein 
kinase that is known to be involved in PD development. PINK1 has been shown to be 
autophosphorylated on specific serine residues (Ser228 and Ser402) (Okatsu et al., 2012; Aerts et al., 
2015), which occurs upon cellular stress and was shown to be essential for the recruitment of Parkin 
to defective mitochondria (Okatsu et al., 2012; Song et al., 2013). Mutations in the kinase domain of 
PINK1 (such as L347P) effectively destabilize the protein and reduce its kinase activity (Beilina et al., 
2005). For LRRK2, increased kinase activity leads to altered phosphorylation of its substrates and 
enlargement of lysosomes (Greggio, 2012; Henry et al., 2015) whereas the inhibition of LRRK2’s kinase 
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activity has been shown to alter binding of proteins and to result in the dephosphorylation of its serine 
residues (Dzamko et al., 2010). Furthermore, this inhibition also altered the cytoplasmic localization 
of LRRK2. Another study showed that DRP1 recruitment for mitochondrial homeostasis (fission/fusion) 
is dependent on LRRK2’s kinase activity, thus highlighting its importance in cellular health (Su and Qi, 
2013). Very recently, Lobbestael and co-workers also showed that the inhibition of LRRK2’s kinase 
activity destabilizes the protein and reduces LRRK2 protein levels (Lobbestael et al., 2016). It is 
therefore crucial to consider all consequences of LRRK2 kinase inhibition on cellular function since it 
is anticipated that a decrease or loss of kinase activity could also be detrimental to cells (Greggio et 
al., 2006), and that both increased and decreased LRRK2 kinase activity could be linked to the 
development of PD (Anand et al., 2009; Rudenko et al., 2012a). 
In our study we show that Q2089R reduces LRRK2’s kinase activity and we speculate that this could 
have further detrimental effects on cellular functions for which LRRK2 is responsible. Consequently, 
from the findings of our study and the evidence provided by many previous studies, we propose that 
decreased kinase activity of LRRK2 could be implicated in PD pathogenesis.  
 
4.5 Q2089R has a more damaging effect on glycolytic and mitochondrial 
respiration than G2019S 
The maintenance of high MMP is essential for mitochondrial health. When the MMP is lost or 
decreased, the import of mitochondrial proteins and oxidative phosphorylation activities are 
disrupted, thus causing mitochondria to become dysfunctional. In the present study, we found that 
Q2089R overexpression resulted in significantly reduced MMP. This decrease in mitochondrial 
polarization was observed under basal conditions while the MMP of cells were not affected by an 
external mitochondrial stressor (CCCP) (Figure 3.13). When investigating the MMP of endogenous 
LRRK2 in patient-derived fibroblasts under basal conditions, we did not observe any differences 
between Q2089R-positive and WT and cells (Figure 3.14 B). However, when we compared cellular 
phenotypes of WT and mutant fibroblasts after treatment with CCCP, we found that Q2089R 
mitochondria were markedly more depolarized than mitochondria in control cells (Figure 3.14 C).  
Additionally, we showed that G2019S decreased MMP when overexpressed in HEK293 cells (Figure 
3.13 ) which is in agreement with previous studies showing decreased MMP in G2019S overexpression 
models (Papkovskaia et al., 2012; Wang et al., 2012b; Cherra et al., 2013). However, when we 
investigated the MMP of G2019S-carrying fibroblasts, under both basal and CCCP-treatment 
conditions, we could not detect any significant differences compared to control cells although a trend 
towards a decrease in MMP was observed when these cells were stressed (Figure 3.14 C). These 
results were unexpected since previous studies, specifically focusing on LRRK2 fibroblasts, showed 
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G2019S to have significantly depolarized mitochondria (Mortiboys et al., 2010; Papkovskaia et al., 
2012; Grünewald et al., 2014; Su et al., 2015). Grünewald et al. (2014) reported that even 
asymptomatic G2019S carriers exhibit reduced MMP under basal conditions (Grünewald et al., 2014). 
Notably, contradictory findings have previously been reported for Parkin mutant fibroblasts where 
Zanellati et al. reported significantly lower MMP for mutant fibroblasts (Zanellati et al., 2015), while 
others showed comparable MMP between mutant and WT Parkin fibroblasts (Grünewald et al., 2010; 
Haylett et al., 2016). 
Somewhat similar to our results, Smith and colleagues could not detected any difference in MMP 
between WT and G2019S fibroblast lines at baseline (Smith et al., 2015). However, upon exposure to 
Valinomycin, a potent antibiotic which acts as a potassium (K+) ionophore, the MMP was reduced. 
They concluded that fibroblasts derived from PD patients carrying LRRK2 mutations exhibit disease-
relevant mitochondrial phenotypes, that were aggravated under conditions of pharmacological stress. 
Even though the results are widely variable between studies, we believe that these discrepancies 
could possibly be explained by the variable penetrance and phenotypic expression of LRRK2 mutations 
(Nuytemans et al., 2010; Wider et al., 2010) as well as the diverse genetic backgrounds of patients 
used in the various studies.   
Next, we investigated the effect of WT and mutant/variant LRRK2 on mitochondrial respiration (as 
measured by OCR) and glycolysis (as measured by ECAR). HEK293 cells overexpressing Q2089R 
exhibited significantly lower basal respiration and severely decreased glycolytic reserve (Figure 3.16 A 
and 3.19 D, respectively). The decreased basal respiration was indicative of defective mitochondrial 
respiration and ETC function. This dysfunction was reflected by the major decrease in glycolytic 
reserve which signifies the inability of Q2089R expressing cells to produce adequate ‘fuel’ for 
glycolysis. 
Overexpression of G2019S, conversely, did not show any differences in either OCR (Figure 3.16) or 
ECAR (Figure 3.19). This was surprising since a previous report, albeit using a Clark-type oxygen 
electrode, showed that G2019S-expressing SHSY5Y cells exhibit increased basal respiration 
(Papkovskaia et al., 2012). It should be noted however that the transfection efficiency of constructs 
was relatively low, between 6% and 8% (Figure 3.11 B), which we believe may have contributed to the 
lack of differences recorded in the overexpression model in our study. To overcome this limitation and 
to determine the effect of LRRK2 mutations ex vivo, we also studied the OCR and ECAR in patient-
derived fibroblasts.  
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Some of our observations in the fibroblasts led us to speculate that the findings of the Q2089R model 
could be as a result of compensatory mechanisms. Protons are typically pumped through the ETC to 
the IMS to create a gradient across the IMM. This gradient is used to drive protons back through 
complex V (ATP synthase) to generate ATP. However, here we observed a major increase in proton 
leak for Q2089R-carrying fibroblasts (Figure 3.17 C), showing that protons leaked back across the 
membrane to the mitochondrial matrix which coincided with a reduced ATP-coupling efficiency 
(Figure 3.17 D). This increase in proton leak could also suggest an increase in membrane permeability 
(Porter et al., 1999). Thus, we speculate that an increase in proton leakage and decreased ATP-
coupling efficiency could signify an underlying mitochondrial deficit in these fibroblasts. However, it 
has been suggested that an increase in proton leakage could be a compensatory mechanism used to 
decrease ROS production (Brand, 2000; Lee et al., 2000; Hayat, 2016). In support of this compensatory 
mechanisms theme, we observed striking increases in both maximal respiration and spare respiratory 
capacity (Figure 3.17 E and F). Maximal respiration is the maximum rate at which the mitochondria 
can respire while spare respiratory capacity is defined as the amount of additional ATP that can be 
produced in case of a sudden energy demand emergency (Nicholls, 2009; Desler et al., 2012). We 
believe that the marked increase in maximal respiration and spare respiratory capacity contributes to 
the compensation of Q2089R fibroblasts to cellular stress and that these cells are attempting to 
enhance ATP production perhaps via increased glycolysis or mitochondrial biogenesis. This mechanism 
was, however, insufficient since basal respiration was only modestly increased and ATP-linked 
respiration was not increased at all (Figure 3.17 A and B). 
When cells were forced to shift from oxidative phosphorylation to glycolytic metabolism to produce 
ATP, Q2089R fibroblasts did not show any significant changes in glycolysis (Figure 3.20 B) but exhibited 
severely reduced glycolytic capacity and glycolytic reserve ECAR (Figure 3.20 C and D). This suggest 
that Q2089R could result in serious cellular damage or even death due to energy demand deficiencies 
in fibroblasts and that the proposed mechanisms could not compensate for the deficit in glycolytic 
metabolism (Das, 2013).  
Cells with high energy demand, such as neurons, rely on oxidative phosphorylation for ATP production 
and are dependent on mitochondrial biogenesis (Uittenbogaard and Chiaramello, 2014). Previous 
studies have implicated increased mitochondrial biogenesis as a compensatory mechanism in muscle 
cells and fibroblasts to improve aging phenotypes and compensate for mitochondrial deficits (Lee et 
al., 2000; Dillon et al., 2012). An increase in mitochondrial biogenesis was found to be directly 
correlated with the increase in expression of the master co-activator peroxisome proliferator-
activated receptor γ co-activator-1α (PGC-1α) (Dillon et al., 2012). Subsequently, the degradation of 
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PGC-1α was shown to cause inhibition of mitochondrial biogenesis which ultimately induced 
neurodegeneration (Xu et al., 2014).  
Interesting to note was the fact that mitochondrial biogenesis was shown to be induced by the cell 
cycle-dependent activation of the TOM protein complex and that this complex is essential for 
adequate mitochondrial biogenesis which increases due to fission of existing mitochondria (Harbauer 
et al., 2014; Uittenbogaard and Chiaramello, 2014; Shiota et al., 2015). Since LRRK2 has been 
implicated in mitochondrial fission/fusion dynamics (Wang et al., 2012b) and showed altered 
mitochondrial respiration in our study, we were interested to determine whether differences in 
mitochondrial copy number between WT and mutant fibroblasts exists. We observed that Q2089R 
fibroblasts had a significantly increased mtDNA copy number, and therefore a possible increase in 
mitochondrial biogenesis, compared to WT and G2019S fibroblasts (Figure 3.21). Taken together, we 
believe that Q2089R-carrying fibroblasts are attempting to overcome their mitochondrial deficiencies 
through compensatory mechanisms such as increases in proton leak, maximal respiration, spare 
respiratory capacity and mitochondrial biogenesis. However, these mechanisms appear to be 
inadequate since mitochondrial ATP-coupling efficiency in these cells was significantly reduced. It 
should be noted however that the compensatory alterations proposed here would differ dramatically 
between different cell types and therefore the effects that we observe in the present study should not 
be directly extrapolated to adaptations or alterations that would occur in neuronal cells. 
Next, we examined G2019S-carrying fibroblasts and found that these cells exhibited an increase in 
basal respiration and ATP-linked respiration (Figure 3.17 A and B, respectively). However, no 
difference in any of the other OCR parameters were detected when compared to control cells (Figure 
3.17 C-F). This was unexpected since previous studies showed G2019S carriers to have decreased basal 
respiration (Cooper et al., 2012; Mortiboys et al., 2015), decreased maximal respiration (Cooper et al., 
2012; Mortiboys et al., 2015), increased proton leak (Grünewald et al., 2014) and decreased ATP-
linked respiration (Mortiboys et al., 2015) using OCR as a measure of mitochondrial respiration. 
Motriboys et al. (2015) specifically showed complex III and complex IV to be defective and not complex 
II as previously reported by their group (Mortiboys et al., 2010, 2015). In the previous study 
mitochondrial ATP synthesis was decreased in G2019S patients (Mortiboys et al., 2010). In another 
study using the Clark-type oxygen electrode, cellular ATP content and spare respiratory capacity was 
decreased whereas proton leak and basal oxygen consumption was increased in G2019S fibroblasts 
(Papkovskaia et al., 2012). These results confirm the uncoupling of mitochondrial oxidative 
phosphorylation and ETC activity.  
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In our study, when G2019S fibroblasts were forced to use glycolytic metabolism, we observed an 
increase in glycolysis (Figure 3.20 B). This suggested that, together with increased basal respiration 
and ATP-linked respiration, G2019S fibroblasts did not display major mitochondrial deficits and that 
mitochondria of G2019S-carrying fibroblasts in our study were able to function relatively well under 
conditions of stress. We speculate that this could possibly be due to a compensatory mechanism which 
remains to be identified. This observation corresponds to our results on MMP of G2019S fibroblasts 
where no depolarization was seen under basal conditions and a non-significant decrease in MMP was 
observed under stress-induced culture conditions (Figure 3.14 C). Cells were stressed for one hour 
only during MMP assays and the pharmacological stressors added during mitochondrial respiration 
tests only measured the fibroblast response over a few minutes. Therefore, an increase in stress 
duration in both MMP and Seahorse experiments might reveal additional underlying information 
regarding mitochondrial respiration or glycolysis that may well have been overlooked.  
It is interesting to postulate that the G2019S fibroblasts used in our study are genetically different 
from G2019S carriers from previous studies and could account for the contradictory results. Also, the 
G2019S-positive individual in our study has been taking numerous prescription medications which 
may influence the cells; the effect of specific medications (and combination of medications) on 
epigenetic changes and long-term cellular function such as mitochondrial respiration and glycolytic 
metabolism, in culture, remains to be elucidated.  
 
4.6 Q2089R increases autophagic flux 
Many previous studies have implicated LRRK2 as a key player in mitochondrial fission/fusion dynamics 
and have associated LRRK2 with the tightly regulated autophagic pathway (Plowey et al., 2008; Wang 
et al., 2012b; Esteves and Cardoso, 2016).  In our study, when we examined Q2089R overexpression 
in HEK293 cells, a significant increase in both LC3 II and P62 levels, and therefore an increase in the 
autophagosome pool size, was observed (Figure 3.22 B and C). Similarly, Q2089R-carrying fibroblasts 
also exhibited significantly increased levels of both autophagic markers (Figure 3.23 B and C, 
respectively). Interestingly, the inhibition of LRRK2 kinase activity was previously shown to stimulate 
macroautophagy, leading to a striking increase in LC3 II levels (Manzoni et al., 2013a). Another study 
subsequently showed that silencing of LRRK2 and the inhibition of LRRK2 kinase activity resulted in 
inadequate autophagy clearance and reduced autophagic degradation, thus highlighting the 
importance of LRRK2 kinase activity in autophagy regulation (Schapansky et al., 2014). Similarly, Tong 
and colleagues reported that the absence of LRRK2 impaired the autophagic pathway, evident by the 
increase in LC3 II and P62 levels (Tong et al., 2010, 2012). Since we showed that Q2089R almost 
completely abolished autophosphorylation (kinase activity) of LRRK2 in vitro (Figure 3.10), the 
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observed increase in autophagosome pool size for Q2089R (in both HEK293 and fibroblasts cells)  
supports the notion that the inhibition of LRRK2’s kinase activity leads to an increase in autophagy 
(Manzoni et al., 2013a; Schapansky et al., 2014; Esteves and Cardoso, 2016).  
The overexpression of G2019S in HEK293 cells in the present study did not result in any significant 
changes in LC3 II or P62 levels, although a trend for an increase in P62 was observed (Figure 3.22). This 
is contradictory to previous studies indicating a significant increase in autophagic vacuoles (AVs) in 
SHSY5Y cells (Plowey et al., 2008) and increased LC3 II in HEK293 cells expressing LRRK2 G2019S (Su 
and Qi, 2013). However, our results were similar to one study indicating that HEK293 cells stably 
expressing G2019S showed no difference in LC3 flux (Orenstein et al., 2013). When examining G2019S 
fibroblasts, we found increased levels of both LC3 II and P62. However, the increase in P62 levels did 
not reach statistical significance (Figure 3.23 C). Consistent with this discovery, results from a previous 
study showed that G2019S patient fibroblasts significantly increased autophagic flux (Su et al., 2015). 
This was also observed in numerous other studies (Sánchez-Danés et al., 2012; Bravo-San Pedro et al., 
2013; Manzoni et al., 2013b; Yakhine-Diop et al., 2014). Likewise, the loss of neurons in transgenic 
mice expressing G2019S also resulted in enhanced autophagy and accumulated AVs (Ramonet et al., 
2011). Although P62 levels were not significantly increased in G2019S fibroblasts in our study, we 
believe that this could be attributed to the fact that the detection of autophagic markers via Western 
blot analysis is less reliable than the detection via microscopy techniques and therefore small changes 
in the levels of these marker proteins could have been obscured. 
Although increased autophagy is commonly associated with cell survival through the removal of 
damaged cellular material, some researchers believe that autophagy plays a key role in the promotion 
of non-apoptotic programmed cell death via the engulfment of the cytoplasm (Nelson and Shacka, 
2013). Thus, it is speculated that cell death can occur from dysregulation of autophagy i.e. it being 
either too active or too inactive.  
 
4.7 LRRK2 associates with and possibly binds to TOM subunits 
Considering the abovementioned evidence, we hypothesized that, LRRK2 could associate with the 
OMM through interaction with the TOM complex. In the present study, we overexpressed WT LRRK2 
in COS7 and HEK293 cells and found that LRRK2 significantly co-localized with the TOM complex using 
both confocal microscopy (Figure 3.24) and SR-SIM (Figure 3.25 – 3.28) under normal and stress 
induced culture conditions. Upon further investigation, we showed that LRRK2, overexpressed in 
HEK293 cells, associated with the TOM complex (Figure 3.29) and proposed that this association could 
be mediated by the potential protein-protein interaction domains surround the central core of LRRK2. 
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Under normal physiological conditions LRRK2 associated with a complex containing TOM22, TOM40 
and TOM70. Interestingly, an association between LRRK2 and TOM20 was only observed when cells 
were stressed using CCCP. The association between LRRK2 and TOM22 and TOM70 markedly 
increased under these conditions while the relationship between TOM40 and this complex 
diminished. We could speculate that these results indicate that more LRRK2 is recruited specifically to 
TOM20 and TOM22 to aid in the phosphorylation of as-yet-unknown proteins that are essential for 
mitochondrial function and biogenesis under conditions of stress and high energy demand. 
Alternatively, we could postulate that TOM20 and more of TOM22 and TOM70 is recruited to this 
complex of proteins with which LRRK2 is associated. TOM20 and TOM22 are responsible for the 
recognition and movement of mitochondrial pre-proteins to TOM40 for import. When we considered 
additional explanations for these interactions, we found that TOM22 contains an F-x-T-x-K (FETEK) 
protein motif. This could imply that TOM22 is likely phosphorylated by LRRK2 (with LRRK2’s consensus 
phosphorylation sequence being F/Y-x-T-x-R/K) (Pungaliya et al., 2010). Additionally, we hypothesize 
that TOM70 could interact with LRRK2 through its tetratricopeptide repeat (TPR) motifs which is 
known to mediate protein-protein interactions and is involved in the assembly of multiprotein 
complexes (Chan et al., 2006). In a previous study it was shown that molecular chaperones, heat shock 
protein 90 (Hsp90) and heat shock protein 70 (Hsp70), deliver pre-proteins to the OMM and more 
specifically to the TPR domains of TOM70 for mitochondrial import (Young et al., 2003). This could 
subsequently explain another possible mechanism of interaction between LRRK2 and the TOM 
complex since LRRK2 has been shown to form a complex with Hsp90 (Wang et al., 2008a; Ko et al., 
2009). 
Although LRRK2 readily associates with a complex containing TOM22, TOM40 and TOM70, whether 
LRRK2 is imported into mitochondria or phosphorylates proteins required for mitochondrial import 
remains to be elucidated. Cui and colleagues previously found that LRRK2 interacts with an OMM 
protein known to be involved in mitochondrial permeability namely, voltage-dependent anion channel 
(VDAC), as well as the ubiquitous mitochondrial creatine kinase (uMtCK) which contains an 
mitochondrial targeting sequence (MTS) and is involved in cellular energy homeostasis (Schlattner et 
al., 2006; Cui et al., 2011). It was further shown that LRRK2, especially G2019S LRRK2, inhibits the 
uMtCK pre-protein from entering into the mitochondria and thereby negatively affects mitochondrial 
energy homeostasis (Cui et al., 2011). Interestingly, TOM40 recognizes and interacts with proteins 
containing MTS which could include uMtCK.  
Furthermore, Harbauer et al. (2014) showed that phosphorylation of Tom6 (in a yeast system) is 
necessary for the assembly of Tom40 which serves as the main protein import channel (Harbauer et 
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al., 2014). The phosphorylation of Tom6 was also shown to aid the import of fusion proteins, to 
activate mitochondrial respiration and to regulate mitochondrial biogenesis in a cell cycle-dependent 
manner. Increased levels of Tom6 resulted in increased TOM complex assembly which in turn led to 
increased mitochondrial biogenesis (Harbauer et al., 2014; Shiota et al., 2015). In our study, we did 
not investigate the interaction between or phosphorylation of TOM6 by LRRK2 as our attention was 
only drawn to TOM6 through the comprehensive literature research when writing the discussion of 
this dissertation. It would, however, be interesting to determine since phosphorylation of Tom6  (in 
yeast) is mediated by cyclin-dependent kinase (CDK1) which is a master regulator of the cell cycle 
(Harbauer et al., 2014).  
Notably, various studies have also implicated other PD-causing genes, such as PINK1, Parkin and SNCA, 
in the interaction with the TOM complex (Bender et al., 2013; Bertolin et al., 2013; Kato et al., 2013; 
Okatsu et al., 2015). For example, the overexpression of both WT and mutant (A53T) SNCA caused a 
reduction in TOM40 levels (Bender et al., 2013) while mutations in Parkin disrupted the interaction 
between Parkin and the TOM complex (Bertolin et al., 2013). Recently, SNCA was also shown to bind 
to TOM20 and inhibit mitochondrial protein import (Maio et al., 2016). PINK1 plays a major role in 
distinguishing between functional and dysfunctional mitochondria and depends on TOM70 for its 
import into mitochondria (Kato et al., 2013) whereas TOM7 has been shown to be essential for 
stabilizing PINK1 on the OMM following mitochondrial damage (Hasson et al., 2013). Also, PINK1 
protects the cell by targeting damaged mitochondria with the assistance of Parkin and forms a 
complex with TOM20, TOM22 and TOM40 (Lazarou et al., 2012; Okatsu et al., 2015). Taken together, 
these studies provide insight into novel mechanisms, via the TOM complex, by which PD-causing 
mutations alter mitochondrial integrity and functioning. In the present study we provided convincing 
evidence for WT LRRK2’s association with the TOM complex. Therefore, it would be of interest to 
investigate whether and the extent to which mutant LRRK2 affects the association with subunits of 
the TOM complex.  
 
4.8 Proposed model for WT and Q2089R LRRK2  
Although we acknowledge that our findings are preliminary and that we did not observe all of the 
phenotypes in both cellular models, with the evidence gathered from our study as well as from 
previous studies, we propose a model for LRRK2’s cellular functions. This model encompasses LRRK2’s 
involvement in mitochondrial (dys)function, mitochondrial biogenesis and the autophagy/lysosomal 
pathway (Figure 4.1). 
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Under basal conditions, WT LRRK2 is involved in mitochondrial fission, fusion and biogenesis by 
recruiting the necessary proteins, such as DRP1 via phosphorylation, from the cytosol to the 
mitochondrial outer membrane (Figure 4.1 A). The recruitment of DRP1 for mitochondrial fission is 
dependent on LRRK2’s kinase activity. LRRK2 also interacts with VDAC which plays a role in membrane 
permeability, possibly to aid in the maintenance of MMP and normal oxidative phosphorylation 
activity (Figure 4.1 A). Earlier evidence show LRRK2 to form a complex with Hsp90 protein, which is 
known to have chaperone activity (Wang et al., 2008a; Ko et al., 2009) and it was found that LRRK2 
controls the trafficking of organelles and proteins (Migheli et al., 2013; Hunn et al., 2015; Manzoni et 
al., 2015; Esteves and Cardoso, 2016). Also, as previously mentioned, the phosphorylation of Tom6 
has been shown to aid in TOM complex assembly and mitochondrial biogenesis and that the PINK1 
protein is imported for degradation into healthy mitochondria via TOM70. In the present study, we 
identified a novel association between LRRK2 and the TOM complex (via subunits TOM22, TOM40 and 
TOM70) (Figure 4.1 A), which we believe could explain additional functions of LRRK2 in mitochondrial 
homeostasis since the TOM complex is essential for mitochondrial protein import and overall 
mitochondrial health. 
Under stress-induced conditions (e.g. mitochondrial depolarization), PINK1 is known to accumulate 
on the OMM and recruit Parkin for the ubiquitination of several OMM proteins, subsequently leading 
to the removal of defective mitochondria via mitophagy. Normally, mitochondrial precursor proteins 
are initially recognized by TOM20 or TOM70 (depending on their mitochondrial target sequences) 
after which they are translocated to TOM22 and then finally to TOM40 for mitochondrial import. We 
speculate that the relationship between LRRK2 and the complex containing the TOM proteins lead to 
increased phosphorylation (possibly of the subunits of the TOM complex) for increased complex 
assembly or alternatively, it acts to target defective mitochondria for degradation by accumulating on 
the OMM at the TOM complex. The latter hypothesis is substantiated by the fact that we saw 
increased association (and thus possible accumulation) of LRRK2 with the complex containing TOM20, 
TOM22 and TOM70 while less TOM40 was associated with this complex under stress. Taken together, 
we believe WT LRRK2 plays an important role in the cell by binding to the TOM complex where it is 
involved in regulating mitochondrial biogenesis and the removal of damaged mitochondria. 
Furthermore, we speculate that the severely decreased autophosphorylation activity of LRRK2 
Q2089R will have major effects on cellular functions (Figure 4.1 B). For example, we showed that 
Q2089R cells exhibit decreased MMP. And since the ATP generation was less efficient in Q2089R cells, 
we believe that the increase in maximal respiration and spare respiratory capacity are indicative of a 
compensatory mechanism(s). This hypothesis is supported by the increase in mtDNA copy number of 
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Q2089R-carrying cells and possible upregulation of mitochondrial biogenesis as part of the cell’s 
compensatory mechanism(s) (Figure 4.1 B).  
  
Figure 4.1 Schematic illustration of the proposed model for the functions of WT and Q2089R 
LRRK2. The solid lines in the figure shows evidence from previously published studies while the 
dotted lines represent interactions and processes proposed by findings from the present study. 
A. LRRK2 WT 
B. LRRK2 Q2089R 
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However, because mitochondria of Q2089R-carrying cells are depolarized and not functioning 
optimally, the upregulation of mitochondrial biogenesis will lead to an accumulation of defective 
mitochondria since new mitochondria are generated from existing ones. This accumulation of 
dysfunctional mitochondria could result in the upregulation of autophagy (mitophagy). Thereafter, 
due to defective autophagosome clearance seen in Q2089R cells (possibly due to the diminished 
kinase activity), defective mitochondria would accumulate in the cytoplasm and lead to major cellular 
damage or even cellular death. It could be speculated that the decrease in LRRK2’s kinase activity may 
also possibly lead to the decrease in TOM complex association or assembly, thereby exacerbating 
mitochondrial dysfunction. 
Although a modest increase in basal respiration was observed (Figure 4.1 B), the decrease in MMP 
was linked to an increase in proton leak and the concomitant reduction of ATP-coupling efficiency 
when Q2089R cells were stressed for a short period (< 30 minutes). When these cells shift to glycolysis 
for energy production, a striking reduction in glycolytic capacity and glycolytic reserve is apparent 
which indicates that Q2089R affect the cells’ ability to supply the necessary energy required for 
optimal functioning under high energy demand conditions. Finally, we postulate that increased stress 
(such as CCCP treatment for longer periods) will aggravate the already dysfunctional pathways 
described above, leading to a more severe phenotype and possibly accelerate autophagic death in 
Q2089R cells. 
Since many of the proposed pathways or interactions can either be a cause or effect or can occur 
simultaneously, it is difficult at this stage to define the step-by-step sequence of events for this model. 
Therefore, we propose that these events all form part of an ongoing process(es) that together may 
contribute to disease pathogenesis. 
 
4.9 Study limitations 
Some of the major limitations of this study are drawbacks with the two cellular models used. Initially, 
we wanted to create a suitable model to study LRRK2 (WT and mutant) using the CRISPR-Cas9 genome 
editing system in combination with the SHSY5Y neuroblastoma cell line. Unfortunately, we could not 
overcome the many technical drawbacks with this system and were not able to generate the 
appropriate ‘genome-edited’ cultures. Consequently, we used HEK293 cells transfected with WT and 
mutant constructs which is a well-established model system to study functional differences. However, 
although these overexpression models provide valuable information and are widely used to study 
neurodegenerative and other diseases, it does represent an ‘artificial’ disease model and results 
obtained from such studies should always be interpreted with caution. Also, we determined that the 
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transfection efficiency of our constructs was rather low between 6% and 8% of our cell population. 
This could produce false negative findings and therefore the transfection efficiency should be 
optimized in future overexpression studies.  
Because of these limitations, we also used patient-derived dermal fibroblasts which have been 
established by others as a reliable, minimally invasive model to study PD (Auburger et al., 2012; Smith 
et al., 2015). It should be cautioned however that dermal fibroblasts are known to have many different 
properties to neuronal cells and therefore results obtained from this cellular model should not be 
directly extrapolated to the molecular mechanisms of neuronal cells or tissues. Also, sample size of 
the fibroblasts was limited (only one individual per mutant and) but this is due to the rarity of these 
variants in our patient group. Another major limitation was the fact that we could not obtain 
fibroblasts from the PD patient harboring Q2089R. At the time of biopsy collection, he had already 
passed away and we could only obtain a skin biopsy from his son, who harbors Q2089R but is 
apparently unaffected (Figure 3.2 A, Individual III:1). We could speculate that this could possibly 
explain some of the proposed compensatory mechanisms observed for this individual’s fibroblasts in 
the mitochondrial respiration and glycolysis results. The control fibroblast cell lines were negative for 
both G2019S and Q2089R however, we did not screen for any other known PD-causing mutations. 
Although this was a limitation of our pilot studyand future work will include extensive mutation 
screening on control cell lines. We will also investigate the additional known mutations of LRRK2 
including R1441C/H/G, I2020T and Y1699C. Another limitation was the lack of age and gender 
matched controls available for these cell lines which will be addressed in future studies. 
Also, when we investigated mitochondrial and glycolytic respiration of these primary cell lines, we 
grouped the WT fibroblasts. This was based on the raw data showing nearly indistinguishable basal 
respiration profiles for each of the control cell lines and on previous studies showing grouped analyses 
of control and patient groups (Grünewald et al., 2014; Haylett et al., 2016; Zandberg et al., 2016). 
However, we recognize the limitations of this since inter-individual variability could have been 
overlooked. Future studies will to take this into account and will aim to recruit additional control and 
G2019S-positive individuals (both affected and unaffected if possible) and possibly additional Q2089R 
carriers. It would also be beneficial to investigate additional LRRK2 mutations including R1441C/H/G, 
I2020T and Y1699C. 
Technical limitations of our study include the measure of autophosphorylation as an indirect indicator 
of kinase activity as opposed to a kinetic kinase assay with purified protein, even though this has been 
confirmed in previous and very recent studies (Sheng et al., 2012; Reynolds et al., 2014; Fraser et al., 
2016). Ribosomal protein s15 has been identified as a key substrate of LRRK2 and more recently a 
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study revealed that LRRK2 regulates a subset of Rab GTPases in vivo and in vitro thus identifying these 
as physiological substrates of LRRK2 (Martin et al., 2014; Steger et al., 2016). Therefore, future studies 
should include these substrates for investigation of LRRK2’s kinase activity. Also, we were not able to 
detect autophosphorylation activity in fibroblast lysates using the pSer1292 antibody and this requires 
further optimization experiments. 
We used an MTT assay (and CyQUANT®) to measure the metabolic activity of HEK293 cells and primary 
cells (fibroblasts) expressing G2019S and Q2089R. However, since this assay does not measure the 
viability of cells, we were unable to determine whether the mutation or variant is actually toxic to the 
cell. Therefore, this requires further attention. 
When investigating autophagy in both PD models, we used LC3 II and P62 detection via Western blot 
analysis. Detection of these markers especially P62, is thought to be less reliable when using Western 
blotting rather than fluorescent microscopy techniques and thus small changes in autophagic marker 
levels might have been missed (Loos et al., 2014). Additionally, we could have considered additional 
markers such as Bcl-1 for further verification of autophagy induction. Therefore, alternative 
techniques such as flow cytometry should be considered for future studies. 
To identify an association between LRRK2 and the subunits of the TOM complex, we made use of co-
immunoprecipitation. Although this method allows for the detection of proteins within a specific 
complex, whether there is a physical or direct interaction between LRRK2 and specific subunits of the 
TOM complex cannot be determined. Future studies should make use of Proximity Ligation assays to 
confirm such direct interactions (Trifilieff et al., 2011; Gauthier et al., 2015). 
And finally, some experiments were only performed in biological and technical triplicates. Although 
this is standard and acceptable practice in experimental protocols, more replicates could have 
increased the statistical power of our experiments.  
 
4.10 Future work 
Further experiments, on the optimization of the CRISPR-Cas9 genome editing system to create an 
appropriate model to study PD, are necessary. Additionally, since we have low passage (< three) 
fibroblast cultures these could be used to culture iPSC-derived neural cells from PD patients and 
healthy individuals that could be used for the genome editing experiments. We should also attempt 
to obtain fibroblasts from other G2019S-positive individuals (both affected and unaffected) to 
increase our sample size for future studies. We would also suggest that future studies include 
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genotyping with microsatellite markers to determine whether the Q2089R-positive control individual 
and the Q2089R-positive proband are related. 
Another important consideration should be to further analyze the WES data and search for 
mitochondrial-related gene variants in the Q2089R proband. This could possibly identify other 
candidate mutations/variants which might explain the functional phenotypes observed in this study. 
Optimization of transfection efficiency and subsequent LRRK2 protein purification should be 
conducted in order to perform a kinetic kinase assay with purified WT, G2019S and Q2089R LRRK2, in 
order to verify the autophosphorylation results. Additionally, as mentioned previously, future 
experiments should verify the cytotoxicity results from this study with independent measures of 
neurite outgrowth in combination with other assays such as Image-iT® DEAD™ Green cytotoxicity 
assay or LIVE/DEAD® Viability/Cytotoxicity assays. 
In addition, the measures of oxidative phosphorylation should be repeated using different equipment 
such as the Oxygraph-2K (Oroboros Instruments) to verify the findings obtained by the Seahorse XF 
analyzer. These experiments have already been planned and will be done in collaboration with Dr. 
Olga Corti at the Brain and Spine Institute, ICM, in Paris, France. 
Furthermore, it would be interesting to investigate the association of LRRK2 with the TOM complex in 
more detail. For instance, future studies should include elucidating whether LRRK2 is imported into 
the mitochondria (using transmission electron microscopy), or if LRRK2 is accumulated at the TOM 
subunits on the OMM during cellular stress. Moreover, additional subunits of the TOM complex 
[including TOM5, TOM7 and in particular TOM6 based on previous studies (Harbauer et al., 2014; 
Shiota et al., 2015)] should be investigated as possible phosphorylation substrates or interactors of 
LRRK2. Importantly, the effect of G2019S and Q2089R on the interaction with the TOM complex should 
also be investigated. Lastly, experiments on mitochondrial fission/fusion should also be included in 
future studies of LRRK2 models since these processes are essential for mitochondrial adaptations to 
environmental changes and quality control.  
 
4.11 Conclusion 
Given the complexity and variability of mechanisms leading to neurodegenerative diseases such as 
PD, more research is needed to identify possible new therapeutic targets and pathways for effective 
disease treatment. The identification and characterization of Q2089R, a variant with functional 
implications, may shed some light on how variants in LRRK2 can influence a variety of cellular 
functions.  
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The identification of potential disease-causing mutations with the use of Next-Generation Sequencing 
is a powerful technique and is essential in developing our understanding of complex disorders such as 
PD, especially in the unique SSA populations. However, the identification of rare variants should 
always be accompanied by functional characterization as these variants cannot automatically be 
regarded as causal. 
Q2089R exhibited decreased autophosphorylation activity, severe mitochondrial defects and 
significantly increased autophagic flux, providing preliminary evidence for its involvement in 
mitochondrial dysfunction and autophagic pathways which could possibly lead to neuronal cell death. 
If corroborated in follow-up studies, our findings challenge the idea that toxic gain-of-function 
mutations in the kinase domain of LRRK2 is the only pathological mechanism and we postulate that 
abolishment of kinase activity could also contribute to neurodegeneration and PD pathogenesis.  
It is clear that this complex multi-domain protein is involved in many different cellular functions, 
however, further studies are needed to elucidate additional functions of LRRK2 and the effect of 
mutations on these functions. It is anticipated that this knowledge may be key to understanding the 
processes that lead to development of PD.   
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Appendix I 
Vector map 
 
 
 
Restriction map and cloning site of the pcDNA-DEST53 vector. The positions of the resistance genes, 
Ampicillin (Amp) and Neomycin (Neo), various promotors such as CMV and T7, the GFP site and the 
attR1 and attR2 sites. Full length LRRK2 sequences were cloned into the vector using Gateway® cloning 
and recombination between the attR1 and attR2 cloning sites indicated by the black arrow. The GFP 
tag was fused to the N-terminal gene inserts. Taken from: 
https://www.addgene.org/browse/sequence_vdb/2088/ and (Fu et al., 2008). 
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Appendix II 
Reagents 
 
1. Solution used in generation of competent cells  
CAP buffer:  
CaCl2         2.21g 
15% glycerol        37.5ml 
PIPES         0.76g 
ddH2O up to 250ml. pH 7.0.  Store at 4°C. 
 
2. Bacterial media 
Luria-Bertani (LB) Media 
Bacto tryptone        5g 
Yeast extract        2.5g 
NaCl         5g 
ddH2O to final volume of 500ml 
Autoclave for 20 minutes at 121°C 
 
       LB Agar Plates  
Bacto tryptone        5g 
Yeast extract        2.5g 
NaCl         5g 
Agar         8g 
ddH2O to final volume of 500ml 
Autoclave for 20 minutes at 121°C and add appropriate antibiotic to media when the 
temperature has reached ±55°C, prior to pouring plates (Ampicillin, 50mg/ml). 
 
3. Electrophoresis solutions 
SB Buffer (20X stock) 
Di-sodium tetraborate decahydrate      38.1g 
ddH2O to a final volume of 1L 
       SB Buffer (1X) 
20X SB buffer        100ml 
ddH2O         2L 
 
       SDS-PAGE Running buffer (10X) 
Tris base        30g 
Glycine         144g 
10% SDS        100ml 
ddH2O to a final volume of 1L 
 
       SDS-PAGE Running buffer (1X) 
10x SDS Running Buffer       100ml 
ddH2O          900ml 
 
4. Gels 
1 % Agarose Gel       
Agarose         1g 
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SB Buffer (1X)        100ml 
Microwave for 2-3 minutes; add 5µl ethidium bromide (10mglml) when temperature reaches 
± 55°C 
 
5. Loading dyes 
Ethidium bromide stock (10mg/ml)  
Ethidium bromide (Sigma)      500mg 
 ddH2O          50ml 
 Stir for 4 hours using magnetic stirrer and store in dark container at 4°C 
 
       Cresol Loading Dye 
 10mg/ml cresol stock solutiom      2% (v/v) 
 Sucrose         0.9933M 
 
       SDS Loading Dye 
 Laemmli sample buffer (Bio-Rad)     950µl 
 β-mercapto-ethanol       50µl 
 
6. Co-IP reagents 
       Lysis buffer 
 1M Tris- HCl pH 7.4       5ml 
5M NaCl        3ml 
Triton-x         1%  
1M MgCl2        150µl 
ddH2O          150ml 
 
Add fresh on day of lysis: 
β-mercapto-ethanol       0.1% 
Halt™ Protease and Phosphatase Inhibitor Cocktail 100x   1%  
 
       TBST (pH7.6) 
 5M NaCl        60ml 
 1M Tris base        40ml 
 0.1% Tween-20        2ml 
 ddH2O to a final volume of 2L 
 
       Membrane blocking solution 
 Powder milk        7.5g 
 Tween-20        15µl 
 TBST solution         150ml 
 
7. Co-localization reagents 
4% Formaldehyde solution 
 16% Formaldehyde        10ml 
 ddH2O         30ml 
 Dilute 4% Formaldehyde in culture media at a ratio of 1:1 
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1% Bovine Serum Albumin (BSA) 
 BSA         0.5g 
 PBS solution         50ml 
 
8. Eukaryotic cell culture media 
Growth Media 
 DMEM (4.5g/L glucose, with L-glutamine)    500ml 
 Foetal Bovine Serum       50ml 
 Penicillin/Streptomycin       5ml 
 Pre-warm to 37°C before use. Store at 4˚C. 
 
       Fibroblast isolation media  
Amniochrome II complete media        95ml  
Chang Medium® D           95ml   
Non-essential amino acids (NEAA)      5ml  
Penicillin/Streptomycin           5ml  
Pre-warm to 37˚C before use. Store at 4˚C. 
 
9. Solutions for functional assays   
5mg/ml MTT stock solution  
Thiazolyl blue tetrazolium bromide     10mg   
PBS         2ml   
 
       40mM CCCP stock solution  
Carbonyl cyanide m-chlorophenyl hydrazone     16.2mg  
DMSO             2ml  
Aliquot and store in the dark at -20˚C. Stable at 4˚C for up to two weeks.   
 
       10μM CCCP working solution  
40mM CCCP stock solution         5µl  
Fibroblast culture media          20ml  
Make up fresh before each use 
 
       5mg/ml JC-1 stock solution  
Tetraethyl benzimidazolyl carbocyanine iodide     5mg 
DMSO          1ml 
 
       20µg/ml Bafilomycin A1 stock solution  
Bafilomycin A1         100µg 
Ethanol         5ml 
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Appendix III 
Generation of CRISPR cell line 
 
 
Figure 1 Repair mechanisms following nuclease-induced double-strand breaks (DSBs). DSBs can 
either be repaired by non-homologous end joining (NHEJ) or Homology-direct repair (HDR) pathways. 
Taken from (Sander and Joung, 2014). 
 
 
Figure 2 Guidelines for designing crRNA specific oligonucleotide primers for CRISPR target 
sequences. A) An example of a top strand of an oligonucleotide primer containing the GTTTT 3’ 
overhang. B) An example of a bottom strand of an oligonucleotide primer containing the CGGTG 3′ 
overhang. C) Annealing the top and bottom strands of the crRNA specific oligonucleotide primers for 
cloning into the GeneArt ® CRISPR Nuclease OFP Vector. 
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Figure 3 The sequences of Exon 41 and 42 of LRRK2. Small parts of the intronic sequences are shown 
in lower case and the capital text indicates the exonic regions of LRRK2. The underlined text shows 
the PAM sequences selected for each exon. A) The WT sequence of LRRK2 exon 41 in which the most 
common PD-causing mutation (G2019S) is located. The WT codon is indicated in purple text (GGA). B) 
The WT sequence of LRRK2 exon 42 in which the novel variant (Q2089R) is found.  The WT codon is 
shown in green text (CAA). 
 
Table 1 Oligonucleotides and templates designed for CRISPR-Cas9 genome editing 
Oligonucleotides Sequence (5’-3’) 
Number of 
bases 
G2019S CRISPR 
top 
ATTGCAAAGATTGCTGACTAGTTTT 
25 
G2019S CRISPR 
bottom 
TAGTCAGCAATCTTTGCAATCGGTG 
25 
G2019S template 
AATGTGCTGCTTTTCACACTGTATCCCAATGCTGCCATCATTG
CAAAGATTGCTGACTACAGCATTGCTCAGTACTGCTGTAGAA
TGGGGATAAAAACATCAGAGGGCACACCAGGTAGGTGA 
123 
Q2089R CRISPR 
top 
GAAATACAAGGAAAATTACCGTTTT 
25 
Q2089R CRISPR 
bottom 
GGTAATTTTCCTTGTATTTCCGGTG 
25 
Q2089R template 
GACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAA
GTTTCCAAATGAGTTTGATGAATTAGAAATACGAGGAAAATT
ACCAGGTAAGTTCTGTTTTCTCTACAATGAAGATTTTTTTTCT
TAATATCAGCAGCTTCA 
143 
The purple text illustrates the introduction of the G2019S mutation (GGC>AGC). The underlined text 
indicates the simultaneous mutation of the PAM site (CGG>CAG). The green text represents the 
introduction of the Q2089R variant (CAA>CGA). The blue text shows the change of the PAM site 
(TGG>AGG). The italic text at the end of each top and bottom oligonucleotide is complementary to 
the overhang sequences in the linearized OFP reporter vector. 
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Appendix IV 
Supplementary tables 
Table 1 Optimized cell seeding densities for HEK293 and COS7 cells 
Plate HEK293 COS7 
96-well 20 000 cells/well  
24-well 100 000 cells/well 50 000 cells/well 
6-well 500 000 cells/well  
 
Table 2 Transfection of HEK293 cells with Lipofectamine 2000 transfection reagent 
Plate SFM Lipo SFM Plasmid DNA 
Transfection 
volume 
Total well 
volume 
96-well 20 µl 0,6 µl 20 µl 0,4 µg 40 µl 200 µl 
24-well 25 µl 1 µl 25 µl 0,6 µg 50 µl 400 µl 
6-well 200 µl 8 µl 200 µl 3 µg 400 µl 2 ml 
Abbreviations: Lipo, Lipofectamine2000; SFM, Serum free media 
 
Table 3 Transfection of COS7 cells with DMRIE-C transfection reagent 
Plate SFM DMRIE-C SFM Plasmid DNA 
Transfection 
volume 
Total well 
volume 
24-well 75 µl 0,70 µl 75 µl 1 µg 150 µl 150 µl 
Abbreviations: SFM, Serum free media 
 
Table 4 List of LRRK2 sequencing primers 
Primer Sequence (5’-3’) Tm (°C) 
LSP 1 TAG GAT CCA TGG CTA GTG G 53.2 
LSP 2 GTC CTC ATG AGT GGC AAT G 53.5 
LSP 3 GCA GCA GTG GTC CCC AAA AT 58.5 
LSP 4 GCA TCA TGG TTG AAT GCT TG 52.7 
LSP 5 TCA GAT GAT TCA CTC AGG TCA 53.0 
LSP 6 GCA TAT TTA TGG TCT AGA GTA GAG A 51.3 
LSP 7 GAA TGC CAC CGA GGA ATC 53.4 
LSP 8 GCC CAA ACA GAA TGT ATT GGC 54.8 
LSP 10 GTC TGG TAC TCT CCT GGT C 53.8 
LSP 11 GTC ATG CTG GTA TTG GGC 53.7 
LSP 12 GTC CTC ATA TCT AGG AAA GAC AC 52.1 
Abbreviations: LSP, LRRK2 sequencing primer; Tm, melting temperature; °C, degree Celsius 
Stellenbosch University  https://scholar.sun.ac.za
140 
 
Table 5 List of universal primers 
Primer Sequence (5’-3’) Tm (°C) 
U6 Forward GGG CAG GAA GAG GGC CTA T 
59.2 
GFP Forward GGT CCT TCT TGA GTT TGT AAC 
51.1 
CMV Forward CGC AAA TGG GCG GTA GGC GTG 
63.9 
T7 Forward TAA TAC GAC TCA CTA TAG GG 
47.5 
Abbreviations: Tm, melting temperature; °C, degree Celsius 
 
Table 6 List of primary and secondary antibodies and their optimized concentrations used in Co-
immunoprecipitation and Western blot assays 
Antigen Dilution Primary antibody Manufacturer 
Blocking 
buffer 
Secondary 
antibody* 
Dilution 
LRRK2 1:300 
Rabbit Monoclonal 
[MJFF (c41-2)] LRRK2 
Abcam 
ab133474 
5% Milk 
Donkey anti-
rabbit 
1:2000 
LRRK2 
pSer1292 
1:100 
Rabbit Monoclonal 
[MJFR-19-7-8] LRRK2 
(phosphor S1292) 
Abcam 
ab203181 
5% Milk 
Donkey anti-
rabbit 
1:2000 
GAPDH 1:10 000 
Rabbit Polyclonal (FL-
225) GAPDH 
Santa Cruz 
Biotechnology 
sc-25779 
5% Milk 
Donkey anti-
rabbit 
1:2000 
GFP 1:4000 
Rabbit Polyclonal GFP-
ChIP Grade 
Abcam ab290 5% Milk 
Donkey anti-
rabbit 
1:2000 
TOM20 1:4000 
Mouse Monoclonal 
TOMM20 
Abcam ab56783 5% Milk 
Donkey anti-
mouse 
1:2000 
TOM22 1:4000 
Mouse Monoclonal [1C9-
2] TOMM22 
Abcam ab10436 5% Milk 
Donkey anti-
mouse 
1:2000 
TOM40 1:2000 
Rabbit Monoclonal 
[ERP6932(2)] TOMM40 
Abcam 
ab185543 
5% Milk 
Donkey anti-
rabbit 
1:2000 
TOM70 1:5000 
Mouse Monoclonal [21] 
TOMM70A 
Abcam 
ab106193 
5% Milk 
Donkey anti-
mouse 
1:2000 
LC3 II 1:1000 Rabbit Polyclonal LC3B 
Cell Signalling 
Technology CST-
2775S 
5% BSA 
Donkey anti-
rabbit 
1:2000 
P62 1:2000 
Mouse Monoclonal 
SQSTM1/p62 
Abcam ab56416 5% Milk 
Donkey anti-
mouse 
1:2000 
*, Santa Cruz Biotechnology Inc., United States.  
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Table 7 List of primary and secondary antibodies and their optimized concentrations used in co-
localization assays 
Antigen Dilution Primary antibody Manufacturer Secondary antibody* Dilution 
GFP 1:4000 
Rabbit Polyclonal 
GFP-ChIP Grade 
Abcam ab290 
Donkey anti-rabbit Alexa 
488 (Green) 
1:500 
GFP 1:2000 
Mouse Monoclonal 
[9F9.F9] GFP 
Abcam ab1218 
Donkey anti-mouse Alexa 
488 (Green) 
1:500 
TOM20 1:1000 
Mouse Monoclonal 
TOMM20 
Abcam ab56783 
Donkey anti-mouse Cy3 
(Red) 
1:500 
TOM22 1:1000 
Mouse Monoclonal 
[1C9-2] TOMM22 
Abcam ab10436 
Donkey anti-mouse Cy3 
(Red) 
1:500 
TOM40 1:100 
Rabbit Monoclonal 
[ERP6932(2)] 
TOMM40 
Abcam 
ab185543 
Donkey anti-rabbit Cy3 
(Red) 
1:500 
TOM70 1:2000 
Mouse Monoclonal 
[21] TOMM70A 
Abcam 
ab106193 
Donkey anti-mouse Cy3 
(Red) 
1:500 
*Jackson ImmunoResearch Laboratories, Inc., United States 
 
Table 8 Co-localization coefficients 
Coefficients Meaning Values 
Weighted Co-
localization 
Coefficient 
Illustrates the contribution of each 
of the two channels to the pixels of 
interest 
0 – 1.0 
If the red channel is 1.0 and the green 
channel is 0.2, it means that all (100%) red 
pixels co-localize with green, but only 20% of 
green pixels co-localize with red. 
Mander’s 
Coefficient  
 
Illustrates the contribution of each 
channel regardless of the pixel 
intensity. A good indicator of the 
proportion of green channel signal 
coincident with a signal in the red 
channel. 
0 – 1.0 
M1 is the ratio of the summed intensities of 
pixels from the green channel for which the 
intensity in the red channel is above zero to 
the total green channel intensity. M2 is 
defined conversely for the red channel. M1 
and M2 can be expressed as % overlap 
between channels. 
Overlap 
Coefficient 
Signifies the actual overlap of 
signals and represents the true 
degree of co-localization 
0 – 1.0 
Where 0.5 suggests that 50% of both 
selected channels co-localize. 
Pearson’s 
correlation 
coefficient 
(Correlation R) 
The correlation of intensity 
distribution between channels 
-1.0 – 1.0 
0 indicates no significant correlation, -1 
indicates negative correlation and 1 
indicates positive correlation. 
Adapted from (Zinchuk et al., 2007; Dunn et al., 2011) and 
https://rsb.info.nih.gov/ij/plugins/track/jacop2.html. 
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Appendix V 
Family pedigree 
 
 
Figure 1 Pedigree of South African family with LRRK2 G2019S  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
143 
 
Appendix VI 
Seahorse XF analyzer plate layouts 
 
Figure 1 Design of 96-well plate layout for the XF Mito Stress Test and Glycolysis Stress Tests for 
transfected HEK293 cells. Rows A, C, E and G were used for the XF Mito Stress Test. Rows B, D, F and H 
were used for the XF Glycolysis Stress Test. The black corner wells indicate blank wells used for background 
corrections. Abbreviations: Mito, XF Mito Stress Test; Glyco, XF Glycolysis Stress Test. 
 
 
Figure 2 Design of 96-well plate layout for the XF Mito Stress Test and Glycolysis Stress Tests for control 
and patient-derived fibroblasts. The black corner wells indicate blank wells used for background 
corrections. Abbreviations: Mito, XF Mito Stress Test; Glyco, XF Glycolysis Stress Test. 
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Appendix VII 
Supplementary methods 
 
Removing DMSO from stocks and culturing cells     
Cells were frozen with freezing media containing DMSO and in order to remove it from the cells, 1ml of 
pre-warmed culture media was added to 1ml of thawed cells. This mixture was transferred to a 15ml 
polypropylene tube containing 4ml of pre-warmed culture media. The suspension was centrifuged at 
3000rpm for 3min in a Sorval® GLC-6 general laboratory centrifuge. The supernatant was discarded and 
the pellet resuspended in 5ml culture media, and the suspension transferred to a T25 tissue culture flask. 
The flasks were incubated at 37°C in in a Farma thermosteri-cycle 5% CO2 humidified incubator until they 
were ready for sub-culturing, DNA extraction, RNA extraction or cell lysis.  
 
Sub-culturing cell cultures 
Cell cultures were passaged every 2 to 4 days (in the case of HEK293 and COS7) or 5 to 7 days (fibroblasts), 
at 70-80% confluency. The growth media was removed from the flasks and the adherent monolayer of 
cells gently rinsed with 3 to 5ml sterile phosphate-buffered saline (PBS) (Lonza, Switzerland). In order to 
facilitate the detachment of cells from the growth surface, 3 to 5 ml of trypsin (0.5g/L, Lonza, Switzerland) 
was added and flasks incubated at 37°C for 5 minutes. To deactivate the trypsin enzyme activity, an equal 
volume of culture media was added to the cells. The suspension was transferred to a 15 ml tube and 
centrifuged at 3000rpm for 3 minutes in a Sorval® GLC-6 general laboratory centrifuge. The supernatant 
was discarded and the pellet resuspended in 3ml culture media before the cells were evenly distributed 
into T75 or T125 tissue culture flasks (Corning Inc., United States) containing final volumes of 12ml or 20 
ml complete growth media, respectively. Alternatively, cells were plated into 6-well, 24-well or 96-well 
plates at pre-determined seeding densities for desired downstream assays. 
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